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“To suppose that the eye with all its inimitable contrivances for 
adjusting the focus to different distances, for admitting different 
amounts of light, and for the correction of Spherical and chromatic 
aberration, could have been formed by natural selection, seems, I 
freely confess, absurd in the highest degree. When it was first said 
that the sun stood still and the world turned round, the common 
sense of mankind declared the doctrine false; but the old saying 
of Vox populi, vox Dei, as every philosopher knows, cannot be 
trusted in science. Reason tells me, that if numerous gradations 
from a simple and imperfect eye to one complex and perfect can 
be shown to exist, each grade being useful to its possessor, as is 
certain the case; if further, the eye ever varies and the variations be 
inherited, as is likewise certainly the case; and if such variations 
should be useful to any animal under changing conditions of life, 
then the difficulty of believing that a perfect and complex eye 
could be formed by natural selection, though insuperable by our 
imagination, should not be considered as subversive of the theory. 
How a nerve comes to be sensitive to light, hardly concerns us more 
than how life itself originated; but I may remark that, as some 
of the lowest organisms, in which nerves cannot be detected, are 
capable of perceiving light, it does not seem impossible that certain 
sensitive elements in their sarcode should become aggregated and 
developed into nerves, endowed with this special sensibility.”
 
“On the Origin of Species”, 1859
Charles Darwin
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1.1 General introduction
The eye is a very fascinating organ that we share with many species. Every eye of 
each species has evolved to optimize its survival in their natural habitat, resulting 
in a diversity of eye types. The human eye has evolved to see objects from a 
distance, but also enables detailed nearby vision. We can see colors and details 
by daylight, as well as some 
colors and details in nightfall. 
The anatomical structure of the 
human eye is depicted in Figure 
1.
Figure 1. (Adapted from Pascal 
Goetgheluck/Science source).
The human retina
Anatomical landmarks
The retina is a complex transparent tissue 
that covers the inside of the back two-thirds 
of the eyeball. The anterior and posterior 
retina are divided by the equator, and the 
ora serrata is the junction between the 
retina and ciliary body. The macula, optic 
nerve and the vascular arcades complete 
the posterior pole.
Figure 2: Topography of the posterior pole of the retina. Color fundus photograph with overlaying 
grid chart to define the subfields of the macula and size/ degrees. 
Anatomy of the retina
The retina is formed 
embryonically from 
neural tissue and is 
connected to the brain 
by the optic nerve. The 
retina consists of several 
layers as depicted in 
Figure 3. 
Figure 3: Adapted from Lober 
et al, 2016 [1].
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Chapter 1
The photoreceptor layer and retinal pigment epithelium layer will be discussed in 
further detail below. 
Photoreceptor cells 
There are two types of photoreceptor cells: rods and cones. They are differentiated 
structurally by their distinctive shapes and functionally by their sensitivity to 
different frequencies and intensities of light.
The rods are the most numerous (92 million) and have the highest concentration 
in the mid-peripheral retina [2]. Rod photoreceptor cells contain rhodopsin [3]. 
They are most sensitive in dim illumination and are responsible for night and 
peripheral vision. Dysfunction of the rods will result in poor night vision and 
peripheral field loss.
The cones are fewer in number (4.6 million) and have their highest concentration 
at the fovea [2]. They are most sensitive in bright light and mediate day vision, 
color vision, and central visual acuity. There are three different cones that allow for 
color vision: the S (“blue”) cones, the M (“green”) cones, and the L (“red”) cones. 
The S cones contain iodopsin that is most sensitive to short-wavelength light, 
while iodopsin in M and L cones are sensitive to medium- and long-wavelength 
light [4, 5]. 
Figure 4: Distribution of rod and cone photoreceptors in the retina, adapted from Osterberg 1935 
[6].
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Retinal pigment epithelium
The retinal pigment epithelium (RPE) is composed of a single layer of hexagonal 
cells. The cells consist of an outer non-pigmented basal element containing the 
nucleus, and an inner pigmented apical section containing melanosomes. The 
cell base is in contact with Bruch’s membrane, and at the cell apices, multiple 
thread-like villous processes that extend between the outer segments of the 
photoreceptors. At the posterior pole, particularly at the fovea, RPE cells are 
taller and thinner, more regular in shape and contain more numerous and 
larger melanosomes than in the periphery. The RPE cells and intervening tight 
junctional complexes (zonula occludentes) constitute the outer blood-retinal 
barrier, preventing extracellular fluid leaking into the subretinal space from the 
choriocapillaris. The RPE cells actively pump ions and water out of the subretinal 
space. Its integrity, and that of Bruch’s membrane, is important for continued 
adhesion between the two, thought to be due to a combination of osmotic 
and hydrostatic forces, possibly with the aid of hemidesmosomal attachments. 
Another function is facilitation of photoreceptor turnover by phagocytosis and 
lysosomal degradation of outer segments following shedding, and preservation 
of an optimal retinal milieu. Maintenance of the outer blood-retinal barrier is a 
key factor, as are the inward transport of metabolites and the outward transport 
of metabolic waste products. The RPE also is involved in storage, metabolism, and 
‘recycling of vitamin A in the visual cycle’. Finally, the dense RPE pigment serves 
to absorb stray light. Adapted from Kanski et al [7]. 
Retinal processes
There are two important processes to transform light into an electrical signal: the 
phototransduction cascade and the visual cycle. 
Phototransduction cascade
This is the process by which the photoreceptors transpose the energy of an 
absorbed photon into a neuronal signal. The phototransduction cascade occurs 
in the photoreceptor outer segments. The membranous discs of the outer 
segment contain a photosensitive pigment, a membrane protein that comprises 
of an opsin protein (green, red or blue opsin in cones, and rhodopsin in rods) 
containing an 11-cis-retinal chromophore. If a light photon reaches the retina, 
it activates rhodopsin by transforming the 11-cis-retinal into all-trans-retinal. 
The activated rhodopsin (metarhodopsin II) induces the activation of transducin, 
which – when bound to GTP – then activates cGMP specific phosphodiesterase 
(PDE). The activated PDEα and -β subunit hydrolyze cGMP to 5-GMP. The 
following decline of cytoplasmic cGMP leads to the closure of cGMP channels in 
the plasma membrane and sodium is not able to enter the cell uninterrupted. This 
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leads to hyperpolarization of the cell. Because of hyperpolarization of the plasma 
membrane, voltage-gated calcium channels at the synaptic terminal will close. 
Consequently, the intracellular calcium concentration reduces abruptly, which 
leads to the inhibition of neurotransmitter (glutamate) release. Concomitantly, in 
the dark there is a continuous release of neurotransmitters, and at the same time 
activation of the photoreceptor induces a decrease of neurotransmitter release 
[8, 9]. 
Succeeding activation of the phototransduction cascade, utilized molecules are 
transposed into their initial form during the recapture phase [10]. Metarhodopsin 
II is inactivated through phosphorylation by rhodopsin kinase and by connecting 
to arrestin which results in free opsin and all-trans-retinal. Then, activated 
transducin and PDE are deactivated by a complex of GTP-ase accelerator protein; 
RGS9-1 and Gβ5L, which together stimulate GTP hydrolysis. From this GTP, 
cGMP is synthesized by guanylate cyclase enzymes (GC-1 and GC-2) and as a 
consequence cGMP concentration is raised to “dark situation levels”. The final 
result is an outer segment in dark state, in which the cation channels are open, 
the photoreceptor is depolarized, neurotransmitter is constantly released from 
the synaptic terminal, all proteins involved in the phototransduction cascade are 
adjusted for the following activation, and all-trans-retinal is set to be recycled in 
the visual cycle. 
Visual cycle
The rod visual cycle is a recycle device which occurs in the RPE and photoreceptor 
outer segment, where it recycles “consumed” all-trans-retinal into 11-cis-retinal 
that can be re-utilized in the phototransduction cascade [11]. As a result of 
inactivation of the phototransduction cascade, all-trans-retinal disseminates 
from the opsin into the disc membranes of the photoreceptor outer segment, 
is then transferred to the cytoplasmic space facilitated by the ABCR protein 
in the disc membrane, and converted into all-trans-retinol (vitamin A) by 
retinol dehydrogenase (RDH12). Subsequently, Vitamin A is released into 
the interphotoreceptor matrix, which is accelerated by interphotoreceptor 
retinoid-binding protein (IRBP), a protein localized in the interphotoreceptor 
matrix that binds all-trans-retinol. All-trans-retinol is then absorbed by the RPE 
cells, facilitated by cellular retinol-binding protein-1 (CRBP1). RPE cells are also 
able to absorb vitamin A from blood in the choroidal circulation. In the RPE 
cell, all-trans-retinol is esterified by lecithin retinol acyl transferase (LRAT) into 
all-trans-retinyl ester, which is the stable and non-cytotoxic storage form of vitamin 
A. As a result, RPE-specific 65-kDA protein (RPE65) isomerizes all-trans-retinyl 
ester into 11-cis-retinol, and – since free 11-cis-retinol inhibits the isomerization 
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of more all-trans-retinyl ester – it then connects to cellular retinal-binding protein 
(CRALBP), and may be temporarily removed from the chemical equilibrium by 
conversion into 11-cis-retinyl by LRAT. 11-cis-retinol is subsequently oxidized 
into 11-cis-retinal, catalyzed by 11-cis-retinol dehydrogenase (RDH5), and then 
released from the RPE cell into the interphotoreceptor matrix, again facilitated 
by IRBP. Eventually, 11-cis-retinal is absorbed by the photoreceptor, where it 
connects to opsin to form the photoactive rhodopsin and the phototransduction 
cascade can start again. The rod photoreceptors are fully dependent on the 
visual cycle in the RPE for the regeneration of 11-cis-retinal. Notably, the visual 
pigment regeneration in cones is 2000-fold higher than in rods, and the maximum 
throughput of the visual cycle is too slow to explain the sustained photosensitivity 
of cones in bright light. Supported by these observation, a new pathway for 
regeneration of visual pigment was discovered in which part of the visual cycle 
in cones takes place in the Müller cells, instead of RPE cells [12]. The existence 
of this alternative visual cycle may function in conjunction with the visual cycle 
in RPE cells, to provide visual chromophores to the cone in the high rate that is 
required for daylight vision (Figure 5).
Figure 5: Visual cycle. Adjusted from Sears AE, Bernstein PS, Cideciyan AV, et al. [13]
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Retinal imaging
Both retinal imaging and functional assessment are necessary to help 
ophthalmologists obtain the right diagnoses. 
Fundus autofluorescence (FAF): a non-invasive imaging technique, which provides 
a topographical map of lipofuscin distribution within the RPE. This technique 
uses short-wavelength light to excite lipofuscin, which autofluorescesce. FAF can 
reveal metabolic changes at the level of the RPE. 
Fluorescein angiography (FA): involves photographic surveillance of the passage 
of fluorescein through the retinal and choroidal circulations following intravenous 
injection. 
Figure 6: Fundus autofluorescence 
of a normal retina 
Optical coherence tomography (OCT): a non-invasive, non-contact imaging system 
which provides high resolution cross-sectional images of the retina, optic nerve 
head, and vitreous. Imaging of the anterior segment is also possible. 
Figure 8: Spectral-domain optical coherence tomography of the retina. A horizontal scan through the 
fovea reveals several hyperreflective layers, which correlate with anatomical structures of the retina. 
Figure 7: Fluorescein angiography 
of a normal retina
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Retinal function tests
Visual field testing: measures sensitivity to light stimuli in both the central and 
peripheral visual fields. A region with decreased light sensitivity surrounded by 
a zone of relatively normal sensitivity is called a scotoma. Dynamic perimetry 
(e.g., Goldmann perimetry) can be used to define the peripheral visual field (and 
its borders) by confrontation of a moving light stimulus into the visual field; this 
technique can also be used to roughly locate a relative or absolute central scotoma. 
Static perimetry (e.g., Humphrey visual field testing) measures the sensitivity of 
the retina within the central visual field by applying several non-moving spots of 
light of varying brightness.
Color vision: several tests are available to measure any deficiency in color vision. 
Color vision test contains the function of three populations of retinal cones; blue 
(tritan), green (deuteron) and red (protan).
Electroretinography (ERG): is the record of an action potential produced by the 
retina when it is stimulated by light of adequate intensity. A light stimulus is 
followed by an initial negative “a-wave”, which arises from the photoreceptors. 
Then follows a “b-wave”, which arises from the Müller and bipolar cells. In 
dark-adapted conditions (scotopic), a weak flash is used to stimulate the rods, 
followed by a very bright flash, which stimulates rods and cones. After exposing 
the eye to light-adapted conditions, an intense flash is utilized to measure the 
photopic potential arising from the cones, and the cone-derived flicker response 
is obtained using a 30 Hz white light flicker stimulus. The International Society for 
Clinical Electrophysiology of Vision (ISCEV) provides a standardized classification 
for ERG [14]. 
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Figure 9: The diagram of the six basic ERGs defined by the ISCEV Standard depicted. These 
waveforms are only given as examples and are not intended to indicate minimum, maximum or 
typical values. Bold arrowheads indicate the stimulus flash; solid arrows illustrate a-wave and 
b-wave amplitudes dotted arrows exemplify how to measure time-to-peak (t, implicit time or peak 
time). Adapted from ISCEV standards [14].
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Retinal dystrophies
Retinal dystrophies (RDs) consist of a group of rare, degenerative conditions of 
the retina, affecting about 1:2000 individuals, and thereby the leading cause of 
vision loss in persons between 15 and 45 years old [15-17]. Retinal dystrophies 
account for ~5% of blindness worldwide, in which blindness is defined by the 
World Health Organization (WHO) as visual field smaller than 10 degrees and/ 
or in the best eye a visual acuity of <20/400 (Snellen). Retinal dystrophies can 
be isolated or syndromic, the progression of disease differs from nearly stable to 
progressive, and the mode of inheritance can be autosomal dominant, autosomal 
recessive, X-linked or digenic. There is a wide clinical and genetic heterogeneity, 
caused by mutations in >261 different genes [18]. See Figure 10
Figure 10: Genetic overlap between non-syndromic monogenic retinal diseases. Clinical diagnoses 
are indicated by colored circles. In the overlapping areas are the number of genes implicated in 
different phenotypes. Colored numbers outside the circles represent the total number of genes 
associated with these phenotypes. RP, retinitis pigmentosa; CNSB, congenital stationary night 
blindness; LCA Leber congenital amaurosis, CD/CRD, cone and cone-rod dystrophy; MD, macular 
degeneration; EVR exudative vitreoretinopathies. With permission from Khan et al. 2019 [18].
The genes involved encode proteins that have a variety functions in development 
and homeostasis of the retina. Mutations within the same gene may cause various 
disease phenotypes, even amongst affected persons within the same family. These 
genes encode proteins involved in retinal cellular structures, photo-transduction, 
the visual cycle, and photoreceptor structure or gene regulation (Figures 11 and 
12).
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Figure 11:  Schem
ati
c representati
on of the roles of the non-syndrom
ic cone disorder-associated proteins in the hum
an reti
na. Schem
ati
c representati
on of 
five m
ajor functi
onaliti
es of hum
an cone photoreceptor cells (PC), M
üller cells and the RPE. The locati
ons and functi
ons of proteins involved in non-syndrom
ic 
CD
s are depicted in diff
erent colors. Proteins w
hich are relevant for the diff
erent cellular processes and not m
utated in CD
s are given in black lett
ering. Som
e 
CD
-associated proteins are not show
n in this figure either because of their w
ide-spread localizati
on in the reti
na (EFEM
P1, FSCN
2, H
M
CN
1), or because they 
localize to structures not show
n (TIM
P3). Panel A
. The reti
noid cycle taking place in cone photoreceptor cells and the RPE. U
pon photoacti
vati
on (indicated 
by a lightning sym
bol), 11-cis-reti
nal is converted into all-trans-reti
nal and dissociates from
 acti
vated cone opsins, O
PN
1LW
 and O
PN
1M
W
 (acti
vated opsins 
indicated by an asterisk). A
ll-trans-reti
nal is then recycled to 11-cis-reti
nal via several enzym
ati
c steps in the RPE. Transport of all-trans-reti
nal is m
ediated by 
A
BCA
4. Panel B. Reti
noid cycle in cones and M
üller cells. U
pon photoacti
vati
on, isom
erizati
on of 11-cis to all-trans-reti
nal in a cone opsin takes place. A
ft
er 
dissociati
on, all-trans-reti
nal is reduced to all-trans-reti
nol by RD
H
8 and then released from
 the cone outer segm
ent into the interphotoreceptor m
atrix w
here 
it is bound by IRBP and taken up by the M
üller cells. A
ll-trans-reti
nol is isom
erized by dihydroceram
ide desaturase-1 (D
ES1) to 11-cis-reti
nol, 9-cis-reti
nol 
and 13-cis-reti
nol, of w
hich 11-cis-reti
nol is subsequently bound to cellular reti
nal-binding protein (CRA
LBP). The interphotoreceptor reti
noid-binding protein 
(IRBP) transports 11-cis-reti
nol to the cone outer segm
ents. 9-cis-reti
nol diff
uses directly to the interphotoreceptor m
atrix and into cone outer segm
ents, 
and together w
ith 11-cis-reti
nol is oxized by an unknow
n reti
nol dehydrogenase to 9/11-cis-reti
nal w
hich subsequently is com
bined w
ith apo-opsin to form
 
a new
 chrom
ophore. Panel C. D
evelopm
ental and structural proteins. Three transcripti
on factors m
utated in non-syndrom
ic CD
s are CRX, N
R2E3 and RA
X2. 
O
ther proteins im
portant in the m
orphogenesis and structure of the cone photoreceptor cell are EYS, IM
PG
1, PRPH
2, PRO
M
1, and PCD
H
21. Panel D
. The 
phototransducti
on cascade in cone photoreceptor cells. U
pon acti
vati
on, am
plificati
on of the signal is m
ediated by the a-subunit of transducin and the 
a0- and ϒ-subunits of cone phosphodiesterase, encoded by PD
E6C and PD
E6H
. This results in closure of the cG
M
P-gated channel com
posed of CN
G
A
3 and 
CN
G
B3, a hyperpolarizati
on of the cell and a reducti
on in glutam
ate release at the synapti
c region. The KCN
V
2 gene encodes a voltage-gated potassium
 
channel subunit together w
ith other channel com
ponents and regulated the potassium
 current in the cell and aff
ects its excitability potenti
al. PD
E6 and 
transducin subunits are m
arked as alpha (a), alpha’ (a0 ), beta (b), and gam
m
a (ϒ). Panel E. CD
-associated proteins involved in transport processes in the 
cone photoreceptor cell. A
IPL1 is a chaperone of the putati
ve farnesylated protein PD
E6C. Farnesylated proteins are m
arked w
ith a red zig-zag icon. C8orf37, 
RA
B28, RIM
S1, and TU
LP1, based on im
m
unolocalisati
on studies, act predom
inantly in transport processes tow
ard and at the base of the connecti
ng 
cilium
, w
hereas RPG
R and RPG
RIP1 act throughout the connecti
ng cilium
. U
N
C119 is responsible for ciliary delivery of m
yristoylated proteins as w
ell as 
the dissociati
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Figure 11
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Figure 12: Schematic representation of three major processes in human rod photoreceptor cells and 
the RPE. Upper panel: The retinoid cycle taking place in rod photoreceptor cells (PC) and the RPE. 
Upon photactivation, 11-cis-retinal is converted into all-trans-retinal and dissociates from activated 
rhodopsin. The all-trans-retinal is then recycled to produce more 11-cis-retinal via several enzymatic 
steps in the RPE. ABCA4 mediates transport of all-trans-retinal to the outside of the photoreceptor 
outer segment disks. The localization and function of proteins involved in AR and XL nonsyndromic 
retinal dystrophies are depicted, with the exception of GCAP, a critical Ca2+-binding interactor of 
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GUCY2D, which is mutated in autosomal dominant CRD (http://www.sph.uth.tmc.edu/Retnet/
home.htm). CRALBP, protein product of RLBP1; IRBP, protein product of RBP3; RAL, retinal; RE, 
retinyl esters; RHOa, photoactivated rhodopsin; ROL, retinol. Middle panel: The phototransduction 
cascade in rod PCs. Upon photoactivation, amplification of the signal is mediated through the 
α-subunit of transducin and phosphodiesterase, which results in closure of the cGMP-gated channel, 
hyperpolarization of the cell, and reduced glutamate release at the synapse. SAG, arrestin. Lower 
panel: Ciliary transport along the connecting cilium. Kinesin II family motors mediate transport 
toward the outer segments; cytoplasmic dynein 2/1b (DYNC2H1) is involved in transport processes 
from the outer segments toward the inner segments. The precise roles of CEP290, Lebercilin, RPGR, 
RPGRIP1, and RP1 in ciliary transport processes are not yet known. AIPL1 (not indicated in this 
figure) is a chaperone for proteins that are farnesylated. For IDH3B and PRCD, the exact cellular 
functions are not known. ADAM9, MERTK, and RGR are secreted by the RPE and localize in the 
interphotoreceptor matrix. The CNGA3, CNGB3, GNAT2, and PDE6C genes are specifically expressed 
in cone PCs and therefore not indicated in this figure. At the right side, a Müller cell (MC) connects to 
the photoreceptor cell with the transmembrane protein CRB1. Usherin, protein product of USH2A. 
Adapted from Den Hollander et al, 2011 [20].
Classification of retinal dystrophies 
There are several types of retinal dystrophies, representing a spectrum of 
cone-dominated (e.g. cone dystrophy, achromatopsia) or rod-dominated 
disorders (e.g. retinitis pigmentosa), and disorders that can show as either 
cone- or rod-dominated (e.g. Leber congenital amaurosis). In addition, the 
sub-classification is based on age of onset, clinical characteristics, and the natural 
course of disease. 
Rod-cone dystrophies
Rod-cone dystrophies includes mainly the spectrum of all retinitis pigmentosa 
(RP) entities. RP comprise the most widely recognized group of patients with 
inherited retinal disorders, with a worldwide prevalence of 1:4000 [21]. It should 
be regarded as a phenotypic description of several related dystrophies of the 
photoreceptors and the RPE. All Mendelian patterns of inheritance have been 
found in these disorders. Patients with X-linked RP (5-15% of RP patients) have a 
more severe disease course compared to patients with autosomal recessive RP 
(50-60% of RP patients), and RP patients with an autosomal dominant inheritance 
(30-40% of RP patients), have the best long-term prognosis according to a spared 
central vision [16, 22, 23]. 
By definition, RP is a progressive disorder. Both rod and, in most types, cone 
photoreceptors are affected early in the course of disease. Eventually, loss of 
photoreceptor elements leads to widespread atrophy of most of the retinal layers. 
Although the clinical findings may be highly variable, these patients typically 
demonstrate night blindness, difficulty with dark adaptation and progressive loss 
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 24
24
Chapter 1
of the peripheral visual field early in the course of their disease. The characteristic 
ophthalmoscopic findings of this retinopathy include hyperpigmentation in the 
form of “bone spicules” that alternate with atrophic regions, attenuation of retinal 
arterioles, and waxy pallor of the optic nerve head. The ERG is the most critical 
diagnostic test for RP because it provides an objective measure of rod and cone 
function across the retina. The full-field ERG typically shows a marked reduction of 
both rod- and cone-mediated responses, although rod loss predominates. In the 
later stages of the disease, cone and rod tracings often become non-recordable 
[24, 25]. Visual field testing is useful for follow-up care of patients with RP and 
typically starts with isolated scotomas in mid-peripheral zones, which progressively 
coalesce to form a partial or complete ring scotoma [21, 26-29].
RP is usually isolated, but may occur as a part of a syndrome. Some of the 
well-known syndromes include: Usher syndrome, Bardet-Biedl syndrome, 
Senior-Loken syndrome, abetaproteinemia (Bassen-Kornzweig syndrome), 
peroxisomal disorders (e.g. Zellweger syndrome or Refsum disease), and 
mitochondrial disorders (e.g. Kearns-Sayre, or Maternally Inherited Diabetes and 
Deafness, abbreviated as “MIDD”). 
Besides the large group that is referred to as RP, a few other peripheral retinal 
degenerations with primarily or initial involvement of rod photoreceptors have 
been discerned. These diseases, such as Bietti crystalline dystrophy, gyrate 
atrophy and choroideremia, all display a unique fundus appearance that enables 
a separate clinical classification. In addition, RP seems to be one of the most 
common underlying diseases in patients with secondary retinal vasoproliferative 
tumors [30].
Cone and cone-rod dystrophies
In general, cone dystrophy (CD) presents in the 2nd decade of life. Symptoms are 
pronounced photophobia, day blindness and progressive loss of visual acuity. 
Color vision abnormalities, commonly of the red-green type, are present at an 
early disease stage. A subtle nystagmus can be noticed in these patients. Fundus 
abnormalities include mostly a bull’s eye maculopathy, or granular pigment 
alterations in the posterior pole. Rarely, a central atrophy of RPE with exposure 
of the larger choroidal vessels may be found. Visual field testing shows central 
scotomas, sometimes with relative central sparing; the peripheral visual field 
remains unaffected. The ERG shows loss of the cone-mediated responses with 
normal rod-mediated responses. A substantial number of patients that are initially 
diagnosed with progressive CD will eventually progress to a cone-rod dystrophy 
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(CRD), with abnormalities in the rod mediated ERG recordings and mostly night 
blindness. Many cases of progressive CD are sporadic. In patients with a family 
history, autosomal dominant inheritance is most common, although autosomal 
recessive and X-linked forms may occur [31, 32]. 
In patients with CRD, the rod photoreceptors are also affected, but their 
symptoms are overshadowed by the abnormalities of the cones, especially in the 
early stages of the disorder. The initial symptoms therefore resemble progressive 
CD and most patients do not develop night blindness until the later stages of 
disease. In addition to the macular abnormalities described in CD, midperipheral 
fundus abnormalities could be observed, indicative of a more widespread retinal 
degeneration. These abnormalities include mild attenuation of the retinal vessels, 
and mild bone spicules or dust-like pigmentations. Atrophy of the RPE may occur 
in the macula, but may extend beyond the vascular arcades. Initially, the visual 
field demonstrates a central scotoma; eventually, partial ringscotomas and large 
paracentral scotomas may be found, as well as mild peripheral constriction. The 
ERG is crucial in the diagnosis and typically shows a more severe reduction in 
cone-mediated responses compared with rod-mediated responses. Nevertheless, 
some patients demonstrate equally reduced cone and rod ERG recordings, despite 
an otherwise typical presentation. Most cases with CRD are either isolated or 
inherited in an autosomal recessive fashion, but all inheritance patterns have 
been identified [32-36]. 
Macular dystrophies
A variety of dystrophies, principally located at the macula, can be distinguished 
according to fundus appearance and inheritance pattern. Despite the term 
“macular dystrophies”, which suggest localized pathology, many of these disorders 
are at a molecular level panretinal diseases, in which the macular region shows 
greater susceptibility to the degeneration. This can be argued for Stargardt disease 
(STGD1), as well for Best disease, where the EOG abnormalities also indicate a 
more widespread retinal dysfunction [37]. The majority of the macular dystrophies 
demonstrate an autosomal inheritance, with X-linked juvenile retinoschizis and 
STGD1 as the most important exceptions. Among the most renowned autosomal 
dominant macular dystrophies are Best disease (vitelliform macular dystrophy), 
adult-onset vitelliform macular dystrophy, the pattern dystrophies, autosomal 
dominant drusen, central areolar choroidal dystrophy (CACD), and Sorsby fundus 
dystrophy. Although these disorders are all characterized by loss of central vision 
and atrophy of the macula and underlying RPE, they are highly heterogeneous 
with regard to the clinical findings and the underlying genetic cause [38, 39]. 
I will continue on the most common macular dystrophy: Stargardt disease (STGD1). 
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1.2 Introduction to Stargardt disease
Stargardt disease
History
The remarkable clinical variations of macular dystrophies were already noted 
in 1917 by Karl B. Stargardt (1875-1927). He proposed to separate these 
clinical entities into different groups, based on the clinical presentation and 
ophthalmoscopic appearance [40]. 
Eight years earlier (1909), he described the clinical features in seven patients at 
ages 12-20 years, from two families. The disease was coined Stargardt disease, and 
initially was also known as fundus flavimaculatus. The patients had good vision in 
early childhood, but had progressive loss of central vision between the age of 
8 and 15 years. In the posterior pole, slight pigment changes with yellow-white 
spots were observed, and a fairly well-defined, central atrophic lesion. In some 
patients, a broad ring of several yellow-white spots evolved around this area. 
Retinal vessels and retinal periphery remained quite normal. In Figure 13 and 14, 
fundus images of two Stargardt patients, drawn and described by Karl Stargardt 
in 1909 are depicted [41]. 
Figure 13: Fundus drawing of Stargardt disease patient. This girl 
started to have complaints of visual loss at the age of 14 years. 
At the age of 20 years, she had a visual acuity of 0.08 (right eye), 
and  0.16 (left eye). In the macula were grayish-yellow flecks 
were described with pigment lesions. Near the arteries and vena 
temporalis inferior, some little yellow-white flecks were seen.
Figure 14: Fundus drawing of Stargardt disease patient. This 
boy started to have complaints of visual loss at the age of 
13 years. At the age of 18 years, he was only able to reach a 
visual acuity of finger counting at 4 meters. With fundoscopy, a 
grayish heart-shaped lesion with a quite sharp border was seen. 
Near this lesion and the optic nerve, there were lots of small, 
yellow-white flecks. 
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Clinical characteristics
Presently, STGD1 is the most prevalent inherited disease that causes visual 
impairment in childhood and young adults, with an estimated prevalence of 
1:10,000 [42]. It is an autosomal recessive retinal dystrophy due to mutations 
in the ABCA4 gene [43]. Both sexes are equally affected. The disease typically 
presents within the first two decades of life, even though initial symptoms can also 
appear as late as the seventh decade. It is typically characterized by a progressive 
bilateral loss of central vision causing blurry vision. Peripheral vision is usually 
unaffected. Most patients also have impaired color vision. Photophobia may be 
present. A timeline of three STGD1 patients are reported in Figure 15. 
However, STGD1 has a wide clinical heterogeneity. Ranging from an early age of 
onset with a cone-rod phenotype in progressed disease, to a late disease onset 
with a foveal sparing phenotype [44, 45]. As a consequence, STGD1 patients could 
present with a range of phenotypes at consultation to an ophthalmologist. In 
Figure 16, several STGD1 patients are described with a wide clinical heterogeneity. 
In recent years, considerable advances have been made in our understanding of 
the clinical phenotypes, natural history and molecular genetics of STGD1. Due to 
the phenotypic spectrum, several classifications have been proposed. Van Driel 
et al. (1998) and Maugeri et al. (1999) first proposed a classification based on the 
expected residual function of the ABCA4 protein by the severity of mutations, 
extending the putative associations of ABCA4 mutations from the presumed 
mildest phenotype of age-related macular degeneration (one ABCA4 variant) to 
more severe phenotypes such as cone-rod dystrophy and RP, the latter carrying 
two severe ABCA4 variants (see Figure 17) [46, 47]. The AMD-association [48, 49] 
in later studies has not been confirmed [50, 51].
Fishman et al. (1999) differentiated three clinical phenotypes: 1) an 
atrophic-appearing macular lesion with localized perifoveal flecks, 2) diffuse 
flecks, and 3) extensive atrophic-appearing changes of the retinal pigment [52]. 
Lois et al. recognized three patterns based on electrophysiological attributes: 
1) severe pattern ERG abnormality with normal scotopic and full-field ERGs, 2) 
additional loss of photopic function, and 3) loss of both photopic and scotopic 
function [53]. 
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Figure 15: Tim
eline of three typical STG
D
1 cases.
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Figure 16: Retinal imaging from five different STGD1 cases with a wide clinical heterogeneity. 
Images contains (from left to right) Color fundus photo, Fundus autofluorescence, and OCT-scan. 
Best corrected visual acuity (BCVA) is given in Snellen.
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A: A 7-year-old boy with complaints of decrease of visual acuity. Imaging from first visit; no 
abnormalities were shown in color fundus photo or autofluorescence, but on OCT a thickened ILM was 
noticed (orange arrow). BCVA 0.6 in both eyes. STGD1 was diagnosed 2 years later, confirmed with 
2 ABCA4 mutations (c.2947A>G (p.(Thr983Ala)); c.5461-10T>C (p.[Thr1821Valfs, Thr1821Aspfs])).
B:A young woman from 21 years old, start to have complaints of visual loss at age 16 years. Central 
choroiretinal atrophy with central to midperipheral lipofuscine flecks is seen on fundus photography. 
Her visual acuity was 0.1. Two ABCA4 mutations were detected: c.2588G>C (p.[Gly863Ala, 
Gly863del]) and c.768G>T (p.Val256=).
C: A 40-year-old woman started to have visual acuity complaints at 24 years. Images are not showing 
the “typical” fundus flecks diffuse in macula or midperiphery, but central choroiretinal atrophy 
surrounding with just some lipofuscine flecks. Het visual acuity was 0.2 in both eyes. Only 1 ABCA4 
mutation was found: c.1822T>A (p.(Phe608Ile)). No mutations in other genes could be detected. 
D: A woman at age 66 years old. She started to have complaints of visual loss at 18 years. Images 
showing chorioretinal atrophy of the macula to midperipheral. BCVA was hand movement at 3 
meter. Two ABCA4 mutations were found: c.5381C>A (p.(Ala1794Asn)) and c.4539+2001G>A (p?).
E: A 49-years-old man, started to have visual complaints at age 44. Imaging present the typical 
pisciform fundus flecks in macula and midperiphery. Central choroiretinal atrophy, but with a spared 
foveal island, as confirmed at OCT-scan. Visual acuity was 1.0 in both eyes. Diagnose was confirmed 
with two ABCA4 mutations: c.5461-10T>C (p.[Thr1821Valfs, Thr1821Aspfs]) and c.4685T>C 
(p.(Ile1562Thr)).
Figure 17: Initial genotype-phenotype correlation model based on the severity of ABCA4 variants.
Unfortunately, in clinical settings, despite these well-defined classifications, it may 
happen that patients get several diagnoses because of different stages of disease 
during life. For example, based on the classification of Lois et al, patients may 
get the diagnosis “cone dystrophy” and may develop during life to a “cone-rod 
dystrophy”. Furthermore, the present classifications offer an “in time” diagnosis, 
instead of a single diagnosis that is informative with respect to clinical course, 
which could help the patient to answer personal questions, like:  “Am I able to 
continue my present work for the next 10 years?”, or “Am I able to see my children 
growing up?” etcetera. Currently, the ophthalmologist identifies a variety of 
phenotypes of STGD1, and it is hard to provide good counseling. 
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ABCA4 Function
STGD1 has only been associated with variants in the ATP-binding cassette 
transporter type A4 (ABCA4) gene [43] which encodes a multidomain 
transmembrane protein located at the rim of the disc membrane in the outer 
segment of photoreceptors [54, 55] (Figure 18A). Low expression of this gene 
has also been found in keratinocytes, fibroblasts and recently in human and 
murine RPE [56, 57]. ABCA4 acts as a flippase for 11-cis and all-trans isomers 
of N-retinylidene-phosphatidylethanolamine across disc membranes, thereby 
facilitating the removal of retinal products from the disc membranes and 
preventing the accumulation of potentially toxic bisretinoid compounds (e.g. A2E) 
in photoreceptor and RPE cells (Figure 18B). The visual cycle in STGD1 is depicted 
in Figure 19.
Figure 18. Protein domain structure and function of ABCA4. A. Topological model for the 
ABCA4 protein. (ECD) exocytoplasmic domain; (H1 or H2) first transmembrane segment; (TMD) 
transmembrane domain; (NBD) nucleotide binding domain. The two Walker motifs (A and B) and 
the C region which lies between them are the hallmark of ABC transporter superfamily members. 
Figure  adapted with permission from Bungert et al. 2001 [58]. B. Proposed function of the ABCA4 
protein. A. All-trans-retinal is released by the photoactivated rhodopsin. B. All-trans-retinal 
enters the hydrophobic disc membrane (DM) and reacts to form a Schiff base with the amine of a 
phosphatidylethanolamine (PE), a phospholipid found on the DM outer segment. C. All-trans-retinal 
or the N-retinylidene-PE complex is transported by ABCA4 to the cytoplasmic side. All-trans-retinal 
is then reduced by all-trans-retinol dehydrogenase and transported to the RPE (not shown). (PM) 
plasma membrane.
Missing heritability in STGD1
Until recently, approximately 25% of STGD1 patients were missing a complete genetic 
diagnosis. The majority of whom only carries one pathogenic ABCA4 variant. This 
large number of mono-allelic STGD1 patients is larger than for any other monogenic 
retinal dystrophy. This was consistently observed in many studies regardless the ethnic 
background of the patients [59-66], which argues against genetic heterogeneity of 
STGD1. The missing heritability for STGD1 could be explained by: 
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STGD1-like phenotypes due to mutations in other genes
Before the causing gene of STGD1 was elucidated, all Stargardt-like phenotypes 
were called: “Stargardt disease”. With techniques to find the underlying genes, 
scientists were able to differentiate four types of Stargardt-like diseases. Therefore, 
the “1” in STGD refers to the causing ABCA4 mutations in what we know presently 
as Stargardt disease. Variants in peripherin 2 (PRPH2) have been associated 
with autosomal dominant multifocal pattern dystrophy, but also were found in 
genetically unsolved STGD patients. The variable expressivity and penetrance of 
the PRPH2 variants combined with the peculiar type and distribution of the flecks, 
strongly resembling the ones observed in the fundus flavimaculatus phenotype 
of STGD1, are the two major causes for misdiagnosis [67]. STGD3 is caused by 
variants in ELOVL4 (elongation of very long chain fatty acids protein 4) gene, and 
STGD4 is associated with variants in the PROM1 (prominin 1) gene. STGD3 and 
STGD4 are well known to be associated with rare autosomal dominant forms of 
Stargardt-like dystrophies [68-70]. 
Figure 19: Visual cycle in STGD1. Adjusted from Sears AE, Bernstein PS, Cideciyan AV, et al. Towards 
Treatment of Stargardt Disease: Workshop Organized and Sponsored by the Foundation Fighting 
Blindness [13]
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To date, modifiers associated with STGD1 have not been reported. However, since 
a synergistic effect of pathologic ABCA4 sequence variations with an autosomal 
dominant form of Stargardt disease (STGD3) has already been demonstrated [71], 
it is very likely that variants in other genes may play a role in ABCA4-associated 
disease and contribute to ameliorating or worsening the clinical outcome of the 
disease.
Structural variations 
Heterozygous deletions or duplications spanning one or more ABCA4 exons will not 
be detected using standard PCR-based mutation analyses methods and therefore 
may explain a percentage of the unsolved STGD1 cases. Likewise, inversions and 
sizeable insertions also would be missed. Currently, only a few studies reported 
on a systematic analysis of copy-number variants (CNVs) in ABCA4, either by 
Southern blot analysis [47, 72] or by NGS [73]. CNVs were detected only in a 
very small proportion (~1%) of STGD1 cases and it therefore has been generally 
accepted that they do not represent a major cause of missing heritability.
Misinterpreted variants 
Non-canonical splice site (NCSS) variants are exonic or intronic variants located at 
the splice donor sites (SDSs) or splice acceptor sites (SASs). Intronic NCSS variants 
are mostly situated at positions +3 to +6 downstream of exons or at positions 
-14 to -3 upstream of exons. Exonic NCSS variants almost invariably are found 
within the first or the last two nucleotides of an exon [74]. These variants are 
often overlooked, their effect on splicing is not assayed and often classified as 
variants of unknown significance (VUS) or even non disease-causing. 
Synonymous variants, which usually occur in the third base of a codon, can be 
misinterpreted as they do not alter the protein sequence. However, only a few 
synonymous variants have been predicted to alter the strength of the splice site 
identified and/or to be significantly enriched in STGD1 patients [75, 76].
Frequent coding variants 
Coding variants having a high allele frequency (AF) in healthy persons could 
be incorrectly deemed not to be associated with the disease. Even though 
rare genetic disorders usually are due to unique sequence changes, there are 
exceptions. Variants with an AF ≥0.01 are normally discharged from further 
analyses, but a comparison of the carrier frequency between non-affected and 
affected individuals may still suggest a possible role for these variants in disease 
[77]. For example, the ABCA4 variant c.5603A>T (p.Asn1868Ile) was previously 
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considered benign due to the high AF of 0.066 in the non-Finnish European 
population (http://gnomad.broadinstitue.org). In a recent study of Zernant et al 
(2017), this common variant accounted for 15% of the ABCA4 alleles in STGD1 
patients, which was three to four times more frequent than expected [78].
Non-coding variants 
A major fraction of deleterious variants could be located in the non-coding 
sequences of ABCA4, constituting 94.5% of the 128-kb sized gene, and therefore 
cannot be detected by exonic sequencing. Unraveling the role of deep-intronic 
variants in human disease-associated genes is a recent research field, and for 
STGD1 the first work that clearly aimed to identify and functionally prove the effect 
of novel non-coding variants in ABCA4 was published in 2013 [79]. By performing 
haplotype analysis in a group of 28 unrelated mono-allelic STGD1 probands, 
Braun and colleagues identified three ABCA4 haplotypes (H1-3) shared among 
ten families. The fact that 64% of the unsolved samples shared no haplotype and 
that not more than four patients shared the same disease-haplotype, suggested 
that highly recurrent deep-intronic variants were not present among unsolved 
STGD1 patients. Deep sequencing of mRNA extracted from human donor retina 
showed that 5% of ABCA4 transcripts carried minor alternate exons, each 
observed in less than 1% of the total mRNA. Sequencing of genomic regions 
containing these alternate exons in the 28 unsolved STGD1 patients revealed five 
deep-intronic variants (c.5196+1137G>A, c.5196+1216C>A, c.5196+1056A>G, 
c.4539+2001G>A, c.4539+2028C>T) some of which were located in splice sites 
or the predicted alternate exons. All variants were present in trans with the first 
pathogenic ABCA4 variant in unsolved patients. The effect of c.5196+1137G>A, 
c.5196+1216C>A and c.5196+1056A>G variants was tested by employing RNA 
from patient-derived keratinocytes and RT-PCR studies revealed the generation of 
pseudoexons (PEs) in intron 36, while for c.4539+2001G>A and c.4539+2028C>T, 
functional studies were not performed. Although this was not a systematic 
analysis of non-coding variants, it paved the way for more complete studies of 
non-coding elements in ABCA4 [73]. 
The predicted ABCA4 promoter sequence has been investigated only in two 
studies [73]; Chapter 3.3), but to date the rare non-coding variants identified have 
not yet been further characterized [73].
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Quality of life in Stargardt disease patients
Currently, the quality of life is determined as a significant outcome for measuring 
the impact of disease, and for estimating the efficacy of treatment. Literature 
suggests that visual impairment is related to loss in quality of life [80-84]; visually 
impaired patients frequently have high levels of anxiety and periods of depression 
[82, 85, 86]. These patients are also at increased risk of accidental injuries, which 
can worsen existing chronic health conditions [87, 88]. Moreover, blindness is the 
third most feared of all chronic disorders, after cancer and AIDS/HIV, by Americans 
[89].
To date, quality of life studies which assess visual impairment are mainly focused 
on elderly patients, and many are not specified for retinal dystrophies [81, 88, 
90-93]. To our knowledge, besides from RP in general [94-99], we know little 
about the quality of life in patients with retinal dystrophies, for example STGD1. 
Knowledge of quality of life in STGD1 patients can gain insight about the impact 
of the disease on daily functioning. These data are important to provide outcome 
measures and indicators of cost effectiveness for emerging clinical trials, such 
as gene augmentation (trial number NCT01367444, NCT01736592), and small 
molecule drugs (trial number NCT02402660) [100, 101]. 
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1.3 Aims and outline of this thesis
STGD1 is one of the most common causes of blindness in young people. Clinically, 
the phenotype is extremely heterogeneous. Little is known about the natural 
course and staging of disease. No useful classification of subtypes is available and 
the underlying genetic causes have only been partially elucidated. Therefore, this 
thesis contains three main goals that are addressed in the following chapters: 
Chapter 2: To define subtypes and genotype-phenotype correlations through 
describing clinical characteristics of STGD1.
Chapter 3: Identification, registry and functional assessment of ABCA4 
variants.
Chapter 4: Information about quality of life in STGD1 patients. 
The overarching goal is to understand the natural course and staging of disease 
enabling the ophthalmologist a better counseling and to provide a more accurate 
diagnosis and prognosis for the patient. Furthermore, it is important to select 
uniform cohorts in upcoming and ongoing trials to provide correct outcome 
measurements.
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CHAPTER 2.1
Early-onset Stargardt disease: phenotypic and genotypic characteristics
“In its natural course, early-onset Stargardt disease initially presents with 
variable full-field electroretinographic abnormalities and funduscopic findings. 
As this retinal degeneration progresses, the spectrum of phenotypes eventually 
converges, causing profound chorioretinal atrophy and severe vision loss.”
Stanley Lambertus
Ramon A.C. van Huet
Nathalie M. Bax
Lies H. Hoefsloot
Frans P.M. Cremers
Camiel J.F. Boon
B. Jeroen Klevering
Carel B. Hoyng
Ophthalmology. 2015 Feb;122(2):335-44.doi: 10.1016/j.ophtha.2014.08.032.
The authors thank L. Ye, MD and P.J.M. van den Wittenboer, MD for their contribution, 
without which this study could not have been completed.
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OBJECTIVE: To describe the phenotype and genotype of patients with early-onset 
Stargardt disease.
DESIGN: Retrospective cohort study.
PARTICIPANTS: Fifty-one Stargardt patients with age at onset ≤10 years.
METHODS: We reviewed patient medical records for age at onset, medical 
history, initial symptoms, best-corrected visual acuity (BCVA), ophthalmoscopy, 
fundus photography, fundus autofluorescence (FAF), fluorescein angiography 
(FA), spectral-domain optical coherence tomography (SD-OCT), and full-field 
electroretinography (ffERG). The ABCA4 gene was screened for mutations.
MAIN OUTCOME MEASURES: Age at onset, BCVA, fundus appearance, FAF, FA, 
SD-OCT, ffERG, and presence of ABCA4 mutations.
RESULTS: The mean age at onset was 7.2 years (range, 1–10). The median times 
to develop BCVA of 20/32, 20/80, 20/200, and 20/500 were 3, 5, 12, and 23 
years, respectively. Initial ophthalmoscopy in 41 patients revealed either no 
abnormalities or foveal retinal pigment epithelium (RPE) changes in 10 and 9 
patients, respectively; the other 22 patients had foveal atrophy, atrophic RPE 
lesions, and/or irregular yellow-white fundus flecks. On FA, there was a “dark 
choroid” in 21 out of 29 patients. In 14 out of 50 patients, foveal atrophy occurred 
before flecks developed. On FAF, there was centrifugal expansion of disseminated 
atrophic spots, which progressed to the eventual profound chorioretinal atrophy. 
Spectral-domain OCT revealed early photoreceptor damage followed by atrophy 
of the outer retina, RPE, and choroid. On ffERG in 26 patients, 15 had normal 
amplitudes, and 11 had reduced photopic and/or scotopic amplitudes at their first 
visit. We found no correlation between ffERG abnormalities and the rate of vision 
loss. Thirteen out of 25 patients had progressive ffERG abnormalities. Finally, 
genetic screening of 44 patients revealed ≥2 ABCA4 mutations in 37 patients and 
single heterozygous mutations in 7.
CONCLUSIONS: In early-onset Stargardt, initial ophthalmoscopy can reveal no 
abnormalities or minor retinal abnormalities. Yellow-white flecks can be preceded 
by foveal atrophy and may be visible only on FAF. Although ffERG is insufficient 
for predicting the rate of vision loss, abnormalities can develop. Over time, visual 
acuity declines rapidly in parallel with progressive retinal degeneration, resulting 
in profound chorioretinal atrophy. Thus, early-onset Stargardt lies at the severe 
end of the spectrum of ABCA4-associated retinal phenotypes.
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Introduction
Stargardt disease (STGD1) is the most prevalent inherited juvenile-onset retinal 
dystrophy, with a mean age at onset of 15.2 years.1,2 The inheritance pattern of 
STGD1 is autosomal recessive, and the disease is characterized by the presence of 
irregular yellow-white fundus flecks in the posterior pole.2–4 Over time, the disease 
progresses to include macular depigmentation and chorioretinal atrophy. Typical 
STGD1 patients have normal—or near-normal—panretinal cone and rod function 
on full-field electroretinography (ffERG); however, progressive abnormalities in 
photopic and scotopic amplitudes have been reported.5–7 Blockage of choroidal 
fluorescence (the so-called dark choroid sign) on fluorescein angiography is 
present in 80% of STGD1 patients.8–10 The aforementioned yellow-white fundus 
flecks are hyperautofluorescent on fundus autofluorescence (FAF), presumably 
owing to an accumulation of lipofuscin fluorophores in the retinal pigment 
epithelium (RPE).11,12 Spectral-domain optical coherence tomography (SD-OCT) 
can reveal changes in the outer nuclear layer, as well as photoreceptor loss, RPE 
abnormalities, and a general thinning of the retina.13
Mutations in the ABCA4 gene have been associated with a spectrum of retinal 
diseases ranging from mild phenotypes (e.g., late-onset STGD1 with relatively 
preserved visual function) to severe, early-onset retinitis pigmentosa accompanied 
by a rapid loss of central and peripheral photoreceptors.14–16 The ABCA4 gene 
encodes the retinal-specific ATP-binding cassette transporter (ABCR).17ABCA4 
is expressed in both cones and rods. In rod cells, the ABCR protein is localized 
at the rim of the outer segment discs, where ABCR transports all-trans-retinal 
from the lumen of the outer segment disc to the cytoplasm of the photoreceptor 
cell.18 The accumulation of all-trans-retinal—and its toxic derivatives—eventually 
results in the death of RPE cells and photoreceptor cells.19–21 The ABCA4 gene 
has high mutation heterogeneity; >700 distinct mutations have been identified to 
date, with a wide range of effects on ABCR protein function. A model to correlate 
the phenotype with the functional severity of the ABCA4 mutation has been 
proposed.22,23 According to this model, STGD1 results from mild to moderate 
ABCR impairment.
Among patients who are diagnosed with STGD1, the disease has remarkably 
wide clinical variability with respect to the general course of the disease, the 
retinal features, and the electrophysiologic findings.5,8,14,15 Stargardt disease has 
both genetic and clinical overlap with cone–rod dystrophy, and this may cause 
confusion among general ophthalmologists; indeed, diagnosing STGD1 can be 
challenging at an early age. Therefore, obtaining an accurate description of the full 
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spectrum of ABCA4-associated retinal dystrophies—including STGD1—is essential 
for providing appropriate patient counseling and adequate disease management, 
and may have important implications for selecting patients to participate in gene 
therapy trials. Although clinical features of STGD1 patients with a very young 
onset have been described in heterogeneous cohorts,5,7,24,25 there is lack of 
studies concerning the natural history of these patients. Herein, we have provided 
a comprehensive description of the initial and longitudinal clinical and genetic 
characteristics of a large number of patients with early-onset Stargardt, which we 
defined as an age at onset ≤10 years.
Methods
Patients and Genetic Analysis
The database of the Department of Ophthalmology at Radboud university 
medical center (Nijmegen, The Netherlands) contains 426 patients with a clinical 
diagnosis of STGD1. For 258 of these patients, the ABCA4 gene was analyzed 
by the Department of Human Genetics at Radboud university medical center 
(Nijmegen, The Netherlands). Known mutations were screened using the 
arrayed-primer extension microarray (Asper Biotech, Tartu, Estonia), and exon 
duplications and/or deletions were detected using multiplex ligation-dependent 
probe amplification (MRC-Holland P151/P152). If no mutations or only a single 
heterozygous mutation was identified, the exons and intron–exon boundaries 
were sequenced using the Sanger method to screen for mutations in the other 
allele. All identified mutations were confirmed using Sanger sequencing. In total, 
199 patients contained ≥1 mutation in the ABCA4 gene. Age at onset of disease 
was defined as the age at which symptoms were first noticed by the patient. If this 
information was not available, we used the patient’s age at which he or she first 
visited an ophthalmologist.
In this study, we included 51 patients with an age at onset of ≤10 years and one 
of the following criteria: ≥2 ABCA4 mutations (n = 37); 1 ABCA4 mutation and the 
presence of yellow-white flecks (n = 7); or in the absence of ABCA4 analysis, the 
presence of yellow-white flecks, and either a dark choroid or an atrophic macular 
lesion (n = 7).
This study was approved by the Institutional Ethics Committee and was performed 
in accordance with the Declaration of Helsinki. All patients provided informed 
consent before giving a blood sample and receiving additional ophthalmologic 
examinations.
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Clinical Evaluation
We defined the duration of disease as the time interval between the patient’s 
age at onset (defined as described) and the age at the last visit. Best-corrected 
visual acuity (BCVA) was measured using a Snellen chart, then transformed into 
the logarithm of the minimum angle of resolution (logMAR) for subsequent 
analysis. A logMAR value of 1.9, 2.3, or 2.7 was assigned to the patient’s ability to 
count fingers, detect hand movements, or perceive light, respectively.26 Fundus 
characteristics were documented for 41 patients using fundus photography 
(Topcon TRC-50IX, Topcon Corporation, Tokyo, Japan). Fundus autofluorescence 
was performed in 32 patients using a confocal scanning laser ophthalmoscope 
(cSLO; Spectralis, Heidelberg Engineering, Heidelberg, Germany) fitted with an 
optically pumped solid-state laser (488-nm excitation). Atrophic chorioretinal 
lesions outside the fovea were stratified into 2 groups: (1) A patchy pattern 
consisting of mild disseminated hypoautofluorescent spots and (2) sharply 
demarcated chorioretinal atrophic lesions with an absence of autofluorescence; 
the extent of these lesions was then classified as either (1) lesions that were limited 
to the posterior pole, or (2) lesions that extended beyond the vascular arcades. 
Cross-sectional images were obtained for 30 patients using SD-OCT (Spectralis, 
Heidelberg Engineering). Fluorescein angiography (Topcon TRC-50IX, Topcon 
Corporation; Spectralis, Heidelberg Engineering) was performed in 32 patients to 
determine the presence or absence of the “dark choroid” sign. Full-field ERG was 
performed in 43 patients in accordance with the guidelines established by the 
International Society for Clinical Electrophysiology of Vision (ISCEV)27 using either 
Dawson-Trick-Litzkow electrodes or contact lens electrodes together with the 
RETI-port system (Roland Consults, Stasche & Finger GmbH, Brandenburg an der 
Havel, Germany). Dawson-Trick-Litzkow and contact lens electrodes have similarly 
high signal stability.28 Based on the ffERG results, the patients were assigned to 3 
groups as described previously5: Group 1 consisted of patients with normal ffERG 
amplitudes, group 2 consisted of patients with reduced photopic amplitude (<5% 
of normal range, <78 μV [B-wave]) and normal scotopic amplitude, and group 
3 consisted of patients with reduced photopic and scotopic amplitudes (<5% of 
normal range, <263 μV [B-wave]).
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Statistical Analysis
Data were analyzed using SPSS version 20.0 (IBM Corp, Armonk, NY). Kaplan-Meier 
“survival” curves were used to analyze the interval between the age at onset and 
the age at which the following endpoints were achieved: Mild visual impairment 
(≥0.2 logMAR; Snellen ≤20/32), moderate visual impairment (≥0.6 logMAR; 
Snellen ≤20/80), severe visual impairment (≥1.0 logMAR; Snellen ≤20/200), and 
blindness (≥1.4 logMAR; Snellen ≤20/500).29 Cox regression analysis was used to 
compare the ffERG groups. Differences with a P value of ≤0.05 were considered 
significant.
Results
Initial Clinical Characteristics
A total of 51 patients (28 men and 23 women) were included in this study. The 
mean (± standard deviation) age at onset was 7.2 (±2.2) years (median, 8; range, 
1–10).
Visual Acuity
In each case, the initial symptom of the disease was a decline in visual acuity noticed 
by the patient, the patient’s parents, or the school physician. Where available (n 
= 41 patients), the mean BCVA at the first visit to an ophthalmologist was 0.51 
(±0.36) logMAR (median, 0.48; range, 0–1.15), Snellen 20/65. In 13 patients, the 
vision loss was initially unexplained. Six of these 13 patients were diagnosed with 
functional vision loss, and 6 other patients were diagnosed initially with cone–rod 
dystrophy. Of the 51 patients, 22 were diagnosed with STGD1 ≥3 years after the 
initial symptoms appeared (range, 3–30).
Retinal Features
Ophthalmoscopy performed at the first visit revealed no retinal abnormalities 
in 10 out of 41 patients. Nine additional patients had foveal RPE changes, and 
the remaining 22 patients had foveal atrophy, atrophic RPE lesions that were not 
limited to the fovea, and/or irregular yellow-white fundus flecks. Fluorescein 
angiography in 29 patients revealed an absence of choroidal fluorescence 
(the so-called dark choroid) in 21 patients. In patient 4, FAF revealed subtle 
hyperautofluorescence of the fovea, and SD-OCT revealed thickening of what 
appeared to be the external limiting membrane (Fig 1A
1,2,3
). One year later, this 
patient developed several small parafoveal hyperautofluorescent flecks with no 
apparent abnormalities on ophthalmoscopy (Fig 1B2).
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Electrophysiologic Findings
At their first visit, ffERG data were collected for 26 patients, and the patients were 
classified based on their findings. Group 1 (patients with normal photopic and 
scotopic amplitudes) contained 15 patients (58%), group 2 (patients with reduced 
photopic amplitude and normal scotopic amplitudes) contained 4 patients (15%), 
and group 3 (patients with reduced photopic and scotopic amplitudes) contained 
6 patients (23%). One patient could not be classified into 1 of these 3 groups 
because only the scotopic amplitudes were reduced moderately, although no 
pigmentary retinopathy was observed. We found no correlation between the 
ffERG group classification at the first visit and progression toward mild visual 
impairment (P = 0.485), moderate visual impairment (P = 0.309), severe visual 
impairment (P = 0.203), or blindness (P = 0.647).
Figure 1. Retinal imaging of patient 4 (age at onset, 6 years; best-corrected visual acuity, 0.24 
logarithm of the minimum angle of resolution; Snellen 20/35; ABCA4 genotype: p.Thr983Ala 
and c.5461-10T>C (p.?)) at 7 (A1,2,3) and 8 (B1,2,3) years of age. Initially, only subtle foveal 
hyperautofluorescence was present (A2); 1 year later, small parafoveal hyperautofluorescent flecks 
were present (the arrow in B2), despite a lack of apparent abnormalities on ophthalmoscopy. 
Spectral-domain optical coherence tomography (SD-OCT) revealed foveal thickening of the band 
representing the external limiting membrane (the arrows in A3–B3). FAF = fundus autofluorescence.
Natural Course
The mean disease duration was 17.1 (±14.5) years (median, 11; range, 0–56). 
The follow-up period ranged from a single examination in 3 patients to 47 years 
(mean, 12.4±12.6; median, 9). The clinical and genetic characteristics of the 
patient cohort at the last examination are summarized in Table 1.
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BCVA
 = best-corrected visual acuity; CF = counti
ng fingers; del = deleti
on; dup = duplicati
on; ff
ERG
 = full-field electroreti
nography; H
M
 = hand m
ovem
ents; 
logM
A
R = logarithm
 of the m
inim
um
 angle of resoluti
on; N
I = not identi
fied; N
P = not perform
ed.
*  A
ge, BCVA
, and ff
ERG
 at last exam
inati
on.
† The abbreviati
ons reflect the B-w
ave am
plitude: N
 = norm
al (equal to or above the low
er 5%
 of the range for a norm
al populati
on: photopic ≥78 μV, 
scotopic ≥263 μ
V
); M
R = m
oderately reduced (1%
-5%
 or norm
al range: photopic ≥69 μV
 and <78 μV, scotopic ≥195 μV
 and <263 μV
); SR = severely reduced 
(<1%
 of norm
al range, photopic <69 μ
V, scotopic <195 μV
); N
D
 = not detectable (flat am
plitudes).
‡ M
ean age at onset of the total cohort is used.
§ In the patient›s m
edical records fundus findings w
ere described “in accordance w
ith Stargardt,” but no detailed description or im
aging w
as m
ade and 
thus w
ere excluded from
 im
aging analysis .
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Visual Acuity
A survival analysis yielded a median interval and 95% CI between age at onset and 
a decline in BCVA to mild visual impairment, moderate visual impairment, severe 
visual impairment, and blindness of 3 (95% CI, 1.1–4.9), 5 (95% CI, 2.2–7.8), 
12 (95% CI, 9.3–14.7), and 23 (95% CI, 
13.2–32.8) years, respectively (Fig 2). 
Mean patient age at the last recorded visit 
was 24.9 (±14.0) years (median, 20; range, 
7–64), and mean BCVA was 1.29 (±0.58) 
logMAR (median, 1.15; range, 0.20–2.30), 
Snellen 20/386.
Figure 2. Kaplan-Meier curves showing the 
cumulative fraction in early-onset Stargardt 
with the following clinical endpoints: mild visual 
impairment (≥0.2 logarithm of the minimum angle 
of resolution [logMAR]; Snellen ≤20/32; triangle), 
moderate visual impairment (≥0.6 logMAR; Snellen 
≤20/80; square), severe visual impairment (≥1.0 
logMAR; Snellen ≤20/200; circle), and blindness 
(≥1.4 logMAR; Snellen ≤20/500; star). Censored 
observations are depicted as vertical bars.
Retinal Features
We observed irregular yellow-white fundus flecks in 47 out of 50 patients. These 
flecks were not always evident at the first examination, but they developed 
within an average of 2.9 (±4.1) years (median, 0; range, 0–17) of the first visit. The 
location of these flecks varied among the patients: In 10 patients, the flecks were 
present exclusively in the central macula; in 17 patients, the flecks were scattered 
throughout the posterior pole, but did not extend beyond the vascular arcades; 
and the remaining 20 patients presented with a fundus flavimaculatus pattern 
with numerous flecks in the central and mid-peripheral retina. Foveal atrophy was 
reported in 38 patients and occurred within 1.9 (±3.3) years (median, 0; range, 
0–13) of the initial visit. Finally, 14 patients developed foveal atrophy before the 
appearance of fundus flecks (Fig 3A1,2).
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Figure 3. Fundus photographs 
and autofluorescence (FAF) 
imaging of patient 37 (age at 
onset, 8 years; ABCA4 genotype: 
p.Phe608Ile and p.Gly1961Glu) 
at 15 (A1,2) and 22 years (B1,2) 
of age, showing isolated foveal 
pigment alterations and a 
hypoautofluorescent lesion 
(best-corrected visual acuity 
[BCVA], 0.52 logarithm of the 
minimum angle of resolution 
[logMAR], Snellen 20/66). Seven 
years later (B1,2), yellow-white 
parafoveal fundus flecks (the 
arrow in B2) developed (BCVA 1.15 
logMAR; Snellen 20/283).
Long-term follow-up data revealed that the initial foveal atrophy progressed 
to more widespread chorioretinal atrophy. Over time, FAF imaging revealed 
centrifugal expansion of disseminated spots in 30 out of 32 patients with a mean 
timeframe of 9.8 (±10.5) years (median, 8; range, 0–40; Fig 4B2). These spots 
extended beyond the vascular arcades in 24 of these 30 patients with a mean of 
11.2 (±11.0) years (median, 9.5; range, 0–40) after the first visit (Fig 4C2). In 22 
out of 32 patients, the spots progressed to chorioretinal atrophic lesions after 
a mean period of 13.5 (±12.3) years (median, 10.5; range, 0–40; Fig 4C2–D2). In 
11 of these 22 patients, the confluence of these lesions extended beyond the 
vascular arcades after a mean period of 23.0 (±10.3) years (median, 23; range, 
5–40; Fig 4E2). The 11 patients who presented with the common phenotype of 
chorioretinal lesions beyond the vascular arcades at the final examination initially 
presented with flecks (n = 3), foveal atrophy (n = 4), or both flecks and atrophy (n 
= 4) at their first examination.
Over time, SD-OCT showed thinning of the outer nuclear layer and loss of the 
ellipsoid zone, which preceded loss of the RPE/Bruch’s membrane complex. In 
addition, hyperreflective abnormalities in the outer retina were present (Fig 4A
3
). 
Progression occurred as an expanding loss of the outer nuclear layer, ellipsoid 
zone, RPE, and choriocapillaris (Fig 4B
3
–E
3
). Hyperreflective deposits in the inner 
layers of the fovea developed, corresponding with intraretinal pigmentations on 
fundus photography (Fig 4C1–C3).
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Figure 4. Overview of the natural course of retinal disease in early-onset Stargardt based on 
findings obtained from 5 separate patients using fundus photography, autofluorescence (FAF), 
and spectral-domain optical coherence tomography (SD-OCT). Early-onset Stargardt includes 
foveal atrophy and parafoveal hyperautofluorescent fundus flecks (A1,2) in an early disease stage. 
On SD-OCT, there is hyperreflective abnormalities in the outer retina, loss of the ellipsoid zone, and 
thinning of the outer nuclear layer (A3). The initial foveal atrophy and parafoveal flecks then extend 
centrifugally (B1,2), and disseminated hypoautofluorescent spots appear (B2). On SD-OCT, there is 
progression of the foveal atrophy, with thinning of the retinal pigment epithelium/Bruch’s membrane 
complex (B3). Further in the course of the disease, the disseminated hypoautofluorescent spots 
become chorioretinal atrophic lesions, the central atrophy expands further (C1,2), and pigmentations 
(C1) are visible as hyperreflective deposits on SD-OCT (C3). Over time, confluence of these lesions 
evolves centrifugally (D1,2), extending beyond the vascular arcades (E1,2), with further retinal thinning 
and atrophy of the choriocapillaris (D3–E3) visible on SD-OCT. A1,2,3, Patient 1 at age 17; B1,2,3, patient 
31 at age 22; C1,2,3, patient 40 at age 24; D1,2,3, patient 8 at age 36; E1,2,3, patient 5 at age 57.
Electrophysiologic Findings
Follow-up data for 25 patients showed that 4 patients progressed from ffERG 
group 1 to group 2 within a mean of 10.5 (±4.4) years (range, 7–16), and 9 patients 
progressed from group 1 to group 3 within a mean of 27.7 (±14.4) years (range, 
3–47).
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Mutation Analysis
The ABCA4 gene was screened for mutations in 44 of the 51 patients; the 
remaining 7 patients refused genetic analysis for personal reasons. In these 44 
patients, mutations in the ABCA4 gene were identified in 81 of the 88 alleles 
(92%). Thirty-three of these patients had 2 ABCA4 mutations, 7 patients had 1 
mutation, 3 patients had 3 mutations, and 1 patient had 4 mutations. In total, 37 
distinct mutations were identified; these mutations are summarized in Table 2. 
The c.768G>T mutation was identified in 25% of the 44 patients and accounted 
for 13% of all identified mutations. The c.5461-10T>C mutation was identified 
in 36% of the patients and accounted for 22% of all identified mutations. The 
most prevalent ABCA4 mutation among Dutch patients with STGD1 (c.2588G>C)23 
was identified in only 4% of the alleles. Table 3 summarizes the non-missense 
mutations that were identified in this study.
Table 2. ABCA4 Mutations in Early-Onset Stargardt Patients
del = deletion; dup = duplication; fs = frame shift. References are shown for mutations that have 
been reported previously.* Stop signal.
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Table 3. Characteristics of the Non-missense ABCA4 Mutations Identified in our Cohort Study
The outcome of 2 protein prediction programs (SIFT = tolerated or not tolerated; PolyPhen = 
benign, possibly damaging, probably damaging), together with Grantham (>60 pathogenic) and 
PhyloP conservation score (>2.5 pathogenic), were used to form the final conclusion. Mutations are 
proposed to be pathogenic when ≥2 categories point to pathogenicity.
Discussion
In this study, we examined the clinical and genetic characteristics of patients 
with early-onset Stargardt, a disease that lies within the spectrum of retinal 
phenotypes linked with mutations in the ABCA4 gene. Whenever a spectrum of 
disorders contains overlapping phenotypes as the rule rather than an exception, 
any cutoff point used to define a particular disease within that spectrum will be 
arbitrary. Therefore, we arbitrarily defined “early-onset Stargardt” as occurring 
with an age at onset of ≤10 years of age; this definition enabled us to avoid 
including patients with a more typical STGD1 phenotype. Only 4% of the 51 
patients in our early-onset Stargardt cohort had visual acuity of ≤0.30 logMAR, 
Snellen <20/40 (measured at age 8 and 18 years of age in these 2 patients), 
compared with 14% to 37% of patients with typical STGD1 and 59% of patients 
with late-onset STGD1.5,14,24 Because patients with a relatively good visual acuity 
tended to return less often than those with progressive problems, these data may 
have overrepresented more severe cases. The majority of our patients for whom 
ffERG data were available developed abnormal ffERG amplitudes, consistent with 
a previous report by Fujinami et al.7 However, we found no correlation between 
the ffERG group classifications (which were based on the nature of the ffERG 
abnormalities) at the age of onset and the speed of vision loss in this early-onset 
Stargardt cohort. This finding differs from STGD1 cohorts that included patients 
with later ages at onset.5,6 Our findings indicate that early-onset Stargardt can 
be considered a distinct severe subtype of STGD1 that is characterized by early 
foveal abnormalities and the rapid loss of visual function; in contrast, in late-onset 
STGD1, foveal sparing is common, and visual acuity is often preserved to a 
relatively advanced age.14
Diagnosis
The natural course of early-onset ABCA4-related retinal disease in our cohort 
reflects a broad clinical spectrum both at the time of onset and at follow-up, 
with varying degrees of ffERG abnormalities and yellow-white flecks and/or 
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atrophy at a variety of locations. Thus, each combination of electrophysiologic 
and funduscopic findings could be considered a unique phenotype at a specific 
time point. Moreover, these phenotypes changed during the course of the 
disease, suggesting progression of the disease. Because both funduscopic and 
electrophysiologic criteria have been proposed for establishing a descriptive 
diagnosis (e.g., Stargardt disease and cone–rod dystrophy), each individual 
patient can potentially receive several diagnoses at 1 time point and at follow-up. 
Importantly, receiving several diagnoses can be extremely confusing to both the 
patient and the referring ophthalmologist.
Nevertheless, we found that the spectrum of fundus presentations in this 
early-onset retinal dystrophy ultimately converges to a single clinical and 
functional endpoint that includes profound chorioretinal atrophy and severe 
vision loss. Therefore, we propose that one diagnosis of “early-onset Stargardt” 
should be given to patients with early-onset central retinal dystrophy and ABCA4 
gene mutations. This approach provides the patient with the benefit of receiving 
a single diagnosis throughout his or her entire life.
Genotype–Phenotype Correlation
Because early-onset Stargardt can be considered a severe phenotype, severe 
combinations of mutations are expected in these patients. In our cohort, the 
c.768G>T and c.5461-10T>C mutations were significantly more prevalent (present 
in 25% and 36% of our patients, respectively) than in other STGD1 cohorts 
(8% and 5%, respectively).30,31 The c.768G>T mutation is predicted to cause a 
splice defect that leads to nonsense-mediated decay owing to absence of the 
corresponding messenger RNA; this mutation is therefore considered to be a 
severe pathogenic mutation. In addition, a founder effect has been suggested for 
this mutation owing to the allele frequency of 8% among Dutch patients with 
STGD1.30 On the other hand, the c.5461-10T>C mutation does not seem to be 
pathogenic, because heterologous expression of this mutation failed to reveal a 
splicing defect.32 This mutation is rare among control patients, but is present in 
5% of patients with general STGD1. Therefore, the c.5461-10T>C mutation may be 
in linkage disequilibrium with another, currently unidentified, severe pathogenic 
mutation.31 Equally important, the most prevalent ABCA4 mutation among Dutch 
patients with STGD1—c.2588G>C, which was reported in approximately one third 
of typical STGD1 cases33—was present in only 4% of the ABCA4 alleles in our 
cohort of patients with early-onset Stargardt. To date, no homozygous carriers 
of this mutation have been identified,23 supporting the hypothesis that this is a 
relatively mild mutation. The low prevalence of this presumably mild mutation 
in our cohort is consistent with a previously proposed genotype–phenotype 
model that correlates the degree of residual ABCR activity with the severity of the 
phenotype.17,23
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We identified ABCA4 mutations in all of our patients who received genetic 
screening; in contrast, the detection rate in routine clinical practice is 73%.34 
This difference can be explained—at least in part—by the inclusion criteria; 
patients who lacked a detected ABCA4 mutation only would have been included 
if yellow-white flecks and either a dark choroid or an atrophic macular lesion 
were present. However, our database did not contain such patients who received 
genetic screening and had an early-onset disease. This finding supports the notion 
that early onset is highly predictive for identifying ABCA4 mutations,34 possibly 
because of the relatively higher percentage of severe mutations, which are more 
readily identified and/or recognized.
It remains unclear why the fovea is affected early in the course of STGD1 in 
some patients, whereas it can be spared—even for many decades—in other 
patients carrying compound heterozygous mutations, including 1 severe ABCA4 
mutation.14,15 Other factors must therefore play a role in the development of 
foveal atrophy in early-onset Stargardt; possible factors can include pathogenic 
mutations or single nucleotide polymorphisms in genes other than ABCA4, as well 
as aberrant cellular processes. For example, the accumulation of all-trans-retinal 
in photoreceptor cells can directly increase cellular stress, thereby triggering 
apoptotic signaling pathways.35 Next-generation sequencing of all retina-specific 
genes may help to identify the genetic factors that determine whether or not the 
fovea is involved early in the course of STGD1.
Clinical Significance
Although diagnosing STGD1 at an early age is challenging, delaying diagnosis 
can have serious consequences. For example, 22 patients in our study did not 
receive the correct diagnosis for ≥3 years, and vision loss was initially unexplained 
in 13 patients. Recognizing early-onset Stargardt early in the disease course 
enables the timely start of potential measures—such as sunlight protection and 
low-vision counseling—and can prevent the inappropriate prescription of vitamin 
A supplements. Therefore, patients who are suspected of having early-onset 
Stargardt should be examined thoroughly using FAF and SD-OCT, particularly 
when no abnormalities (or mild foveal abnormalities) are present in a child with 
central vision loss that is otherwise unexplained. This diagnosis should also be 
confirmed by screening for the presence of ABCA4 mutations. Finally, in light of 
future therapeutic options, such as gene therapy for treating ABCA4-related retinal 
disorders, obtaining a thorough understanding of the phenotypic spectrum and 
clinical course of STGD1 is essential for identifying the patients who will benefit 
most from these treatments.
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CHAPTER 2.2
The absence of fundus abnormalities in Stargardt disease
“A lack of obvious fundus abnormalities left an alarming number of children with 
Stargardt disease without the correct diagnosis. We hope that greater awareness 
of this subtype avoids misdiagnosis and years of inappropriate treatment.”
Nathalie M. Bax
Stanley Lambertus
Frans P.M. Cremers
B. Jeroen Klevering
Carel B. Hoyng
Graefe’s Archive for Clinical and Experimental Ophthalmology, 2019 
Jun;257(6):1147-1157. 
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PURPOSE: To raise awareness of Stargardt disease (STGD1) patients without 
fundus abnormalities.  
METHODS: Medical records were evaluated for age at onset, initial symptoms 
and diagnosis, reason for delay of diagnosis, age at STGD1 diagnosis, 
best-corrected visual acuity (BCVA), ophthalmoscopy, fundus photography, 
fundus autofluorescence (FAF), fluorescein angiography (FA), spectral-domain 
optical coherence tomography (SD-OCT), full-field electroretinography (ffERG), 
color vision test, and the presence of ABCA4 variants.
RESULTS: In 11.1% of our STGD1 cohort of 280 patients, no fundus abnormalities 
were observed at first ophthalmic consultation. The median age at onset was 8 
years (range, 1-18). There was a median delay in diagnosis of 3 years (range, 0 
– 19) in 27 out of 31 patients, which resulted in a median age at diagnosis of 12 
years (range, 7-26). Patients were misdiagnosed with amblyopia, myopia, optic 
disk pathology, mental health problems, tension headache, neuritis bulbaris, and 
uveitis. Subtle abnormalities, such as lipofuscin accumulation, were seen on FAF 
at an earlier disease stage than in ophthalmoscopy. On SD-OCT, this included 
a thickened external limiting membrane. Color vision tests showed red-green 
insufficiency in 79% of patients. Reduced ERG amplitudes were only present in 26% 
(N=8), and a dark choroid sign in 65% of the patients. Visual acuity considerably 
fluctuated in the first 5 years after onset. The majority of the patients (65%) 
carried a least one variant with a severe effect on ABCA4 function. 
CONCLUSIONS: Childhood-onset STGD1 patients were diagnosed with a delay 
of median 3 years. The presence of accurate competence, equipment and 
the possibility for genetic screening is required, therefore we recommend to 
refer children with visual complaints without initial fundus abnormalities to a 
specialized ophthalmologic center. In particular, to diagnose patients at an early 
stage of disease is of increased importance with the advent of new therapeutic 
possibilities.
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Introduction
Stargardt disease (STGD1) is arguably the most common retinal dystrophy and 
affects 1:10000 people worldwide.1 This autosomal recessive disease is caused 
by variants in the ABCA4 gene that encodes for a retinal-specific ATP-binding 
cassette transporter protein. Dysfunction of the ABCA4 protein leads to toxic 
accumulation of byproducts from the visual cycle in the photoreceptor cell and 
retina pigment epithelium (RPE), which eventually leads to irreversible damage of 
the outer retinal layers. 2,3
Up to 5,962 variants in the ABCA4 gene have been identified; the specific 
combinations of variants in conjunction with largely unknown modifying factors 
in each patient result in a highly heterogenic phenotype. 4 Patients with STGD1 
present with progressive vision loss, which typically occurs in young adulthood, 
but early and late forms have been well recognized.5-7 In general, the fundus 
picture is characterized by the presence of irregular yellow-white fundus flecks in 
the posterior pole. During the course of the disease, macular atrophy develops, 
sometimes with a ‘beaten bronze’ aspect; in other patients a bull’s eye pattern 
can be observed. Lipofuscin accumulates in the outer retinal layers, which results 
in a ‘dark choroid’ on the fluorescein angiogram in approximately  80% of the 
patients.8-11 In early forms with a disease onset ≤ 10 years of age, atrophy of 
the macula is a prominent and early feature; the yellow flecks may be absent 
or hardly notable.5,12,13 The flecks are much more common in the classic form of 
STGD1 with an age of onset in the early teens, sometimes extending beyond the 
vascular arcades resulting in the fundus flavimaculatus phenotype.14,15 Late-onset 
forms of the disease are characterized by atrophy of the retinal pigment atrophy, 
subtle flecks, and foveal sparing.6,16,17
The diagnosis of STGD1 can be challenging in early disease especially, as no 
apparent changes may be present on ophthalmoscopy despite the loss of visual 
function.5 This lack of clinical signs in combination with the limited capabilities 
for expression in young children may delay the correct diagnosis. Not only is early 
identification of these patients essential for the emotional aspect of a timely 
diagnosis, it is also important in the light of emerging therapeutic options for STGD1 
disease, such as gene augmentation (trial number NCT01367444, NCT01736592), 
stem cell therapy (trial number NCT01469832), and small molecule drugs (trial 
number NCT02402660).
In this study, we describe —in detail— the clinical and molecular genetic findings 
in a group of STGD1 patients, which presents without initial fundus abnormalities 
in ophthalmoscopy. We hope that a heightened awareness avoids misdiagnosis, 
such as functional visual loss in these children and, in worst case scenarios, years 
of inappropriate treatment.
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Methods
Patients 
The database with STGD1 patients of the Department of Ophthalmology, Radboud 
university medical center, (Nijmegen, the Netherlands) contains 280 patients of all 
ages and disease-onset, of whom one or more ABCA4 variants could be identified. 
We included 31 patients who did not show obvious fundus abnormalities at the 
first presentation. This study was approved by the Institutional Ethics Committee 
and was performed in accordance with the Declaration of Helsinki. 
Clinical evaluation 
We collected the clinical data from the medical records. These included age at 
onset, initial symptoms, initial diagnosis and examinations or therapy, age at 
STGD1 diagnosis, delay of diagnosis and reason for this delay, number of referrals 
before diagnosis, and general medical history. Age at onset was defined as the 
first manifestation of the disease, these symptoms could have been noticed 
by the patient, but also their family members and/or the school physician. If 
visual complaints of the patient was initially diagnosed due to stress or need for 
attention, we used the term “mental health issues”.  
The standard ophthalmic examination included best-corrected visual acuity 
(BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) or Snellen 
charts, slit-lamp biomicroscopy and detailed fundus examination. BCVA was 
transformed into the logarithm of the minimum angle of resolution (logMAR) for 
statistical analysis. For fundus photography, we used the Topcon TRC50IX (Topcon 
Corporation, Tokyo, Japan). Fluorescein angiography (FA) and cross-sectional 
images using spectral-domain optical coherence tomography (SD-OCT) centered 
at the macula were obtained with the Spectralis (HRA+OCT, Heidelberg 
Engineering, Heidelberg, Germany). Short-wave fundus autofluorescence imaging 
(FAF) (λ = 488 nm, emission 500–700 nm) was performed using a confocal 
scanning laser ophthalmoscope (Spectralis HRA+OCT or HRA2, Heidelberg 
Engineering, Heidelberg, Germany). The field of view was set at 30°×30° or 
55°×55°, centered at the macula. For evaluation of color vision we employed the 
Ishihara or Panel D-15 test. Full-field electroretinography (ERG) was performed 
using Dawson-Trick-Litzkow (DTL) electrodes and the RETI-port system (Roland 
Consults, Stasche & Finger GmbH, Brandenburg an der Havel, Germany). The 
recordings were performed in accordance with the guidelines of the International 
Society for Clinical Electrophysiology of Vision (ISCEV).18 We grouped ERG results 
as described by Lois et al.19 Group 1: patients with normal ERG responses; Group 
2: patients with reduced photopic amplitudes (<5% of normal range) and Group 3: 
patients with reduced photopic and scotopic amplitudes (<5% of normal range).
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Genetic analysis
Genetic analysis of the ABCA4 gene was performed at the Department of 
Human Genetics at the Radboud University Medical Center using arrayed primer 
extension analysis (APEX, Asper Biotech, Tartu, Estonia). If the Asper microarray 
screening revealed only one ABCA4 variant, exon and intron-exon boundaries 
were sequenced in the ABCA4 gene to identify additional variants. All variants 
were confirmed with Sanger sequencing. The following variants were defined 
as severe: protein-truncating, canonical splice-site variants, as well as deletions 
spanning at least one exon.
Statistical analysis
We used SPSS version 22.0 (IBM Corp, Armonk, NY) for statistical data analysis, 
using descriptive statistics by median and range for continuous variables, and 
percentages for categorical variables. We employed Kaplan-Meier estimators to 
analyze the interval between age at onset and age at which four different visual 
endpoints were reached. These four points were based on the classification of 
visual impairment of the World Health Organization: (near-)normal to mild visual 
impairment ≥0.2 logMAR (≤20/32 Snellen), moderate visual impairment  ≥0.6 
logMAR (≤ 20/80 Snellen), severe visual impairment ≥1.0 logMAR (≤20/200 
Snellen), and blindness ≥1.4 logMAR (≤20/500 Snellen). 
Results
Clinical characteristics
In 31 of 280 (11.1%) STGD1 patients, no obvious fundus abnormalities were 
observed at the first ophthalmic consultation. The group consisted of 15 males 
and 16 females with six siblings from three different families, and 25 isolated 
cases. An overview of the clinical findings and the diagnostic process is given in 
Table 1. In one-third of cases, symptoms of a decreased visual acuity were not 
noticed by the patient, but by the parents or a school physician. Age at onset 
occurred at a median age of 8 years (range, 1-18). In 87% of the patients, there 
was a delay in diagnosis: a median delay of 3 years (range, 0 -19), which resulted 
in a median age at diagnosis of 12 years (range, 7-26). The main reason for 
delayed STGD1 diagnosis was misdiagnosis, in particular amblyopia treated with 
occlusion therapy (6 patients) and mental health issues (5 patients). The majority 
of patients (94%) visited more than two hospitals before the correct diagnosis was 
made. All patients were finally diagnosed with STGD1 in tertiary referral centers. 
The first fundus abnormalities were observed at a median time of 3 years (range, 
0.5-16) after first symptoms. These included central retinal pigment epithelium 
(RPE) alterations (43%), bull’s eye maculopathy (33%), and/or parafoveal flecks 
(24%). Once these features had been observed, STGD1 was generally diagnosed 
relatively quickly in the majority of patients (median; 0.7 years, range; 0.1-3). 
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 72
72
Chapter 2.2
ID
= identi
ficati
on pati
ent in this study, m
= m
ale, f= fem
ale, VA
= visual acuity, BCVA
= best-corrected visual acuity, RPE=reti
nal pigm
ent epithelium
. 
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 73
73
Clinical characteristics of Stargardt disease
2
Table 1.  Clinical characteristi
cs and diagnosti
c process in Stargardt disease (STG
D
1) pati
ents w
ithout initi
al fundus abnorm
aliti
es
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 74
74
Chapter 2.2
We could retrieve the BCVA at the first ophthalmic visit in 21 out of 31 patients; 
the median BCVA  at that time was 20/32 Snellen (20/20 - 20/400). The median 
interval and 95% confidence interval (CI) between the age at onset and decline in 
BCVA to mild, moderate, severe visual impairment and blindness was 1 year (95% 
CI, 0.0 - 2.25), 4 years (95% CI, 3.1 - 4.9) and 12 years (CI 95% 7.8 – 16.2). One 
patient reached blindness 34 years after the first symptoms of onset at age 9. In 
many patients, the visual acuity findings were quite variable early in the course of 
the disease as shown in Figure 1. 
Figure 1: Course of the best-corrected visual acuity (BCVA) in logMAR in ten patients. The visual 
acuity varies greatly during the first five years after first ophthalmic consultation. LogMAR 0 = 20/20 
Snellen, LogMAR 0.5 = 20/63 Snellen, LogMAR 1.00 = 20/200 Snellen, LogMAR 1.50 ≈ 20/630 Snellen, 
LogMAR 2.00 = 20/2000 Snellen. Each patient (ID= identification) is shown in a different color. 
In 29 out of 31 patients, fundus flecks were eventually noticed at a median time of 
3.5 years (range, 0.1 -16.5) after the initial ophthalmic consultation. In 17 patients 
(59%), subtle parafoveal flecks could be seen, in 5 patients (17%) flecks were 
noticed within the vascular arcades, and in 7 patients (24%) flecks extended to 
the periphery. In 2 patients, no fundus flecks were reported at any time during the 
course of the disease (follow-up time, 1 and 10 years). 
In 23 of 31 patients, the first SD-OCT was performed at 9 years (range, 0.1-24) 
after disease onset. No SD-OCT scans were performed in the remaining 8 patients. 
All OCT scans showed abnormalities by disorganized or absent RPE. A thickened 
external limiting membrane (ELM) was seen in 2 patients (0.5 and 1 year after 
disease onset). A dark choroid was observed in 15 of 23 (65%) patients in whom 
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FA was performed. In 22 patients, the first FAF was performed 3.5 years (0.5-24) 
after onset. No atrophy was seen (median, 1 year after onset) in 5 patients, (peri)
foveal atrophy in 9 (median, 4 years after onset), atrophy within the vascular 
arcades in 7 (median, 15 years after onset), and panretinal atrophy (15 years after 
onset) in 1. In 4 patients, abnormalities were seen on FAF, but were missed on 
ophthalmoscopy. 
The first ERG was performed 2 years (0.1 – 27) after onset in 27 patients. Normal 
ERG recordings (Group 1) were present in  20 patients (74%), 2 years (0.1-21) after 
disease onset.  We found Group 2 ERGs in 4 patients (15%) with 1 year (0.1 – 3.5) 
after onset, and Group 3 recordings in 3 patients (11%) with 18 years (6-27) after 
onset. Follow-up for ERG recordings was available in 21 patients. In 4 of these 
patients progressed from Group 1 to Group 2 (median time, 8 (7-16) years), 2 
patients progressed from Group 2 to Group 3 (within 2 and 3 years), and 1 patient 
progressed from Group 1 to Group 3 in 6 years. In 17 patients color vision was 
tested. In 15 patients (79%) abnormalities were noticed, red-green defects in 14 
patients and a blue-yellow defect in 1 patient.
Various imaging modalities of patient 28 and patient 21 are depicted respectively 
in Figure 2 and 3. 
Genetic characteristics
Overall, genetic analysis was not performed at first visit, but with a median delay 
of five years (range, 0 - 30) after first visit. An overview of ABCA4 variants in our 
cohort is described in Table 2.  
Variants in the ABCA4 gene were identified in 59 of 62 alleles (95%). Three variants 
were found in one patient, two ABCA4 variants in 27, and one variant in three. 
In total, 32 distinct variants were detected. The majority of the patients (65%) 
carried at least one variant with a severe effect on ABCA4 function (Table 2, in 
bold). 
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Figure 2: Three-and-a-half year follow-up in patient ID28. Age at onset at 6.5 years, one year later 
the fundus auto-fluorescence showed a perifoveal ring of hyper-fluorescence (A2), and on OCT a 
discrete thickening of the external limiting membrane can be seen (A3, red arrow). Only 6 months 
later, a subtle hyper-fluorescent perifoveal lesion developed as shown in B2, red arrow. Over time, 
the hyper-fluorescent flecks become more visible on autofluorescence imaging. In addition the 
flecks became noticable on color fundus photographs. The thickened external limiting membrane 
remained present during the entire follow-up time (red arrows A3, C3, D3, E3, F3, H3). 
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Figure 3: Multimodal imaging in ID21 at age 25, 15 years after the first symptoms. The visual 
acuity is now 20/1000 Snellen OU. Color fundus photography (A) shows attenuated retinal vessels 
(especially the veins), para-arteriolar pigmentations and diffuse chorioretinal atrophy. The fundus 
autofluorescence (B) shows widespread hypofluorescence, especially at the macula, indicative 
of RPE cell loss. The fluorescence angiogram (C) shows widespread granular hyperfluorescent 
lesions as result of RPE damage, and on the OCT  (D) loss of the outer retinal layers, as well as 
thechoriocapillaris, can readily be observed. 
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Discussion
A lack of obvious fundus abnormalities left a high number of children with 
STGD1 disease without the correct diagnosis. Instead, these patients underwent 
unnecessary investigations, such as psychic evaluations, brain MRIs or CTs, and 
lumbar punctures. Many of these children were treated for mental illness and/
or amblyopia with pointless and possibly harmful treatments, including years of 
occlusion therapy.
In patients with adult-onset STGD1, initial ophthalmoscopic features typically 
include yellow-white flecks and central macular atrophy, and cases without 
fundus abnormalities have not been described.6 In young children, the clinical 
presentation can be confusing for the general ophthalmologist. Fujinami et al 
noticed that one third of their child cohort (<17 years) initially had a normal 
fundus appearance.7 Lambertus et al described a cohort of 41 STGD1 patients 
younger than 10 years, and 10 of these patients (24%) also did not have fundus 
abnormalities.5 These studies show that the absence of readily observable fundus 
abnormalities in young STGD1 patients is not an isolated finding, but a relative 
common part of the clinical spectrum.
Recently, Khan et al. reported the earliest features of ABCA4-associated 
retinopathy.20 In their study, they included 8 children (6 prospectively) to describe 
their ophthalmologic features. At the first visit, four children were asymptomatic 
and four had complaints of visual decline. In 6 out of 8 children, the central macula 
appeared normal or had an altered foveal reflex. This is similar to the findings in 
our study. In contrast, their study focused on the (most prospectively) appearance 
of abnormalities in ABCA4-related dystrophy even if they were asymptomatic. 
Our study is focused, retrospectively, on STGD1 patients initially without fundus 
abnormalities, despite having visual complaints. Besides the natural course 
of this phenotype, we describe the reasons of delay in diagnoses and to find 
similarities within this group of patients in order to provide recommondations for 
ophthalmologists in general. Therefore, this study is a contribution from another 
point of view of children with STGD1 which initially present without fundus 
abnormalities. 
In our cohort, when fundus abnormalities did occur, these were often not the 
typical yellowish flecks but rather RPE alterations, often in a bull’s eye pattern. 
A hypothesis for the absence of typical fundus flecks may lie in the relative high 
pathogenicity of ABCA4 variants. As the majority of our cohort (65%) carried at 
least one severe variant, there may be little ABCA4 function left in these patients, 
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leading to a very early manifestation of the disease. The built up of toxic A2E in RPE 
cells develops rapidly, thereby causing early cell death without the opportunity 
for lipofuscin to accumulate and subsequent fleck formation. 
Blocking of the choroidal vessels on FA resulting a dark or silent choroid is 
frequently used as diagnostic marker for STGD1. The prevalence of this FA finding 
in STGD1 patients has been described in up to 86% of patients.21 A dark choroid 
was present in 65% in our relatively small cohort. A correlation has been described 
between the presence of yellow-white fundus flecks and the appearance of dark 
choroid, which might account for the relative low percentage of patients with a 
dark choroid in this cohort. 9,22 FAF imaging is a relative new modality that may be 
used to identify early and subtle lipofuscin.23 In addition, a thickened ELM on OCT 
may also serve as an early marker for STGD1.24 However, in the study of Lee et 
al, this distinct ELM thickening was described to occur in all (26/26) cases. In our 
cohort, only 2/23 cases with performed OCT (0.5 and 1 year after disease onset), 
were observed to have this feature. The delay of performing an OCT (mean: 9 years 
after disease onset), could be an explanation of the difference in appearance of 
ELM thickening in both cohorts. Abnormal color vision was observed in 79% of our 
STGD1 patients, which corresponds with the previously reported percentages.25 
Fluctuation of visual acuity in 10/31 children in the first 5 years of ophthalmic 
consultation suggests that visual acuity is an ambiguous symptom at early stages 
of STGD1. This could be explained by lowered reading performance due to ring 
scotomas that allow for good visual acuity, but cause visual field impairment.26 
Although STGD1 is the most common juvenile macular dystrophy, it remains a 
relative rare disorder. Clinicians in a general ophthalmic practice may lack the 
experience to identify and interpret the subtle abnormalities in these young 
children. When we take into account the relative difficulty associated with the 
ophthalmic examination of (very) young children, the high number of misdiagnoses 
in the early-onset STGD1 patient group may not come as a surprise. Therefore, 
we want to make ophthalmologists aware of early findings in STGD1, especially 
appearing in children. First, visual acuity often fluctuates in these patients which 
should not automatically rule out the possibility of a photoreceptor disease. 
Second, a fundus photograph can be helpful in discerning very subtle fundus 
abnormalities and may be useful in follow-up. Third, non-invasive investigations 
such as OCT (thickening of the ELM), FAF (subtle lipofuscin accumulation) and 
color vision tests may help in the diagnostic process. FA is invasive, apart from the 
oral variant, but may also be less helpful in patients without fundus abnormalities 
in the light of the relative low percentage of dark choroids in these patients. 
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In children with visual disturbances, retinal dystrophies should be considered 
and ruled out when possible, even in the absence of fundus abnormalities on 
ophthalmoscopy, because STGD1 may be a cause of low vision in normal fundus. 
Instead of wait and see, we would recommend referring these children to a 
tertiary ophthalmic center and performing OCT and FAF to define early findings 
of STGD1. In addition, early identification may prove important in the light of 
emerging therapeutic options.  
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Foveal sparing in Stargardt disease
“Foveal sparing mainly occurs in patients with late-onset Stargardt and 
characterizes the mild end of the clinical variations in Stargardt disease. Long-term 
follow-up data provided insight in the natural course of foveal sparing. Although 
the etiology is unclear, we hypothesize on possible underlying factors. Knowledge 
on these fovea-protective factors can provide opportunities for future therapeutic 
strategies.”
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PURPOSE: To provide a clinical and genetic description of a patient cohort with 
Stargardt disease (STGD1) with identifiable foveal sparing.
METHODS: Patients with retinal atrophy (defined as an absence of autofluorescence) 
that surrounds the fovea by at least 180° and does not include the fovea were 
defined as having foveal sparing; eyes with visual acuity (VA) worse than 20/200 
were excluded. We reviewed the medical files and extracted data regarding 
medical history, VA, ophthalmoscopy, static perimetry, fundus photography, 
spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography 
(FA), fundus autofluorescence (FAF), and electroretinography (ERG). We screened 
each patient’s ABCA4 gene for mutations. 
RESULTS: Seventeen eyes with foveal sparing were identified in 13 unrelated 
patients. In 4 eyes, the fovea gradually became atrophic after the initial foveal 
sparing. The mean age at onset was 51 years (range: 32-67 years). VA was 20/40 
or better in all foveal sparing eyes, and 20/25 or better in 41%. FAF imaging 
revealed hyperautofluorescent flecks and parafoveal retinal atrophy, SD-OCT 
revealed sharply delineated atrophy, and perimetry revealed parafoveal scotomas 
with intact foveal sensitivity. Finally, genetic screening identified mutations in 19 
of the 26 ABCA4 gene alleles. 
CONCLUSIONS: Foveal sparing occurs mainly in patients with late-onset STGD1 
and represents the milder end of the clinical spectrum in STGD1. The anatomy, 
metabolism, and biochemistry of the retina, as well as genetic variations in 
genes other than ABCA4, can influence the etiology of foveal sparing. Identifying 
these fovea-protecting factors will facilitate the future development of strategies 
designed to treat STGD1.
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Introduction
Within the retina, the macula provides the highest visual acuity and contains the 
highest density of cones.1, 2 Therefore, a loss of central vision is a hallmark feature 
of macular dystrophies. There are, however, exceptions to this rule. Foveal sparing 
is an intriguing phenomenon in which retinal atrophy surrounds a relatively 
preserved fovea, leaving central visual acuity largely unaffected. Although foveal 
sparing has been reported in a variety of conditions, including Stargardt disease 
(STGD1),3-5 mitochondrial retinal dystrophy associated with the m.3243A>G 
mutation,6 and geographic atrophy in age-related macular degeneration (AMD),7-11 
its etiology remains poorly understood.
STGD1 is an autosomal recessive retinal dystrophy that typically presents within 
the first two decades of life.12 Although the clinical presentation of STGD1 varies 
widely, it is usually characterized by a progressive loss of central vision, irregular 
yellow-white fundus flecks, and the so-called “beaten bronze” atrophic macular 
lesions.13-15 STGD1 has been linked to mutations in the ABCA4 gene, which 
encodes an adenosine triphosphate (ATP)-binding cassette transporter (ABCR) 
expressed specifically in the cones and rods of the retina.16, 17 Defects in ABCR 
function cause the accumulation of all-trans-retinal and its cytotoxic derivatives 
(e.g., diretinoid-pyridinium-ethanolamine) in photoreceptors and retinal pigment 
epithelial (RPE) cells, ultimately causing RPE cell death and the subsequent loss 
of photoreceptors.18 
Mutations in ABCA4 have been linked to a spectrum of phenotypes ranging from 
mild macular dystrophy to severe early-onset panretinal dystrophy.3, 19-22 We 
previously postulated that disease severity may be correlated to the functional 
severity of the particular mutation in the resulting ABCR protein.19, 23-25 The 
substantial clinical variability among patients with STGD1—including an age at 
onset of the symptoms that can range from 5-72 years of age, diverse fundoscopic 
features, diverse electrophysiological findings, and a variable time course of vision 
loss—suggests the presence of several strong modifying factors.3,13, 14 
Recently, Fujinami et al. reported the clinical and molecular genetic findings of a 
cohort of STGD1 patients with relatively preserved foveal structure and function 
(based on seemingly normal autofluorescence at the fovea). Their study revealed 
the presence of two basic—yet distinct—STGD1 phenotypes, namely STGD1 
patients with foveal sparing and STGD1 patients with early-onset foveal atrophy.26 
However, the onset of foveal involvement in STGD1 can vary substantially and can 
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occur in later disease stages, for example in late-onset STGD1.3 This heterogeneity 
complicates the selection of homogeneous cohorts for clinical studies to 
investigate the subtype of STGD1 patients with foveal sparing. 
Here, we report the clinical characteristics and the natural course of foveal sparing 
in a cohort of STGD1 patients with foveal sparing, and we explore the mechanisms 
that may underlie this phenomenon. 
Methods
Patients and genetic analysis
The patient selection process is depicted in Figure 1. The database of the 
Department of Ophthalmology at Radboud University Medical Center (Nijmegen, 
the Netherlands) contains 425 clinically suspected cases of STGD1. For 257 of 
these patients, an ABCA4 genetic screen for known mutations was performed 
in the Department of Human Genetics at Radboud University Medical Center 
(Nijmegen, the Netherlands) using arrayed primer extension analysis (APEX) 
microarrays (Asper Biotech, Tartu, Estonia). Because STGD1 is autosomal 
recessive, if the Asper microarray screen revealed only one mutation in a given 
patient, we sequenced the exons and intron-exon boundaries in ABCA4 to identify 
the mutation in the second allele. All mutations were confirmed using Sanger 
sequencing. The presence of one or two mutations in the ABCA4 gene confirmed 
the diagnosis of STGD1 in 198 patients. For our study, we selected cases in 
which foveal sparing was documented using fundus photography and/or fundus 
autofluorescence (FAF) imaging. Patients with RPE atrophy (defined as an absence 
of autofluorescence surrounding the fovea by least 180°) that did not include the 
fovea were defined as having foveal sparing. Eyes with visual acuity of 20/200 
or worse were presumed to have little or no foveal function and were therefore 
excluded. Twelve unrelated STGD1 patients with foveal sparing in at least one eye 
were included in this study. We also included one additional patient who initially 
presented with foveal sparing; in this patient, the fovea became atrophic as the 
disease progressed. To exclude pseudo-Stargardt pattern dystrophy,27 the PRPH2 
gene was sequenced in all 13 patients. 
This study was performed in accordance with the tenets of the Declaration of 
Helsinki, and all participating patients gave their informed consent prior to 
providing a blood sample and receiving additional ophthalmologic examinations. 
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Figure 1. Flow-chart depicting the selection process of Stargardt patients with foveal sparing for 
inclusion in the study. FAF, fundus autofluorescence; FP, fundus photography; STGD1, Stargardt 
disease.
Clinical examination 
Clinical data were collected from the medical records of the 13 eligible patients. 
The data collected included the patient’s age at onset, medical history, initial 
symptoms, and the overall course of the retinal disorder. Age at onset was defined 
as the age at which the initial symptoms were noted by the patient. We defined 
the duration of symptomatic disease as the time from the age at onset to the 
patient’s current age. In the patients who were initially asymptomatic, the age at 
their first visit to the ophthalmologist was used to define disease duration. 
The standard ophthalmic examination included a measurement of best-corrected 
visual acuity (BCVA) using Snellen visual acuity charts and ophthalmoscopy. 
The central visual field was assessed using a Humphrey perimeter (Carl Zeiss 
Meditec, Jena, Germany) using central 10-2, 24-2, or 30-2 threshold tests in 
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two, two, and four patients, respectively. Fundus photography (Topcon TRC50IX, 
Topcon Corporation, Tokyo, Japan) was performed in ten patients. Fluorescein 
angiography (FA) was performed in ten patients to screen for the presence of the 
dark choroid sign. Full-field electroretinography (ffERG; 8 patients) and multifocal 
ERG (mfERG; 7 patients) were performed using Dawson-Trick-Litzkow (DTL) 
electrodes and the RETI-port system (Roland Consults, Stasche & Finger GmbH, 
Brandenburg an der Havel, Germany). Both the ffERG and mfERG recordings were 
performed in accordance with the guidelines of the International Society for 
Clinical Electrophysiology of Vision (ISCEV).28
Cross-sectional images were obtained using spectral-domain optical coherence 
tomography (SD-OCT; Heidelberg Engineering, Heidelberg, Germany) in 12 
patients; a 20°x15° 19-line scan covering the fovea was used. Total retinal 
thickness, outer nuclear layer (ONL) thickness, and photoreceptor-RPE (PR+RPE) 
complex thickness were measured at the foveal dip and at 0.25, 0.5, 1, 1.5, 2, 
and 2.5 mm eccentric distances using Heidelberg Eye Explorer software (Version 
1.6.4.0, Heidelberg Engineering, Heidelberg, Germany). ONL thickness was 
measured from the outer plexiform layer to the external limiting membrane (ELM), 
PR+RPE thickness was measured from the ELM to Bruch membrane, and total 
retinal thickness was measured from the vitreous-retinal interface to RPE-Bruch 
membrane complex. Clinically normal values for total retinal thickness, ONL 
thickness, and PR+RPE thickness were obtained from 25 age-matched individuals 
(mean age: 46 years; range: 27-62 years) with no retinal or vitreoretinal disease; 
we performed a post-acquisition interpolation of the normal data using custom 
programs (MatLab R2011a, The MathWorks Inc., Natick, MA).
We acquired FAF images using a confocal scanning laser ophthalmoscope (cSLO, 
Spectralis, Heidelberg Engineering, Heidelberg, Germany). After the pupil was 
dilated, 30° and/or 55° field-of-view FAF images were obtained from all patients 
(except case 11) using an optically pumped solid-state laser with 488-nm excitation. 
Two independent observers (authors R.A.C.v.H. and N.M.B.) measured the size 
of the atrophic lesions (determined using the absence of autofluorescence) as 
described previously.29
Results
Clinical characteristics
Of the 198 patients with a confirmed diagnosis of STGD1, 13 unrelated patients 
(7%) had foveal sparing. The clinical characteristics of these 13 patients (including 
all 26 eyes) are summarized in Table 1. This cohort included five women and eight 
men; all 13 patients were of Caucasian descent, with a mean age at onset of 52 
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years (range: 32-67 years). The mean disease duration was 9 years (range: 1-34 
years). These patients were diagnosed between the age of 39 and 82 years (mean: 
57 years). None of the patients were using hydroxychloroquine at the time of the 
study, nor had they used this drug in the past.
Foveal sparing was present in 17 of the 26 eyes (65%), and five of the 13 patients 
(38%) had bilateral foveal sparing. In seven of the patients with unilateral foveal 
sparing, five of the contralateral eyes had no signs of RPE atrophy or parafoveal 
atrophic RPE lesions that surrounded the fovea by less than 180°. In the remaining 
two eyes, and in both eyes in patient 12, the fovea degenerated after initial foveal 
sparing (Table 1).
Nine of the 13 patients (69%) initially experienced a decline in visual acuity. 
Other initial symptoms included paracentral scotoma in four patients (31%), 
metamorphopsia in two patients (15%), and nyctalopia in one patient (8%). Two 
patients (patients 2 and 13; 15%) initially experienced no visual complaints, but 
were referred to our department because of fundus abnormalities found during 
ophthalmologic screening for glaucoma or thyroid eye disease; after nine and six 
years, respectively, these two patients experienced a perceived decrease in visual 
acuity (Table 1). BCVA was 20/40 or better in all 17 eyes with foveal sparing; 7 
of these 17 eyes (41%) had a BCVA of 20/25 or better. In the four eyes in which 
atrophy ultimately affected the fovea, BCVA had decreased to ≤20/200 from an 
initial acuity of 20/25 to 20/40 when the fovea was spared.
In 12 patients, a fundus examination revealed irregular flavimaculatus flecks 
scattered throughout the posterior pole and occasionally extending anterior to 
the vascular arcades (Figures 2A-B and 3A). One patient had small perifoveal 
yellow-white dots. Patient 12, who had bilateral foveal degeneration, developed 
extensive chorioretinal atrophy of the posterior pole and the midperiphery 
during the patient’s 26 years of follow-up (Figure 2C). Masking of the choroidal 
background fluorescence (i.e., a so-called “dark choroid”) was evident on FA 
imaging in seven patients, four of whom carried a single heterozygous ABCA4 
mutation (Tables 1 and 2). The flavimaculatus flecks were visible as an irregular 
pattern of hyperfluorescence and hypofluorescence on FA imaging (Figure 3B), 
and they appeared as hyperautofluorescent flecks on FAF imaging (Figures 3C and 
4). The chorioretinal atrophy corresponded with sharply delineated areas that 
included both an absence of autofluorescence and structural thinning of the outer 
retinal layers on OCT (Figure 3D). Static perimetry revealed sharply delineated 
absolute parafoveal scotomas (Figure 4) with subnormal foveal sensitivity 
(median: 35 dB; range: 20-39 dB). Foveal sensitivity was not measurable (<0 dB) in 
patient 12, which is consistent with the anatomical findings and other functional 
results obtained from this patient.
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Figure 2. Fundus photographs of three patients with STGD1. A, Fundus photograph of the right eye 
of patient 4 (at age 60), showing fundus flavimaculatus flecks and parafoveal atrophy of the retinal 
pigment epithelium (RPE). B, Fundus photograph of the left eye of case 5 (at age 45), showing fundus 
flavimaculatus flecks and parafoveal atrophy of the RPE. C, Mosaic of fundus photographs of the 
right eye of case 12 (at age 73), showing profound central atrophy of the RPE; this patient previously 
had foveal sparing.
Figure 3. Multimodal imaging of the right fundus of patient 3 at age 62. A, Fundus photograph 
showing irregular flavimaculatus flecks and atrophy of the central retinal pigment epithelium 
(RPE); note that the fovea is spared. B, Fluorescein angiograph showing the “dark choroid” sign, 
hyperfluorescence, visible choroidal vessels due to window defects, and a normal-appearing 
fovea. C, Fundus autofluorescence image showing hyperautofluorescent flecks and RPE atrophy 
with foveal sparing. The green horizontal line indicates the scanning level of the optical coherence 
tomography (OCT) scan in panel D. D, An OCT scan through the fovea clearly shows the preserved 
cone photoreceptors in the fovea surrounded by atrophy of the outer retina and RPE.
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Figure 4. Natural course of fundus and perimetric changes in STGD1 with foveal sparing. FAF imaging 
can be used to identify the three stages that occur in foveal sparing. In stage 1, confluent parafoveal 
RPE lesions surround the macula, leaving several connections of intact RPE with the surrounding 
vital RPE (stage 1; A, C). Over time, the RPE atrophy progresses, and the lesions interconnect, leaving 
only one isthmus of RPE (stage 2; E, G). Further disease progression leads to an isolated fovea that 
is surrounded completely by RPE atrophy (stage 3; I, K). Eventually, RPE atrophy overcomes foveal 
resistance, leading to foveal degeneration (post-foveal sparing; L, N). Static perimetry examination 
reveals absolute perifoveal scotomas with intact foveal sensitivity in all eyes with foveal sparing 
(B, D, F, H, J). Large absolute scotomas with diminished foveal sensitivity were observed in the 
post-foveal sparing eyes (M, O). A/B, FAF (A) and 24-2 perimetry (B) in patient 13 at age 63. C/D FAF 
(C) and 30-2 perimetry (D) in patient 4 at age 60 and 61, respectively. E/F FAF (E) and 10-2 perimetry 
(F) in patient 3 at age 64 and 65, respectively. G/H, FAF (G) and 24-2 perimetry (H) in patient 5 at age 
45. I/J, FAF (I) and 30-2 perimetry (J) in patient 8 at age 66 and 65, respectively. K, FAF in patient 6 at 
age 58. L/M, FAF (L) and 30-2 perimetry (M) in patient 10 at age 53. N/O, FAF (N) and 30-2 perimetry 
(O) in patient 12 at age 73.
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*The abbreviati
ons reflect the am
plitude: N
, norm
al (equal to or above the low
er 5%
 of the range for a norm
al populati
on: photopic ≥78 µV, scotopic ≥263 
µV
); M
R, m
oderately reduced (1-5%
 of norm
al range: photopic ≥69 µV
 and <78 µV, scotopic ≥ 195 µV
 and <263 µV
); SR, severely reduced (<1%
 of norm
al 
range: photopic <69 µV, scotopic <195 µV
).
A
O
, A
ge at onset; BE, both eyes; CF, counti
ng fingers; F, fem
ale; FA
, fluorescein angiography; ff
ERG
, full-field electroreti
nography; FS, foveal sensiti
vity; LE, 
left
 eye; M
, m
ale; N
P, not perform
ed; RE, right eye; RPE, reti
nal pigm
ent epithelium
; VA
, decrease in visual acuity.
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Table 1 Clinical characteristi
cs of the pati
ents included in this study at m
ost recent visit.
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Figure 5. OCT analysis of Stargardt patients with foveal sparing. Panels A through E show the 
structural aspects of the macula in a healthy individual (A; age 51), case 2 (B; age 60), case 3 (C; age 
45), case 8 (D; age 65), and case 10 (E; age 53). The white arrows in panel D indicate the locations 
of signs resembling outer retinal tubulation. The black arrowheads in panels C, D, and E indicate the 
locations of abrupt photoreceptor layer disturbances without gradual outer and/or inner segment 
loss. The white arrowhead in panel C indicates the presence of microcysts in the inner nuclear layer. 
F, Summary of thickness measurements of the total retina (top panel), ONL (middle panel), and 
PR+RPE (lower panel). The gray shaded areas show the distribution (mean ± 2SD) of the total retinal, 
ONL, and PR+RPE thickness in 25 age-matched healthy individuals (mean age: 46 years). ONL, outer 
nuclear layer; PR+RPE, photoreceptor-retinal pigment epithelium complex.
The results of the ffERG recordings in ten eyes with foveal sparing are summarized 
in Table 1. In these ten eyes, photopic amplitude was normal in seven eyes (70%) 
and moderately reduced in three eyes (30%), and scotopic amplitude was normal 
in eight eyes (80%) and moderately reduced in two eyes (20%). In the four eyes 
that developed an atrophic fovea after initial foveal sparing, the photopic and 
scotopic amplitudes were either normal or severely reduced (Table 1). In three 
patients (patient 5, right eye; patient 8, left eye; and patient 13, left eye), the 
scotopic amplitude was reduced more markedly than the amplitude of photopic 
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flash responses, although none of these patients had peripheral pigmentary 
retinopathy. No clear correlation was found between ffERG response and disease 
duration, visual acuity, or fundoscopic characteristics. We also measured mfERG 
in eight eyes with foveal sparing and found that the P1-response amplitudes in the 
central two rings (representing the foveal retina) were relatively intact compared 
to the outer three rings, which showed severely reduced responses.
Retinal structure
SD-OCT imaging was performed in 12 patients and revealed highly localized 
damage to the lamellar architecture of the macula. We observed parafoveal 
atrophy of photoreceptors and RPE cells with sharp borders, represented by a 
loss of the bands associated with the ELM, the ellipsoid inner segments, and the 
RPE (Figure 5B-E).30 These bands were present in the fovea, however, although 
many of the bands that corresponded to the ELM and ellipsoid inner segments 
were irregular. In addition, the longer outer segments—which are characteristic 
of cone photoreceptors in the foveal dip—were not observed in any of these 
12 eyes (Figure 5A-D). In three eyes, we observed signs reminiscent of outer 
retinal tubulation at the border of the atrophic lesions (Figure 5D), although no 
rosette-like structures (as described by Zweifel and colleagues) were observed.31 
Microcystoid macular edema was present in three eyes (Figure 5C), and epiretinal 
gliosis with retinal wrinkling extending over the fovea was observed in one eye.
An analysis of the retinal lamellar architecture revealed that the overall retinal 
thickness in the foveal and parafoveal regions was generally decreased (Figure 
5F). The thickness of both the ONL and PR+RPE layers was normal at the foveal 
center in most patients. However, in the parafoveal region, the PR+RPE was 
usually nearly absent, whereas the ONL was progressively thinner in this region 
(Figure 5F). 
Natural course of foveal sparing
An analysis of the longitudinal FAF data, which were available for six patients, 
enabled us to investigate the natural course of foveal sparing. In general, fundus 
flavimaculatus flecks were observed in the early stages, in some cases even before 
symptoms developed. Within one to two decades of diagnosis (range: 10-18 
years), one or more sharply delineated parafoveal RPE atrophic areas appeared 
(Figure 4A). Over time, these lesions expanded and reached confluence around the 
fovea, thus producing the foveal sparing phenotype. We observed three distinct 
stages in the development of foveal sparing; these stages characterize the natural 
course of the phenomenon. In stage 1, parafoveal atrophic lesions emerge, with 
several intact RPE connections between the fovea and the surrounding vital RPE 
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(Figure 4A and 4C). In stage 2, the atrophic RPE lesions interconnect, leaving only 
a single isthmus of RPE, thus resulting in a “peninsula-like” appearance (Figure 
4E and 4G). Stage 3 is characterized by an isolated fovea that is surrounded 
completely by RPE atrophy (Figure 4I and 4K). We measured the expansion rate 
of the atrophic lesions in four patients using the FAF follow-up data (Table 2). The 
rate of expansion ranged from 0.832 to 2.363 mm2/year in these patients, and 
the rate was positively correlated to the size of the atrophic lesions. Given this 
wide range of expansion rates, it is unclear how long foveal sparing is present 
before the foveal structure and function become significantly affected by the 
profound atrophy; however, we observed that the foveal structure and function 
were relatively preserved for up to six years in patients 8 and 12. Eventually, the 
remaining foveal tissue became progressively smaller, and atrophy of the central 
fovea was observed in four eyes (in patients 10, 11 and 12, Figures 4L, 4N and 5E); 
this was accompanied by a decline in central vision to 20/200 or worse.
Table 2. Results of progression analysis on fundus autofluorescence (FAF) imaging during follow-up 
in STGD1 patients with foveal sparing.
*Measurements were performed by two authors (RACvH and NMB), and the average of the two 
measurements are shown. Mean interobserver variance was 2.7% (range: 0.4%-9.8%).
Genetic analysis and mutation screening
An examination of the pedigrees of the 13 unrelated patients with foveal sparing 
revealed a recessive inheritance pattern in five patients; the other eight patients 
appeared to be isolated cases. Mutations in the ABCA4 gene were identified in 19 
of the 26 alleles (73%, Table 3). We identified compound heterozygous mutations 
in six patients (46%) and single heterozygous mutations in the other seven 
patients (54%). In total, 13 different ABCA4 variants were identified, including 
nine missense mutations, two splice site mutations, one nonsense mutation, and 
one synonymous variant that affects splicing.23 Each of these variants has been 
described previously (Table 3).
The mutational effects of five of the identified mutations have been reported 
previously (Table 4). Although functional data regarding the effects of the other 
eight mutations is not available, we can speculate on the functional effect of 
the nonsense mutation (p.Gln1292*). Assuming that the resulting mRNA is not 
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subject to nonsense-mediated decay, the resulting truncated protein will lack 
the second extracytoplasmic domain and the nucleotide-binding domain, which 
are involved in substrate and ATP binding, respectively.32 Table 5 summarizes 
the identified missense mutations in ABCA4, including allele frequencies in the 
exome variant server (EVS) and scores obtained from selected predictive tools. 
No differences in phenotype were observed between patients carrying severe 
mutations and patients carrying mild mutations. Finally, no pathogenic mutations 
in the PRPH2 gene were identified in this cohort, thereby excluding the possibility 
of pseudo-Stargardt pattern dystrophy.27 
Table 3. ABCA4 mutations in STGD1 patients with foveal sparing
NI, not identified. * = nonsense mutation. NA, not applicable
Discussion
Here, we present the clinical characteristics of 13 STGD1 patients with foveal 
sparing in one or both eyes. The majority of these patients were diagnosed with 
late-onset STGD1; only three patients developed symptoms prior to the age of 
45 (Table 1). In eyes with foveal sparing, visual acuity was relatively preserved; 
nevertheless, most of the patients experienced some loss of vision, which caused 
them to seek ophthalmologic care. In these instances, ophthalmoscopy readily 
revealed advanced retinal disease, with yellow-white irregular pisciform flecks 
and profound RPE atrophy adjacent to the fovea. Automated perimetry revealed 
perifoveal scotomas of various sizes with intact foveal sensibility. This combination 
of mild vision loss together with profound retinal abnormalities is typical among 
STGD1 patients with foveal sparing. 
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Table 4. Functional implications of ABCA4 mutations
ATP, adenosine triphosphate; ATPase, adenosine triphosphatase.
Recently, Fujinami et al. reported the clinical and molecular findings of a cohort 
of Stargardt patients with a foveal sparing phenotype.26 In their study, the authors 
included STGD1 patients with a functional fovea, irrespective of the presence of 
parafoveal RPE atrophy; thus, they studied a heterogeneous cohort of 40 patients. 
In contrast, in our cohort we defined foveal sparing as profound RPE atrophy that 
surrounded the fovea by at least 180 degrees and spared the fovea’s structure 
and function. This clinical presentation is an rare finding among STGD1 patients, 
and our strict selection criterion resulted in a small but homogeneous cohort 
with a consistent phenotype and excluded STGD1 patients with late-onset disease 
that initiated with foveal atrophy. Moreover, our definition of foveal sparing is 
consistent with previously reported cases of foveal sparing in patients with other 
degenerative diseases.6, 8, 33, 34 Despite the differences between our cohort and that 
the cohort described by Fujinami et al., the visual acuity and electrophysiology 
findings in their paper are similar to the findings in our study; nevertheless, none 
of our patients were carriers of the ABCA4 p.Arg2030Gln missense mutation, 
which was suggested previously to be prevalent among STGD1 patients with 
foveal sparing.26
The etiology of foveal sparing
In our study, screening the ABCA4 gene identified 19 pathogenic mutations that 
were described previously in STGD1 and/or other ABCA4-associated retinopathies 
(Table 3);16, 23, 35-45 interesting, however, foveal sparing was not described in any 
of the patients who were previously reported to carry these mutations. In a 
previously proposed model that links phenotype severity to the degree of residual 
ABCR function,23, 24 late-onset STGD1 with foveal sparing was placed at the mild 
end of the spectrum of ABCA4-associated retinopathies.3 Indeed, none of our 
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STGD1 patients with foveal sparing had two ABCA4 variants that are associated 
with a severe loss of ABCR function. However, our knowledge regarding the 
functional consequences of ABCA4 mutations identified to date is limited (Table 
4). It can be extremely difficult to assess the effect of most missense variants 
using in silico predictions and allele frequencies in healthy individuals, for whom 
this information is often incomplete (Table 5); in addition, assessing the combined 
effect of carrying two ABCA4 variants is particularly difficult. Functional assays 
are needed in order to form definitive conclusions regarding the effects of these 
mutations. 
Because foveal sparing can be present in phenotypes that are independent of 
ABCA4 mutations, including AMD and mitochondrial retinal dystrophy,6, 8-12, 17, 20, 25, 
44, 45 genetic factors other than ABCA4 mutations are likely involved. These factors 
could include single-nucleotide polymorphisms (SNPs) and even mutations in 
retina-specific genes other than ABCA4, which suggests that a digenic or triallellic 
trait—in combination with the identified ABCA4 mutations—may underlie the 
degenerative pattern observed in our patients. Moreover, anatomical, metabolic, 
and/or biochemical factors may underlie foveal sparing. For example, the average 
peak density of cones in the fovea is 199,000 cones/mm2, but can range from 
98,200 to 324,100 cones/mm2.2 The initial number of cones in the fovea cones 
may play a role in the development of foveal sparing; however, adaptive optics 
imaging techniques—which can provide the resolution needed to determine 
photoreceptor density in vivo—are not generally available in most ophthalmology 
practices. Another factor to consider is that S (“blue”) cone photoreceptors, 
which are absent in the foveal center, seem to be more vulnerable to retinal 
disease than M and L cones, although this selective vulnerability has not been 
reported in STGD1.46, 47 Moreover, parafoveal rods appear to be more vulnerable 
than cones to the effects of aging and all-trans-retinal‒mediated damage.48-50 This 
difference may arise from the sole dependence of rods on the RPE for replenishing 
11-cis-retinal; in contrast, cones are also supplied by Müller cells.51 Furthermore, 
cone cells have a slower turnover rate of outer segments compared to rods,52 
although this does not necessarily result in higher all-trans-retinal levels in RPE 
cells, as regeneration is faster in cones than in rods.51 Macular pigments, which 
can filter out high-energy light, may also serve a protective role, given that light 
exposure is crucial in the pathogenesis of STGD1.53, 54 In addition, rod-derived 
cone viability factor (RdCVF), which is believed to prevent cone degeneration,55 
may also play a role. Importantly, the absolute levels of macular pigments and 
RdCVF may differ between STGD1 patients with foveal sparing and STGD1 patients 
without foveal sparing. 
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Differential diagnosis and clinical significance of foveal sparing
When forming a diagnosis, foveal sparing‒associated clinical entities other than 
late-onset STGD should be considered, including geographic atrophy in AMD, 
mitochondrial retinal dystrophy associated with the m.3243AàG mutation, 
central areolar choroidal dystrophy, and pseudo-Stargardt pattern dystrophy.6, 
9, 10, 27, 29 Importantly, misdiagnosing this condition can lead to inappropriate 
genetic counseling (these diseases display unique inheritance patterns) and/
or an inaccurate estimate of the prognosis. Furthermore, in the event of an 
incorrect diagnosis of AMD, prescribing vitamin A‒rich nutritional supplements 
can accelerate the accumulation of all-trans-retinal‒derived toxins and increase 
the rate of disease progression, as shown in the retinas of homozygous 
Abca4-knockout mice.56 STGD1 with foveal sparing can be diagnosed based 
on the presence of characteristic pisciform flecks together with RPE atrophy 
surrounding the fovea, a “dark choroid” sign on FA, and genetic analysis of the 
ABCA4 gene. FAF imaging can clearly highlight the fundus flecks, which appear 
as hyperautofluorescent flecks, and RPE atrophy, which appears as an absence 
of autofluorescence. Retinal dystrophies that closely resemble STGD1 can follow 
other patterns of inheritance—for example, due to mutations in mitochondrial 
DNA—or can be autosomal dominant, with variable penetrance and expression. 
The fact that the “dark choroid” sign is present in approximately 85% of patients 
with STGD157 suggests a pivotal role for genetic analysis in the diagnosis of retinal 
dystrophies.  
In conclusion, foveal sparing is a clinical phenomenon that occurs primarily in 
patients with late-onset STGD1 and is associated with the relative preservation 
of visual acuity, although visual acuity ultimately deteriorates by the end-stage of 
the disease. STGD1 patients with foveal sparing may be promising candidates for 
future therapeutic trials, as delayed degeneration of the fovea increases the time 
window for applying therapeutic interventions such as gene therapy. Although 
the mechanisms that underlie foveal sparing are currently unclear, expanding our 
knowledge of the metabolic and biochemical processes that lead to foveal sparing 
can facilitate the development of therapeutic strategies aimed at preserving 
foveal function. 
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Foveal sparing in central retinal dystrophies
“Foveal sparing occurs in patients with Stargardt disease, central areolar 
choroidal dystrophy, mitochondrial retinal dystrophy, and pseudo-Stargardt 
pattern dystrophy. The presence of foveal sparing in central retinal dystrophies 
with distinctly different underlying mechanisms suggests a disease-independent 
mechanism that prolongs the survival of the fovea. Long-term follow-up data 
provided insight in the natural course of foveal sparing. The associated preservation 
of visual acuity is important for the individual prognosis and has implications for 
the design of future therapeutic trials for inherited retinal disease.
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PURPOSE: To describe foveal sparing (FS) in central retinal dystrophies (RD).
METHODS: Participants for this retrospective study were identified from the 
retinal dystrophy database of the Department of Ophthalmology at Radboud 
University Medical Center. FS was defined as an intact foveal structure surrounded 
by at least 180° of chorioretinal atrophy, and a best-corrected visual acuity 
(BCVA) of <1.0 LogMAR (>20/200 Snellen). Eligible eyes were identified using 
fundus autofluorescence (FAF) images, and FS was confirmed using near infrared 
reflectance (NIR) imaging and spectral-domain optical coherence tomography 
when available. Clinical and demographic data were extracted from medical 
records. We performed quantification of FS and chorioretinal atrophic areas using 
semi-automated software on FAF and NIR images. We calculated the chronological 
change using eye-wise linear regression. 
RESULTS: We identified 36 patients (56 eyes) with FS. RDs included: Stargardt 
disease (STGD1;20 patients), central areolar choroidal dystrophy (CACD;7 
patients), mitochondrial retinal dystrophy (MRD;6 patients), pseudo-Stargardt 
pattern dystrophy (PSPD;3 patients). Median age at first presentation was 60 
[inter-quartile range (IQR) 54–63] years. Median BCVA at first presentation 
ranged from 20/25 Snellen in STGD1, to 20/38 Snellen in MRD. Progression of 
the chorioretinal atrophic area ranged from 0.26 [0.25–0.28] mm/year in PSPD, 
to 0.14 (0.11–0.22) in CACD. Change in FS area over time was similar between the 
different dystrophies.
CONCLUSIONS: The presence of FS in different RDs suggests a disease-independent 
mechanism that prolongs the survival of the fovea. The associated preservation of 
BCVA is important for the individual prognosis and has implications for the design 
of therapeutic trials for RDs. 
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Introduction
Retinal dystrophies (RDs) are among the leading causes for legal blindness in 
industrial countries.[1-3] Despite differences in underlying mechanisms, the 
common pathway in these disorders involves a selective atrophy of outer retinal 
layers, retinal pigment epithelium and associated choroidal layers, functionally 
paralleled by the development of absolute scotomas.[4] 
Typically, patches of chorioretinal atrophy initially occur in the parafoveal retina. 
With spread over time, multifocal atrophic areas coalesce, and new atrophic 
areas may occur. On clinical examination, the fovea may remain uninvolved from 
chorioretinal atrophy until late in the course of the disease, when the fovea finally 
becomes atrophic. This phenomenon is referred to as “foveal sparing”,[5-9] and 
can be observed in several RDs, such as autosomal recessive Stargardt disease 
(STGD1),[8, 10-13] central areolar choroidal dystrophy (CACD),[14] and maternally 
inherited diabetes and deafness (MIDD).[15, 16] Geographic atrophy and reticular 
pseudo-drusen in age-related macular degeneration may also show a tendency to 
spare the fovea for a prolonged period of time.[7, 9, 17-20] 
Although there is no consensus definition of the term “foveal sparing”, it could be 
distinguished from a perimacular ring scotoma, which is located more peripherally 
in the macula, resulting in a central visual island frequently observed in retinitis 
pigmentosa (RP).[21] Bull’s eye maculopathy is another separate entity, where 
an intact fovea is surrounded by a – usually oval shaped – area of outer retinal 
atrophy. 
Historically, the term “foveal sparing” was coined by Hart et al. to describe 
the sparing of the fovea from hemifield defects.[22] In the context of macular 
disorders, Hart et al. were the first to describe a “sparing of foveal sensitivity in 
macular disease”,[22] while Sarks et al. specified an “enlargement and coalescence 
of atrophy into an almost complete ring around the fovea”.[7] These perimetric 
and funduscopic terms were brought together by Sunness et al. using the term 
“foveal sparing”, defined as an intact foveal structure surrounded by outer retinal 
and RPE atrophy.[20] The atrophy may either arrange as multiple independent 
spots, or in a ring or horseshoe-like fashion.[20] 
The etiology of foveal sparing remains unclear, but it is highly remarkable that 
such a distinct preservation of the central macular tissue occurs in a variety of 
heterogenic retinal disorders. This suggests that the underlying mechanism of 
foveal sparing is, to a certain degree, disease-independent.
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To date, the manifestations of foveal sparing in retinal dystophies has not 
been analyzed systematically. Knowledge regarding the natural history of this 
peculiar phenomenon becomes even more important in the light of emerging 
therapeutic modalities aimed at prevention or slowing down of progressive 
chorioretinal atrophy in RDs (e.g. NCT01367444, NCT01736592, NCT01469832, 
and NCT02402660 on www.clinicaltrials.gov). 
A better understanding of the disease course of foveal sparing enables better 
stratification when including patients into a clinical trial and allows for a 
tailor-made prognosis. In addition, insight in the underlying mechanisms resulting 
in foveal sparing could open up new avenues for therapeutic approaches aimed 
at foveal preservation. In this study, we will provide a detailed description of 
foveal sparing in a large cohort of RD patients. We will analyze commonalities 
and discriminating features among the different RDs, and we will discuss the 
consequence for pathophysiological mechanisms regarding foveal sparing. 
Methods
Patients selection
For this retrospective study, we employed the RD database of the Department of 
Ophthalmology at Radboud University Medical Center. The 1800 patients in this 
database have all been diagnosed with some form of inherited retinal disease, 
the large majority of which have been analyzed genetically. To readily identify 
patients with foveal sparing, we limited our search to patients with at least one 
fundus autofluorescence imaging (FAF) investigation. A genetically confirmed 
clinical diagnosis was also a requirement to be included in the search. In the 
context of this study, the foveal sparing had to fulfill two criteria. First, the fovea 
had to be surrounded by at least 180° of chorioretinal atrophy.[6, 8, 9] Second, a 
best-corrected visual acuity (BCVA) of ≤1.0 logMAR (≥ 20/200 Snellen) had to be 
present.[8] Both eyes of a patient were included unless foveal sparing was only 
present in one of them.
The goal of the research is to study chorioretinal atrophy localized to the posterior 
pole, therefore we excluded generalized chorioretinal atrophy disorders like; 
retinitis pigmentosa, choroideremia, Bietti crystalline dystrophy, and gyrate 
atrophy. We excluded retinopathies with solely loss of photoreceptors encircling 
the fovea, like in Bull’s eye maculopathy, because these entities do not fulfill the 
criteria of chorioretinal loss. 
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This retrospective study was approved by the Institutional Ethics Committee 
at Radboud University Medical Center (Nijmegen, The Netherlands), and was 
performed in accordance with the Tenets of the Declaration of Helsinki. All patients 
provided informed consent prior to additional ophthalmologic examinations to 
complete the clinical assessment and blood collection.
Clinical data and image acquisition
A detailed medical and ophthalmologic history, including historical BCVA data, 
age at onset, age at diagnosis, and initial symptoms, was obtained from the 
medical records. Age at onset was defined as the age at which the patient first 
experienced visual complaints. In asymptomatic persons and patients where the 
age at onset could not be determined, the age at disease onset was considered 
equivalent to the age at diagnosis.
Standard imaging protocols were followed in the acquisition of retinal images. 
The FAF and NIR images were acquired using Spectralis HRA+OCT (Heidelberg 
Engineering, Heidelberg, Germany). The field of view was set to 30° x 30° or 
55° x 55° with a minimum resolution of 768 x 768 pixels and centered on the 
macula. Single images were automatically aligned and averaged to maximize 
the signal-to-noise ratio using the manufacturer’s software (automatic real-time 
[ART]-mode, Heidelberg Eye Explorer, Heidelberg Engineering). The SD-OCT scans 
were performed with the same device, and up to 100 single images were averaged 
to improve image quality. SD-OCT scans were 6.3 mm horizontal line scans through 
the fovea and follow-up mode was used for follow-up images. Furthermore, color 
fundus photographs (CFP) were obtained using a Topcon TRC50IX retinal camera 
(Topcon Corporation, Tokyo, Japan).  
Image grading
Qualitative assessment
Atrophy of retinal pigment epithelium and outer retina is typically associated by a 
sharply demarcated zone of dramatic reduction of autofluorescence (analogous to 
the previously employed definition of “definitely decreased autofluorescence”).
[23] Where available, spectral-domain optical coherence tomography (SDOCT) 
was used to confirm foveal outer retinal integrity. If foveal sparing was lost during 
follow-up, all later visits were excluded from the analysis. 
Qualitative assessment of the available FAF and SD-OCT images was performed 
to identify characteristic morphological features and atrophy patterns. In this 
explorative study, image analysis was performed by one trained reader (ML). As a 
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result of the retrospective nature of this dataset, some of the image grading tasks 
could not be performed in every eye or for every visit, because image availability 
varied per patient visit.
Quantitative assessment 
Measurements of atrophic area and foveal sparing area were performed as 
previously described,[9] [24] using the RegionFinder software (Heidelberg 
Engineering, version 2.5.5.0). In brief, the dramatic decrease of the FAF signal in 
GA areas compared with non-atrophic retinal areas is used by the Region-Finder 
for the segmentation of atrophy areas. The examiner/operator is required to 
define the center of each atrophic area. The software’s so-called region-growing 
algorithm then identifies the borders of each atrophic area by the sharp change 
in signal intensity between atrophic and non-atrophic retina. This employed 
version of the RegionFinder includes a feature that automatically registers FAF 
to corresponding NIR images and allows the operator to easily switch from one 
modality to the other, thereby semi-automating the quantification of retinal 
pigment epithelium (RPE) atrophy and foveal sparing areas. In case no NIR images 
were available, measurements were only performed if the atrophy could be 
clearly discriminated from the physiologically decreased foveal autofluorescence 
due to the physiological attenuation of the autofluorescence signal in the foveal 
area by macular pigment. Atrophy measurements were performed in either 30° 
x 30° or 55° x 55° images within a single eye, as the software does not allow for 
quantitative comparison between images of different sizes. Only areas of sharply 
demarcated RPE atrophy, or “definitely decreased autofluorescence” (DDAF), 
were quantified, and quantification of foveal sparing required an area of DDAF 
surrounding the fovea by at least 270°.[9] Therefore, the foveal sparing area was 
not quantified in eyes with horseshoe-shaped atrophy surrounding the fovea by 
<270°. In case of incomplete foveal sparing, a constraint was placed by manually 
drawing a line at the most narrow place of the incomplete part of the residual 
foveal island.
Subfoveal retinal thickness (SRT) was assessed in SDOCT scans, transversing 
the foveola, as the distance between the internal limiting membrane (ILM) and 
the outer border of OCT band 4 (corresponding to the RPE/Bruch’s membrane 
complex),[25] using the Heidelberg Eye Explorer “distance tool” (Heidelberg 
Engineering). A representative example is given in supplementary Figure 1. 
Furthermore, the integrity of the retinal bands at the fovea was assessed.
As a result of the retrospective nature of this study, some of the image grading 
tasks could not be performed in every eye or for every visit, because image 
availability varied per patient visit.
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 117
117
Clinical characteristics of Stargardt disease
2
Genetic analysis
All samples were processed by the Department of Human Genetics of the 
Radboud University Medical Center in Nijmegen, the Netherlands. Genetic testing 
was targeted conform the clinical diagnosis. 
Stargardt disease (STGD1): ABCA4 analysis was performed using arrayed primer 
extension analysis (APEX) microarrays (Asper Biotech, Tartu, Estonia) and 
Sanger sequencing validation. The presence of two variants in the ABCA4 gene 
confirmed the diagnosis STGD1. In cases where only one variant in ABCA4 was 
identified, but the phenotype was characteristic for STGD1, this was deemed 
sufficient for the diagnosis. The following genetic variants were defined as 
severe: protein-truncating, canonical splice-site variants, as well as deletions 
spanning at least one exon. In case of missense variants, severity was predicted 
by bio-informatic means (SIFT, Polyphen, MutationTaster, and CADD). Cases with 
a clinical Stargardt-like phenotype and a mutation in the PRPH2 gene, with or 
without an additional variant in a single ABCA4 allele, were considered having 
pseudo-Stargardt pattern dystrophy (PSPD).[26]
Central areolar choroidal dystrophy (CACD): analysis of PRPH2 was conducted 
using Sanger sequencing. One variant in the PRPH2 gene, combined with the 
typical CACD phenotype, was considered sufficient to establish the diagnosis.
Mitochondrial retinal dystrophy (MRD): mitochondrial DNA was screened for 
mutations. The presence of the m.3243A>G mitochondrial mutation, combined 
with a characteristic clinical picture and visual symptoms, was required for the 
diagnosis of mitochondrial retinal dystrophy.
Statistical analysis
R version 3.3.0 was used to perform statistical analysis. Decimal-scale visual acuity 
data were converted to LogMAR (Log(10) of the Minimal Angle of Resolution).
The rate of atrophy progression, and foveal sparing area loss over time, were 
calculated by eye wise linear regression from square-root transformed values, to 
reduce the dependency of enlargement rates on baseline lesion size, as previously 
suggested.[27] In this retrospective analysis, data for these parameters were 
not available for every single visit in every patient. To avoid exclusion of all data 
from a particular visit in case of a single missing parameter, subsets of visits were 
analyzed, when necessary. In these cases, cohort sizes and observation intervals 
were calculated separately. Unless stated differently, all data given represent 
medians and corresponding inter-quartile ranges. In this exploratory analysis, 
statistical tests for significance were not performed. 
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Results
A total of 336 patients from the database of 1800 patients met the search criteria: 
FAF images and a genetically confirmed clinical diagnosis. In this cohort of 336 
patients, we identified 36 individuals (56 eyes) with foveal sparing as previously 
defined. In 20 patients (56%), foveal sparing was present or developed in both 
eyes. Overall, this cohort included 20 of 176 (11.4%) STGD1 patients (31 eyes), 7 
of 103 (6.8%) patients diagnosed with CACD (10 eyes), 6 of 21 (28.6%) MRD cases 
(10 eyes), 3 of 36 (8.3%) PSPD patients (5 eyes). A comprehensive overview of all 
patient characteristics is provided in Table 1. Retinal images of foveal sparing in 
each of the conditions are depicted in Figures 1-4. 
Table 1: Summary of patient characteristics
VA = visual acuity. Some patients mentioned two initial complaints. Y= years
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Figure 1: Longitudinal retinal imaging of a representative eye with Stargardt disease (STGD1)
Serial fundus autofluorescence images (upper row), and spectral-domain optical coherence 
tomography (SD-OCT) scans centered on the fovea (lower row), of a representative right eye with 
foveal sparing in a patient with STGD1. Multiple atrophic lesions may be seen that coalesce over 
time. Cystoid lesions in the inner retina (asterisks) and elevation of the borders of outer retinal 
atrophy (arrowheads) may be seen. Location of the SD-OCT scan is indicated by the green line. 
Figure 2: Retinal imaging of two representative central areolar choroidal dystrophy (CACD) cases
Fundus autofluorescence (FAF), near infrared reflectance and spectral domain optical coherence 
tomography (SD-OCT) scans of the left eyes of two patients with CACD. Foveal sparing may 
demarcate only poorly on FAF. Arrow: center of the foveal pit; Yellow bar: areas of intact retinal 
pigment epithelium in proximity to the foveal depression. Location of the SD-OCT scan is indicated 
by the green line.
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Figure 3: Longitudinal retinal imaging of a representative eye with mitochondrial retinal dystrophy (MRD)
The left eye of a patient with MRD showing gradual contraction of the remaining foveal island 
in 21 months. Fundus autofluorescence (upper row) and near infrared reflectance (lower row) 
demonstrate retinal pigment epithelium atrophy encircling the fovea by 360°. The relatively spared 
fovea almost exactly centers on the foveal depression, as also shown by the spectral-domain optical 
coherence tomography scan (position is indicated by green line). 
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Figure 4: Retinal imaging of two representative pseudo-Stargardt pattern dystrophy cases (PSPD)
Fundus autofluorescence (left) and near-infrared reflectance image (right) of two right eyes of 
patients with PSPD. Multifocal areas of macular atrophy are usually observed in conjunction with 
more peripheral atrophic spots. Spectral-domain optical coherence tomography (inset, centered on 
the fovea) discloses outer retinal atrophy and disruption of retinal structure. The yellow bar indicates 
preservation of the retinal pigment epithelium.
Baseline
There was little variability in the age at first clinical presentation among the 
different RDs included. Median age at first presentation was 60 [54 – 63] years. 
Median values ranged from 56 years in CACD to 62 in PSPD (Table 1). Variability 
in the duration from experienced symptoms onset to the time where a dystrophy 
was diagnosed was more pronounced, with median values ranging from 0.8 [0.3 
- 2.3] years in CACD to 15 [12 - 38] years in PSPD (Table 1). 
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At first presentation, median BCVA values were relatively high, ranging from 0.11 
[0.09 – 0.26] LogMAR (20/25 [20/24 – 20/36] Snellen) in STGD1, to 0.28 [0.15 – 
0.30] LogMAR (20/38 [20/28 – 20/39] Snellen) in MRD. 
Qualitative assessment of the available FAF and SD-OCT images revealed 
characteristic features of foveal sparing morphology and atrophy progression. At 
baseline (first visit), foveal sparing was present in 52 eyes of 36 patients (bilateral 
in 15 patients). Thirty-two eyes (62%) presented with a multifocal atrophy pattern 
(e.g. Figure 1), 15 eyes (29%) presented with a horseshoe-type pattern (e.g. Figure 
1), and we observed a solitary foveal island in 5 eyes (e.g. Figure 3). Sixteen eyes 
did not show sufficient atrophic changes to warrant the diagnosis and in six eyes 
there may have been foveal sparing, but at the time of investigation the foveal 
tissue was already lost. We compared both eyes in these 36 patients. We observed 
a high degree of symmetry between both eyes in individual patients: in MRD and 
PSPD, foveal sparing could be observed bilaterally in 66.6% of cases. Slightly lower 
values of 55% and 43% were found in STGD1 and CACD (Table 1).
Follow-up
Over time, BCVA remained relatively stable when grouped according to underlying 
conditions. Decline of BCVA was most noticeable in STGD1 and PSPD, with a loss 
of 0.11 [0.01 – 0.13], and 0.13 [0.06 – 0.15] LogMAR, respectively. 
Follow-up was available in 21 patients (58%). Of the 16 eyes without foveal sparing 
at baseline, five eyes developed foveal sparing over a median period of three 
years (range 1 - 4 years). We noticed this development only in STGD1 patients, 
and in none of the other conditions. Foveal sparing was lost during follow-up in 
five eyes over a median period of five years (range 3 – 8 years). In four of these 
eyes, a multifocal pattern was present at baseline, and foveal sparing was initially 
not present in one eye. 
In all conditions, we noticed three distinct and consecutive patterns of atrophy, 
starting with multifocal atrophic lesions immediately adjacent to the fovea, to 
a horseshoe-type pattern into an isolated foveal island before the occurrence 
of central atrophy. Figure 5 shows these four stages in the progression of foveal 
sparing in both eyes of a patient with STGD1.
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Figure 5: Foveal sparing atrophy progression pattern
Fundus autofluorescence images of the right (A – C) and left (D – F) eye of a Stargardt patient 
with asymmetrical foveal sparing. Multifocal areas of retinal pigment epithelium (RPE) atrophy (A) 
develop and coalesce over time, forming a horseshoe-type atrophy pattern (B). In the last picture (C) 
the isthmus is severed leaving an isolated foveal island. The left eye reveals a similarly progressive 
atrophy pattern, albeit in a earlier stage.
5C is has been published earlier in “Foveal sparing in Stargardt disease”, by Van Huet and Bax et al, 
IOVS, October 2014.
5E has been published earlier in “Clinical and genetic characteristics of late-onset Stargardt’s 
disease” by Westeneng- van Haaften et al, Ophthalmology, June 2012.
Atrophy progression rates varied between 0.26 [0.25 – 0.28] mm/year in PSPD, to 
0.14 [0.11 – 0.22] mm/year in CACD (Figure 6A). Loss of surface area of the spared 
fovea ranged from 0.06 [0.08 – 0.02] mm/year in STGD1 to 0.10 [0.15 – 0.10] mm/
year in MRD (Figure 6B), and loss of SRT ranged from 13.84 [19.92 – 9.47] µm/
year in MRD to 0.90 [5.13 – 1.50] µm/year in CACD. 
A summary of all BCVA measurements and quantitative retinal image analyses 
can be found in Table 2.
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Figure 6: Change of atrophy area and foveal sparing area over time
Change of atrophy area (A) and foveal sparing 
area (B) over time as measured in registered 
fundus autofluorescence images in eyes with 
distinct retinal dystrophies and foveal sparing. 
STGD1: Stargardt disease, CACD: Central areolar 
choroidal dystrophy, MRD: Mitochondrial retinal 
dystrophy, PseudoSTGD: pseudo-Stargardt 
pattern dystrophy, mm/y = millimeter per year.
Please note progression rates were square 
root transformed to reduce the dependency 
of enlargement rates on baseline lesion size. 
The horizontal bar inside the boxes represents 
the median, the hinges correspond to the 25th 
and 27th percentiles. The upper and the lower 
whiskers extend to the largest (resp. smallest) 
value no further than 1.5 * IQR from the hinges.
Genetic analysis
An overview of all genetic variants is given in Table 3. In only six of twenty STGD1 
cases (30%) two ABCA4 variants were detected. The most prevalent variant is 
c.5461-10T>C (5/26 = 19%). At least one severe ABCA4 variant was detected in 
19 cases (95%). In all CACD cases the same PRPH2 missense variant (p.Arg142Trp) 
was identified. Likewise, in all MRD cases the same variant (m.3243A>G) was 
detected in the mitochondrial DNA.
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 125
125
Clinical characteristics of Stargardt disease
2
Table 2: Sum
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ary of clinical and reti
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 = best corrected visual acuity, FS = foveal sparing, logM
A
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*c.5461-10T>C is found in cis w
ith c.5603A
>T, but the latt
er com
m
on coding variant does not contribute to the pathogenicity of this allele and thus om
itt
ed
**c.2588G
>C is not analyzed for presence of c.5603A
>T
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Discussion
Foveal sparing is a regularly encountered phenomenon in a variety of retinal 
disorders, including RDs like STGD1 and geographic atrophy in age-related 
macular degeneration. This study analyses the characteristics of foveal sparing 
in a wide range of retinal dystrophies, including STGD1, CACD, MRD, and PSPD. 
All the patients were in their 5th decade or older at first presentation, indicating 
that foveal sparing mainly manifests in RD patients with a relatively low rate of 
progression, where visual loss occurs later in life. The manifestation of foveal 
sparing in this heterogenic group of disorders is remarkably similar, in particular 
with regard to the kinetics of atrophy progression towards the fovea, which varies 
only slightly between disorder types. In general, RPE atrophy in foveal sparing 
progresses in a relatively fixed pattern, starting with small, multifocal areas of 
atrophy that surround the fovea. These, then gradually expand in all directions 
and coalesce, forming a horseshoe-type atrophy. The bridge of retinal tissue 
connecting the fovea to the non-atrophic part of the macula gradually narrows 
until this isthmus disappears, leaving a solitary foveal island. In the final stage 
this island is lost to atrophy. This sequence of steps is a common finding in these 
patients and can be of great prognostic help, although the rate of progression 
may differ. This pattern of RPE atrophy was symmetrical in 80% of the bilateral 
cases. This indicates, as already suggested by others,28 that the fellow eye cannot 
automatically serve as control in therapeutic intervention trials for RDs in patients 
with foveal sparing. 
Although the frequency of foveal sparing in our cohort was highest in the MRD 
group (29%), this was much lower than the previously reported number of 84% 
in a 2013 study by de Laat et al.[16] This may be an underestimation on our side 
due to inclusion bias since this study was not primarily designed to estimate the 
prevalence of foveal sparing in RDs, including MRD. 
To date, the underlying mechanism of foveal sparing is incompletely understood. 
Disease independent factors are likely at play in view of the high heterogeneity of 
the underlying disorders. This notion is supported by the virtually identical kinetics 
of atrophy progression towards the fovea observed among most conditions 
(0.06 – 0.10 mm/year). The presence of multifocal areas of chorioretinal atrophy 
surrounding the fovea, and very similar square-root transformed atrophy 
progression rates of 0.116 mm/year were observed in age-related macular 
degeneration.[9] [28] The similarities between the phenomenon of foveal sparing 
in monogenic and multi-factorial disorders further supports the hypothesis of 
disease-independent mechanisms that shape the foveal sparing phenotype.
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The general susceptibility to retinal degeneration may lie in metabolic differences 
between regions of the macula. Those differences may be associated with physical 
characteristics of foveal and peripheral cones; foveal cone outer segments 
physically resemble those of rods rather than peripheral cones. Furthermore, 
Müller cells are short and exist in a 1:1 ratio with fovealar cones, but are longer 
and have a lower ratio extrafoveally. [29]
A number of underlying mechanisms have been proposed involving the 
rod-derived cone viability factor (RdCVF), variations in macular pigment and peak 
distribution as well as cone density, increased vulnerability of certain parafoveal 
photoreceptors, and factors related to RPE and choroid. The RdCVF is secreted 
from rod photoreceptors and protects cones from degeneration.[30] An increased 
sensitivity of foveal cones to RdCVF, possibly complemented by higher secretion 
levels of RdCVF, may result in improved central cone survival. 
A second hypothesis involves the macular pigments: lutein, zeaxanthin and 
meso-zeaxanthin. These carotenoids protect against macular damage through 
their antioxidant properties and by filtering potential harmful blue light. In 
eyes with foveal sparing, an uneven distribution of macular pigment might 
lead to protection of the most central photoreceptors, leaving the parafoveal 
photorecepotors relativeley unprotected.[31, 32] Another explanation may lie in 
the highly variable peak cone density ranging from 98,200 to 324,100 cones/ mm2. 
This remarkable inter-individual variability is much less pronounced in the area 
surrounding the fovea and may contribute to the phenomenon of foveal sparing.
[33] In vivo determination of cone density with adaptive optics could solve the role 
of peak cone density in foveal sparing. Another factor that may be of influence 
is the increased vulnerability to age and degenerative disease of respectively rod 
photoreceptors and short wavelength (blue) S-cone photoreceptors.[34] [35] Both 
rods and S-cones are absent in the foveal center and the increased susceptibility 
to aging and/or disease may explain the relative preservation of the fovea in 
certain patient. An explanation may also lie in the unfavorably high ratio of rods 
per RPE cell in the parafoveal retina that could lead to an earlier decompensation 
of metabolic function promoting perifoveal atrophy.[16, 36] Finally, the unique 
choroidal blood supply to the fovea has been put forward as a factor leading to a 
local protective effect.[37, 38]
A common finding in these foveal sparing patients is late age at which the diagnosis 
is made. The well-preserved visual acuity leads to patient’s delay and at the time 
of the first ophthalmologic consultation large areas of atrophy are already present. 
We know from this and other studies that the atrophy progression rate is relatively 
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slow,[39-41] disease-specific changes have therefore been present for years. In 
the 37 patients with foveal sparing in this study, only one patient experienced 
a scotoma as initial symptom. The large majority (N=26; 72%) patients present 
with loss of visual acuity. This late recognition of patients with foveal sparing 
RDs narrows the window of opportunity for therapeutic intervention, which 
is becoming increasingly important as novel therapeutic approaches emerge 
(NCT01367444, NCT01736592, NCT01469832, and NCT02402660 on www.
clinicaltrials.gov).
In the group of STGD1 patients, the high frequency of self-reported “decreased 
visual acuity” as initial symptom goes together with a high baseline visual acuity 
(0.11 [0.09 – 0.26]) LogMAR (approximately 20/25 Snellen). This is likely due 
to the fact that parafoveal scotomas affect high resolution visual tasks like face 
recognition and reading, whereas BCVA tests rely on the maximum resolution of 
the fovea.[7, 19, 20, 42] It is important to be aware that visual acuity tests are 
an imperfect measurement for macular function – in particular in patients with 
foveal sparing. 
Preservation of the foveal tissue in the late stage of a RD is beneficial to the 
patient. The ProgSTAR study recently showed a stable BCVA in the STGD1 cohort 
with foveal sparing over the course of 3.24 years. In contrast, in the STGD1 cohort 
without foveal sparing and equivalent baseline visual acuity, an average loss of 
one line per year could be observed.[43] 
Recently, it was shown that discrimination between foveal sparing and non-foveal 
sparing STGD1 phenotypes can be made as early as the time the first atrophic 
lesions become apparent, based on parameters like a late age-at-onset and 
thinning of the outer nuclear layer and ellipsoid zone.[8, 40] Yet, biomarkers that 
could predict foveal sparing at an even earlier stage are not available. 
With regard to genetic predisposing factors, it has been suggested that the 
presence of relative mild genetic variants correlate with a less severe phenotype 
and a generally later age of onset.[11, 44] In 14 of the 20 (70%) STGD1 patients 
with foveal sparing, only one ABCA4 variant could be detected. The percentage 
of unidentified second mutations is much lower (30%) in patients with a typical 
Stargardt phenotype with an age-at-onset in the second to third decade, a second 
mutation has not been identified. (In personal communication with Frans P.M. 
Cremers).
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Deep-intronic variants were found in several mono-allelic cases.[45-48] Very 
recently, the hypomorphic intronic variant c.4253+43G>A was found to be 
associated with late-onset STGD1.[49] Zernant and colleagues determined that 
c.5603A>T (p.Asn1868Ile), previously suspected to be benign because of its 
high prevalence in the general population (minor allele frequency of 0.07), is 
disease-causing[50]. This variant was typically found in a compound heterozygous 
manner with a severe ABCA4 variant in ~50% of mono-allelic cases and in ~80% 
of late-onset STGD1 cases.[50] Runhart et al. in addition found significant 
differences in age-at-onset between affected siblings and even non-penetrance 
in three families with asymptomatic bi-allelic siblings of affected persons.[51] The 
penetrance of this variant, when present together with a severe ABCA4 variant in 
the other gene copy, was estimated to be less than 5%, suggesting a crucial role for 
genetic or environmental modifiers in STGD1. In the present study, the c.5603A>T 
variant was found in 3/20 (17%) of STGD1 cases with foveal sparing. In two other 
STGD1 cases where both alleles were identified, mild variants (p.(Ala1038Val) 
and p.[Gly863Ala, Gly863del]) were also found, corroborating the hypothesis that 
late-onset STGD1 can partially be explained by the combination of a severe with 
a mild ABCA4 variant.
Therapeutic approaches for RDs are currently emerging. Recently, the Food and 
Drug Administration (FDA) approved gene therapy for RPE65-associated retinal 
dystrophy, a form of Leber congenital amaurosis. In addition, therapy trials for 
STGD1, choroideremia, Usher syndrome type 2A and several more are underway 
(NCT01367444, NCT01736592, NCT01469832, and NCT02402660 on www.
clinicaltrials.gov). To accurately assess efficacy of new therapeutic modalities in 
clinical trials, careful patient selection and well-thought out outcome measures 
are essential.[52] Eyes with foveal sparing could be candidates for inclusion into 
clinical trials, due to the clearly demarcated, well-measurable areas of progressive 
RPE atrophy and preserved BCVA, allowing for visual stabilization as one of the 
outcome measurement. In addition, in about half of the patients with foveal 
sparing, this phenomenon occurs in both eyes, which opens the opportunity of 
inter-eye comparison. Finally, these patients may benefit greatly from successful 
therapeutic intervention, as prolonged preservation of the fovea is paramount 
to daily functioning, and by extension to quality of life. The use of eyes with 
foveal sparing for clinical trials inevitably also comes with certain pitfalls. A long 
follow-up period would be necessary to accurately assess treatment effect if BCVA 
is used as parameter. And in our cohort, only 43% of the cases has a symmetrical 
disease progression. In such cases, an alternative outcome measure like atrophy 
progression, or change in the size of the spared fovea over time, is preferable.[41] 
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In summary, the phenomenon of foveal sparing was observed in several distinct 
retinal dystrophies. All patients presented with late-onset disease, and the 
pattern of perifoveal RPE atrophy progression was identical in all conditions. 
Remarkable similarities between foveal sparing pattern in RDs and age-related 
macular degeneration may suggests disease-independent mechanisms to shape 
the pattern of foveal sparing. Importantly, the observations made in this study 
will allow ophthalmologists to provide affected patients with a more accurate 
prognosis, and the characteristic aspects in terms of visual function loss and 
atrophy progression should be considered when including foveal-sparing and 
non-foveal sparing eyes in clinical trials. 
Further research – including histopathology studies and detailed retinal imaging 
with adaptive optics – is necessary to elucidate the mechanisms involved in foveal 
sparing. The new insights gleaned from these studies might pave the way for new 
disease-independent (gene-)therapeutic approaches for prolonged preservation 
of foveal tissue in degenerative retinal disease. 
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Supplemental material
Supplemental Figure 1:  Subfoveal retinal thickness (SRT) was assessed in SD-OCT scans. The fovea 
was identified by scrolling through the volumetric SD-OCT dataset. SRT was then measured as 
the distance between the internal limiting membrane (ILM) and the outer border of OCT band 4 
(corresponding to the RPE/Bruch’s membrane complex) using a Caliper tool (yellow) included into 
the sofware. This figure is from a patient with Central areolar choroidal dystrophy (left eye).
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Asymmetric inter-eye progression in Stargardt disease
“Asymmetric inter-eye progression in Stargardt disease is most likely observed 
in patients with a later onset and patients carrying lower pathogenic ABCA4 
combinations. This needs to be considered in novel therapeutic trials with a 
fellow-eye paired controlled design to optimize the power of a study.”
Stanley Lambertus
Nathalie M. Bax
Joannes M.M. Groenewoud
Frans P.M. Cremers
Gert Jan van der Wilt
B. Jeroen Klevering
Thomas Theelen
Carel B. Hoyng 
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6824-6830.
The authors thank the Diagnostic Image Analysis Group, Department of Radiology 
and Nuclear Medicine, Radboud university medical center (Nijmegen, The Neth-
erlands) for providing the image analysis algorithm.
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PURPOSE: Asymmetry in disease progression between left and right eyes can occur 
in Stargardt disease (STGD1) and this needs to be considered in novel therapeutic 
trials with a fellow-eye paired controlled design. This study investigated the 
inter-eye discordance of best-corrected visual acuity (BCVA) and progression of 
retinal pigment epithelium (RPE) atrophy in STGD1.
METHODS: We performed a retrospective cohort study collecting 68 STGD1 
patients (136 eyes) with ≥ 1 ABCA4 variants and ≥ 0.5 year follow-up on BCVA 
and fundus autofluorescence. We compared inter-eye correlations of RPE atrophy 
progression between early-onset (≤ 10 years), intermediate-onset (11 – 44), and 
late-onset (≥ 45) STGD1 and ABCA4 variant combinations by χ²-tests. We identified 
associations of discordant baseline BCVA and RPE atrophy with discordant RPE 
atrophy progression by odds ratios (OR). We defined discordance by differences 
> 1.5 interquartile ranges ± first/third interquartiles.
RESULTS: Progression of RPE atrophy correlated moderately between eyes (ρ = 
0.766), which decreased with later onset (P = 9.8 × 10-7) and lower pathogenicity 
of ABCA4 combinations (P = 0.007). Twelve patients (17.6%) had discordant 
inter-eye RPE atrophy progression, associated with baseline discordance of RPE 
atrophy (OR, 6.50 [1.35 – 31.34]), but not BCVA (OR, 0.33 [0.04 – 2.85]).
CONCLUSIONS: Lower inter-eye correlations are more likely found in late-onset 
STGD1 and patients carrying low pathogenic ABCA4 combinations. To achieve 
the highest power in a therapeutic trial, early-phase studies should minimize 
inter-eye discordance by selecting early-onset STGD1 patients carrying severe 
ABCA4 variants without evidence of asymmetry at baseline.
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 141
141
Clinical characteristics of Stargardt disease
2
Introduction
Stargardt disease (STGD1) is one of the most common retinal dystrophies. Loss 
of macular function causes bilateral loss of visual acuity—usually at childhood.1, 2 
The first manifestations of the disease may also occur in older patients, up to the 
seventh decade.3, 4 In general, the severity of the disease is associated with the 
age of onset: young patients tend to do worse.5 The variation in age of onset and 
rate of progression is, for the most part, the result of combinations of over 900 
variants in the ABCA4 gene.6
ABCA4 encodes the adenosine triphosphate (ATP)-binding cassette, subfamily 
A, member 4 transporter protein, which actively removes all-trans-retinal with 
its conjugate N-retinylidene-phosphatidylethanolamine from the photoreceptor 
outer segment disks.7 Impaired removal results in condensation reactions, 
which lead to toxic levels of bisretinoids in the outer segment disks. Through 
phagocytosis of these outer segments, bisretinoids accumulate as lipofuscin 
deposits in the retinal pigment epithelium (RPE). These lipofuscin deposits are 
observed as yellowish-white flecks in the posterior pole.8 The accumulation of 
toxic lipofuscin eventually leads to atrophy of the retinal pigment epithelium 
(RPE) and photoreceptors with subsequent loss of the neurosensory retina and 
choriocapillaris.9
Over time, RPE atrophy progresses, as uni- or multifocal areas enlarge and 
coalesce. However, there is considerable variability in these patterns of atrophy; 
they range from large central atrophic areas in early-onset STGD1 patients that can 
be seen at adolescence2 to relatively small atrophic lesions encircling the fovea in 
older patients with late-onset STGD1.3 The difference in atrophic lesion not only 
varies between patients10, but also the patterns of RPE loss may differ significantly 
between eyes of one patient. Even though the extent of abnormalities is often 
similar between left and right eyes,11, 12 some cases with remarkable differences 
have been described.13
Profound inter-eye differences in disease progression have impact on the statistical 
power in clinical trials; treated and untreated eyes must demonstrate a larger 
difference than do the inter-eye differences by their natural course. Otherwise, 
the required sample size will be unreasonably large. However, in early-phase 
clinical trials for novel treatments of STGD114-16 and other retinal dystrophies, 
small therapeutic effects have to be evaluated generally within two years with no 
more than a few dozen patients. Thus, better knowledge of inter-eye correlations 
is needed for fellow-eye paired controlled trials in which the untreated eyes of 
participants serve as a control.
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In view of these upcoming interventional trials, we have studied the extent of 
asymmetric inter-eye progression of RPE atrophy in patients with STGD1. Fundus 
autofluorescence (FAF) imaging is a valuable tool to evaluate progression of 
RPE atrophy over time.17-20 We therefore analyzed inter-eye discordance of RPE 
atrophy progression using FAF imaging along with visual acuity. We hypothesized 
that a later disease onset and less pathogenic combinations of ABCA4 variants 
contribute to asymmetric inter-eye progression, and that the asymmetry will 
increase when asymmetry at baseline is already present.
Methods
Patient selection
We selected patients from the STGD1 database, containing 454 cases, of the 
Department of Ophthalmology at Radboud university medical center (Nijmegen, 
The Netherlands). We included patients in whom the clinical diagnosis of STGD1 
was supported by the presence of ≥ 1 (likely) pathogenic ABCA4 variants with a 
follow-up data of ≥ 6 months on FAF imaging. Ninety-three STGD1 patients met 
these inclusion criteria.
Ten cases were excluded because no RPE atrophy had developed during the entire 
follow-up time. Nine cases displayed RPE atrophy to such a degree that the lesions 
extended beyond the limits of the FAF image. One case was excluded because 
choroidal neovascularization occurred in one eye. Five cases were excluded 
because they participated in an interventional trial.21 The remaining 68 cases were 
included in this study. The patient inclusion process is shown in Supplemental 
Figure 1. This retrospective cohort study was approved by the Institutional Ethics 
Committee and was performed in accordance with the Declaration of Helsinki.
Measurements
We documented sex, age at onset, age at baseline, and follow-up time. Age at 
onset was defined as either the age at which visual complaints were first noted, 
or, if unavailable, the age when the diagnosis was made. Disease onset groups 
were based on previously reported cut-off points: early-onset STGD1, ≤ 10 years2 
and late-onset STGD1, ≥ 45 years.3 The remaining patients were grouped as 
intermediate-onset STGD1, 11 to 44 years. The age at baseline was the first visit 
with available imaging and visual acuity tests. 
Best-corrected visual acuity (BCVA) was measured with a Snellen or Early Treatment 
Diabetic Retinopathy Study chart, then transformed into the logarithm of the 
minimum angle of resolution (logMAR) for analysis. Fundus autofluorescence (λ = 
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488 nm, emission 500 –700 nm) imaging was performed using a confocal scanning 
laser ophthalmoscope (Spectralis HRA+OCT; Heidelberg Engineering, Heidelberg, 
Germany). The field of view was set at 30° × 30° or 55° × 55° and was centered on 
the macula.22
Image quantification
The total RPE atrophy area was automatically quantified in FAF images by an 
observer-independent image analysis algorithm. The algorithm automatically 
segmented the area starting from an arbitrarily selected seed point inside the 
atrophic area. This method was based on a combination of a region growing 
algorithm and a dynamic, user-independent threshold selection procedure using 
Otsu thresholding. Areas were square-root (√) transformed to correct for baseline 
RPE atrophy area.23  A good agreement has previously been observed between 
manual area measurements and the automatically quantified values (Sanchez CI, 
et al. IOVS 2015;56:ARVO E-Abstract 5258), and was found to be consistent with 
the agreement within this cohort (intra-class correlation coefficient, 0.977; 95% 
confidence interval [CI], 0.951 – 0.987).
Genetic analysis
All reported ABCA4 variants (Supplemental Table 1) were classified as follows: 
1) pathogenic: truncating alleles, significantly enriched in ABCA4-LOVD (http://
www.LOVD.nl/ABCA4, in the public domain), which contains 6903 variants (861 
unique variants) reported in 3987 persons with STGD1 or autosomal recessive 
cone-rod dystrophy (Cornelis SS, Cremers FPM, unpublished data, 2016); 2) likely 
pathogenic: nontruncating alleles, significantly enriched in ABCA4-LOVD; 3) likely 
benign: allele frequency (AF) ABCA4-LOVD/AF ExAC non-Finnish Caucasian < 1; 
4) benign: ExAC AF >0.006; 5) unknown pathogenicity: AF ABCA4-LOVD/AF ExAC 
non-Finnish Caucasian > 1, however not significantly enriched. Patients were then 
grouped by combinations of ABCA4 pathogenicity: 1) Pathogenic/Pathogenic, 
2) Pathogenic/Likely pathogenic, 3) Likely pathogenic/Likely pathogenic, 4) 
Pathogenic in combination with unknown pathogenicity, (likely) benign, or a 
variant that was not published until 31 December 2015, 5) Likely pathogenic in 
combination with unknown pathogenicity or (likely) benign (Cornelis SS, Cremers 
FPM, unpublished data, 2016).
Statistical analysis
We analyzed BCVA and RPE atrophy measurements using SPSS version 22 (IBM 
Corp., IBM SPSS Statistics, Chicago, IL, USA) with parametric tests. Retinal pigment 
atrophy progression rates were calculated by the difference at the baseline and 
last follow-up visit divided by the follow-up time. Differences in disease duration 
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and follow-up time between disease onset groups were analyzed with the 
Kruskal-Wallis test.
We used Pearson’s correlation coefficients (r) to assess inter-eye correlations of 
baseline BCVA, baseline RPE atrophy, and RPE atrophy progression. We compared 
these correlations between disease-onset groups and ABCA4 variant combination 
groups by first performing a Fisher transformation: ----------------Then, these 
z’-scores were compared for homogeneity. The test for homogeneity employs the 
X2-distribution for two and four degrees of freedom:
where the summation is over the three disease-onset groups and five ABCA4 
variant combination groups, respectively.24
Baseline BCVA and RPE atrophy differences between measurements and the 
average measurements of both eyes were calculated and plotted according to the 
method of Bland and Altman to assess the intra-individual agreement graphically.25 
Limits of agreement between eyes were plotted for each disease-onset group.
Lin’s concordance correlation coefficient  was calculated to evaluate the extent 
of inter-eye symmetry of baseline BCVA, baseline RPE atrophy, and RPE atrophy 
progression.26-28 The  consists of the product of a precision coefficient (Pearson’s ) 
and an accuracy coefficient .The accuracy coefficient  indicates how far the best-fit 
line of all paired left- and right-eye measurements deviates from the 45° line on a 
square scatter plot, and is defined as  --------------  , where scale shift
and location shift relative to the scale ----------------  (OD, right eye; OS, left eye).29 
If all paired measurements exactly lie on the 45° line, a coefficient of 1 would 
be found, indicating perfect symmetry. Strength-of-agreement criteria were as 
follows: almost perfect, > 0.90; substantial, 0.80 – 0.90; moderate, 0.65 – 0.80; 
poor, < 0.65.30
As standard deviations can be affected by extreme differences and rely on 
distributional assumptions, box-and-whisker plots were used to identify outliers 
by differences >1.5 interquartile ranges (IQR) below the first (Q1) or above the 
third (Q
3
) interquartiles in baseline BCVA, baseline RPE atrophy, and RPE atrophy 
progression. Odds ratios were calculated to identify associations of discordant 
BCVA and RPE atrophy at baseline with RPE atrophy progression.
We performed sample size calculations and a sensitivity analysis for a theoretical 
intervention using nQuery Advisor 7.0 (Statistical Solutions, Boston, MA). We 
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used a two-sided paired t-test for differences in means of RPE atrophy progression 
with a test significance level (α) of 0.05 and a power of (1 – β) of 0.80. Standard 
deviations of differences between RPE atrophy progression of treated and 
nontreated eyes were obtained from the standard deviations and correlations of 
left and right eyes using the formula: σd = √(σ1² + σ2² - 2ρσ1σ2).
Results I: Patient characteristics
A total of 68 patients (136 eyes) were included in this study (26 men, and 42 
women). The median age at onset was 8.5 (range, 4 – 10), 20 (range, 11 – 42), and 
50 (range, 45 – 69) years for 14 early-onset STGD1, 33 intermediate-onset STGD1, 
and 21 late-onset STGD1 patients, respectively. At baseline, the median disease 
duration was 5 years (range, 0 – 39). The distribution did not differ between the 
three disease-onset categories. Details of patient characteristics and inter-eye 
correlations at baseline and follow-up are depicted in Table 1.
Table 1. Characteristics and Inter-Eye correlations at Baseline and at Follow-up in 68 Stargardt Patients
Median and ranges are shown for time variables. Mean and standard deviations are shown for all 
other variables. *Kruskal Wallis for differences in disease duration and follow-up; † χ² with 2 degrees 
of freedom for differences in inter-eye correlations.
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Baseline inter-eye correlations of Best-corrected visual acuity
At baseline, the mean (± standard deviation) BCVA in the right and left eyes was 
0.66 (± 0.51) logMAR and 0.72 (± 0.53) logMAR, respectively. Twenty-four right 
eyes and 23 left eyes were identified as the better seeing eye; 21 pairs of eyes had 
equal BCVA. The overall inter-eye correlation (ρ) in BCVA at baseline was 0.756 
and did not differ between disease onset groups, although a trend of decreasing 
correlations at later disease onset was also observed at follow-up.
Next, we compared the average and differences of baseline BCVA between the 
left and right eyes by a Bland-Altman plot (Supplemental figure 2A), revealing 
discordance up to 1.70 logMAR. This discordance was most pronounced in 13 
patients (two early-onset STGD1, seven intermediate-onset STGD1, and four 
late-onset STGD1), as defined by outlying differences below Q1 – 1.5 × IQR or 
above Q
3
 + 1.5 × IQR (Supplemental figure 2B). Overall, this resulted in an inter-eye 
agreement () in baseline BCVA of 0.751 (95% confidence interval (CI), 0.626 – 
0.838). 
Baseline inter-eye correlations of Retinal pigment epithelium atrophy
At baseline, the mean √ RPE atrophy area in the right and left eyes was 1.56 mm (± 
1.36) and 1.45 mm (± 1.36), respectively. Twenty-nine right eyes and 34 left eyes 
had the smallest RPE atrophy area; 5 pairs of eyes had no RPE atrophy. Although 
baseline RPE atrophy between the left and right eyes was highly correlated (ρ = 
0.878), the correlation was significantly decreased in late-onset STGD1 patients.
The Bland-Altman plot (Supplemental figure 3A) showed inter-eye differences up 
to 2.49 mm of baseline √ RPE atrophy area. An inter-eye difference below Q1 – 1.5 
× IQR or above Q
3
 + 1.5 × IQR (Supplemental figure 3B), that is, discordant RPE 
atrophy at baseline, was identified in eight patients (intermediate-onset STGD1, 
four patients; late-onset STGD1, four patients). The overall inter-eye agreement () 
of baseline RPE atrophy was 0.876 (95% CI, 0.806 – 0.921).
Results II: Discordance of RPE atrophy progression rates
Inter-eye correlations of retinal pigment epithelium atrophy progression
The median follow-up time was 3.9 years (range, 0.5 – 9.7), of which the 
distribution did not differ between all disease-onset categories. The mean √ 
RPE atrophy progression rates in the right and left eyes were 0.21 (± 0.20) mm/y 
and 0.20 (±0.21) mm/y, respectively. Thirty-five right eyes and 31 left eyes were 
identified as the eye with the slowest progression rate. Two pairs of eyes showed 
no progression in 3.0 and 3.4 years, respectively. The progression rates of √ RPE 
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atrophy correlated between the left and right eyes with ρ = 0.766, and increased 
with earlier disease-onset groups (P = 9.8 × 10-7). Evaluating the inter-eye 
agreement in progression of RPE atrophy, the agreement between the eyes was  
= 0.765 (95% CI, 0.645 – 0.847) (Figure 1). 
Figure 1. A square scatter plot of inter-eye √ RPE progression. Circles are patients with differences 
in baseline √ RPE atrophy between their eyes within Q1,3 ± 1.5 × IQR. Triangles are patients who fall 
outside the Q1,3 ± 1.5 × IQR for differences in baseline √ RPE atrophy. Dashed line: 45° line of perfect 
agreement. Q1, first interquartile; Q3, third interquartile; IQR, interquartile range.
Discordant progression rates of RPE atrophy
Twelve out of 68 patients (early-onset STGD1, two patients (14%); 
intermediate-onset STGD1, four patients (12%); late-onset STGD1, six patients 
(29%)) had discordant RPE atrophy progression rates between their eyes by 
differences below Q1 – 1.5 × IQR or above Q3 + 1.5 × IQR. In four of these patients, 
the eye with the largest RPE atrophy area progressed faster than the other eye, 
thus increasing inter-eye discordance of RPE atrophy over time (mean difference, 
0.26 (± 0.10) mm/year; Figure 2A). In the other eight patients, the eye with the 
smallest RPE atrophy area progressed faster than the other eye, therefore reducing 
inter-eye discordance of RPE atrophy (mean difference, 0.30 (± 0.12) mm/year; 
Figure 2B). The remaining 56 patients had similar progression rates between their 
eyes (mean difference, 0.05 (± 0.04) mm/year, within Q
1,3 
± 1.5 × IQR; Figure 2C).
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Figure 2.  Concordant and discordant inter-eye progression in Stargardt disease. (A) 60-year 
old female with a disease duration of 1 year and increasing inter-eye differences. ABCA4variants: 
c.5461-10T>C:p.[Thr1821Valfs*13,Thr1821Aspfs*6]/c.2757A>C:p.(Glu919Asp). (B) Eighty-one-year 
old female with a disease duration of 26 years and decreasing inter-eye differences. ABCA4 variants: 
c.5196+1G>T:p.(?)/+. (C) Twenty-six-year old female with a disease duration of 6 years and similar 
progression rates between eyes. ABCA4 variants: c.1853G>A;4297G>A:p.(Gly618Glu;Val1433I-
le)/c.2588G>C:p.[Gly863Ala;Gly863del].
Baseline RPE atrophy and genetic associations with discordant RPE atrophy 
progression
Discordant RPE atrophy at baseline was associated with discordant RPE atrophy 
progression (odds ratio, 6.50; 95% CI, 1.35 – 31.34); this association was not found 
for discordant BCVA at baseline (odds ratio, 0.33 (95% CI, 0.04 – 2.85).
Furthermore, decreasing pathogenicity of ABCA4 variant combinations were 
significantly associated with increasing discordant inter-eye progression (P = 
0.007). Proportions and correlations are depicted in Table 2.
Table 2. Proportions of Combinations of ABCA4 Variants and Discordant RPE Atrophy Progression
The second ABCA4 variant was likely benign, of unknown pathogenicity, or not found.
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Results III: Power calculations of a theoretical intervention trial
The power of a paired-control intervention trial will depend on the strength of 
correlations between pairs, that is, the left and right eye of each patient, and 
the expected treatment effect. For each two-fold increase in expected treatment 
effect, approximately a four-fold decrease in patient numbers is needed for a 
study at equal power. Stronger inter-eye correlations will have a linear beneficial 
effect on the number needed to include. The impact on these numbers is highest 
when a relatively modest treatment effect is expected. For instance, a correlation 
of ρ = 0.766 would require 44 patients, whereas this number is reduced to 20 in 
the case of a correlation of ρ = 0.9 (Figure 3). The specific inclusion criteria, for 
example, disease onset, ABCA4 variant combinations, and baseline discordance 
can significantly affect the number needed to include.
Figure 3.  A sensitivity analysis for the power calculation of a theoretical intervention trial. 
Assuming a 30% reduction in disease progression (treatment effect), 44 patients are needed 
(inter-eye correlation ρ = 0.766; β = 0.20, α = 0.05, two-sided paired samples t-test). The sample 
size will decrease to 20 in the case of an inter-eye correlation of 0.9. In the case of a correlation in 
disease progression of 1, 0.8, 0.6, 0.4, 0.2, and 0 between left and right eyes, 3, 38, 73, 108, 143, or 
178 patients are needed, respectively.
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Discussion
Based on longitudinal FAF data in our current study, the overall agreement of 
inter-eye RPE atrophy progression in STGD1 was only moderate; it was highest in 
early-onset STGD1 and lowest in late-onset STGD1. Discordant progression rates 
were found in 12 out of 68 (17.6%) patients—which is surprisingly high—given 
that STGD1 is assumed to be a symmetrical inherited retinal disease. Discordant 
progression rates resulted in eyes either converging or diverging in atrophy size. 
Discrepancies of RPE atrophy progression rates were associated with discrepancies 
of RPE atrophy at baseline and less pathogenic ABCA4 variant combinations. 
Autosomal retinal dystrophies are expected to be symmetrical owing to the similar 
genetic and environmental background of both eyes. The majority of STGD1 
patients exhibit bilateral symmetry in retinal features. Chen et al. illustrated this 
symmetry in left and right eyes of 24 STGD1 patients; they had highly correlated 
areas of RPE atrophy (Pearson’s ρ = 0.998).12  McBain et al. studied the atrophy 
progression rates in 12 STGD1 patients, reporting a strong inter-eye correlation 
(Spearman’s ρ = 0.846).11 In our cohort, these inter-eye correlations of RPE atrophy 
were substantially lower, but they can be explained by inclusion of late-onset 
STGD1 patients, which decreased the overall correlation. Inter-eye correlations of 
late-onset STGD1 were previously estimated to be moderate (ρ = 0.52).20 When 
late-onset STGD1 patients are excluded, our inter-eye correlations were similar to 
those reported by others.
Previous studies were limited by standard analyses of correlations, which 
cannot address the absolute symmetry within a patient. In contrast, we used 
Lin’s concordance correlation coefficients and descriptive Bland-Altman plots, 
which are more appropriate and previously described in age-related macular 
degeneration.27 In addition, there is an inherent increase in variability of inter-eye 
differences when the magnitude of atrophic areas increases. We corrected this 
by expressing the inter-eye differences as the square root, thus the differences 
were proportional to the magnitude of measurements. Moreover, square-root 
transformation corrected baseline dependence, which was reported previously 
with an average atrophy enlargement increase of 0.016 mm2/y for each month of 
follow-up.10 
Although we found that progression rates for atrophy are more likely to be 
discordant in eyes that differ more at baseline, progression rates are rather 
unpredictable between patients and between eyes within a patient. McBain et al. 
suggested that electroretinography could predict the rate of atrophy progression, 
but they did not account for baseline atrophy size. It would be interesting if 
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discordance in electroretinography between eyes of a patient would also predict 
inter-eye differences in progression, independent of their baseline atrophy size.10 
Burke et al. indicated that changes on optical coherence tomography would 
precede RPE atrophy and may thus predict the rates of atrophy progression.31 
These potential predictors for disease progression need to be addressed in future 
work.
The lower inter-eye correlations in older patients could be explained by the 
increased time within which stochastic factors, for example, small initial differences 
leading to significant differences later, can influence phenotypic expression. 
Differences in ABCA4 variant expression may alter disease severity between eyes 
with mild variants, which can have a slightly different pathogenicity. In contrast, 
differences in expression would not influence progression speed much in severe 
ABCA4 combinations as both variants would cause an equally severe phenotype. 
The statistical power of a randomized controlled trial increases when differences 
are measured between correlated left and right eyes. To this extent, we 
recommend a fellow-eye paired trial design for retinal dystrophies, for example, 
as applied in a phase II gene therapy trial for choroideremia with 30 patients 
enrolled (ClinicalTrials.gov, NCT02407678). To achieve 80% statistical power 
in this trial, an effect size of at least 0.53 is required.32 For the same expected 
effect size, a patient-controlled trial would need 58 patients in each arm.33 Even 
in multicenter trials, such high sample sizes are difficult to obtain in rare retinal 
dystrophies. However, it is important to bear in mind that a fellow-eye paired 
control is impossible for pharmaceutical strategies in which both eyes of a patient 
are being treated (ClinicalTrials.gov, NCT02402660). Furthermore, it is preferred 
that an effect on relatively slow retinal degeneration is detected to identify a 
potential long-term benefit rather than a temporary gain of visual function.34
A therapeutic trial will gain a major advantage from a fellow-eye control in early-onset 
STGD1 because of their high inter-eye correlations. However, discordance was 
also present in some of these younger patients. As the progression can be better 
predicted in similar rather than in discordant eyes, retinal asymmetry needs to 
be considered as an exclusion criterion for small early-phase trials. Such stringent 
criteria will increase the chance of detecting efficacy with fewer patients. Criteria 
would include early-onset STGD1 patients with concordant retinal abnormalities 
between their eyes carrying severe ABCA4 variants; not only do these patients 
have the highest inter-eye symmetry in disease progression, but they are also 
expected to have the most severe disease course.1, 2 In these patients, therapy 
will potentially provide the most benefit, and in these patients, its effect has the 
highest chance to be detected.
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Supplementary material
Supplementary Figure 1. Flow chart depicting the selection process for patient inclusion in this study.
FAF = fundus autofluorescence, RPE = retinal pigment epithelium.
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Supplementary Figure 2. (A) Bland-Altman plot of best-corrected visual acuity (BCVA). The average 
BCVA of all paired eyes (right minus left eye) were compared with the differences in BCVA between 
the eyes. The mean differences and limits of agreement are shown for (Purple) early-onset Stargardt 
disease (STGD1), (Turquoise) intermediate-onset STGD1, and (Red) late-onset STGD1. 
(B) Box-and-whisker plot of the differences in BCVA: dots are outlying differences below Q1 - 1.5 × 
IQR or above Q3 + 1.5 × IQR, and asterisks are extreme differences below Q1 – 3 × IQR or above Q3 
+ 3 × IQR. Q1 = first interquartile, Q3 = third interquartile, IQR = interquartile range.
Supplementary Figure 3. (A) Bland-Altman plot of √ RPE atrophy area. The average area of all 
paired eyes (right minus left eye) were compared with the differences in measurements between 
the eyes. The mean differences and limits of agreement are shown for (Purple) early-onset Stargardt 
disease (STGD1), (Turquoise) intermediate-onset STGD1, and (Red) late-onset STGD1.
(B) Box-and-whisker plot of the differences in √ RPE atrophy area: dots are outlying differences be-
low Q1 - 1.5 × IQR or above Q3 + 1.5 × IQR, and asterisks are extreme values below Q1 – 3 × IQR or 
above Q3 + 3 × IQR. Q1 = first interquartile, Q3 = third interquartile, IQR = interquartile range.
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Supplementary Table 1. ABCA4 variants identified in this cohort. 
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“Pathogenic” = Truncating alleles, significantly enriched in ABCA4-LOVD; “Likely pathogenic” = 
Non-truncating alleles, significantly enriched in ABCA4-LOVD; “Unknown pathogenicity” = (AF 
ABCA4-LOVD/AF ExAC non-Finnish Caucasian) > 1, however not significantly enriched; “Likely 
benign” = (AF ABCA4-LOVD/AF ExAC non-Finnish Caucasian) < 1; “Benign” = ExAC AF >0.006. AF = 
allele frequency.
† These unreported variants either result in a premature stop codon or a frame shift ending 
in a stop codon. The mRNA produced might be targeted for nonsense mediated decay. 
‡ The unreported variant c.6285T>C does not alter the protein sequence. 
§ The unreported variants c.6428T>G (phyloP: 9.18 and Grantham: 91) and c.2757A>C (phyloP: 
0.44 and Grantham: 45) are expected to be likely pathoge-nic and likely benign, respectively. 
|| This unreported variant very likely results in a skip of exon 27 resulting in a frameshift.
Several cases were mentioned earlier:
a) Westeneng-van Haaften SC, Boon CJ, Cremers FP, Hoefsloot LH, den Hollander AI, Hoyng CB. Clinical 
and genetic characteristics of late-onset Star-gardt’s disease. Ophthalmology 2012;119:1199-1210.
b) van Huet RA, Bax NM, Westeneng-Van Haaften SC, et al. Foveal sparing in Stargardt disease. 
Invest Ophthalmol Vis Sci 2014;55:7467-7478.
c) Lambertus S, van Huet RA, Bax NM, et al. Lambertus S, van Huet RA, Bax NM, et al. Early-onset 
Stargardt disease: phenotypic and genotypic characteris-tics. Ophthalmology 2015;122:335-344.
d) Sangermano R, Bax NM, Bauwens M, et al. Photoreceptor Progenitor mRNA Analysis Reveals Exon 
Skipping Resulting from the ABCA4 c.5461-10T-->C Mutation in Stargardt Disease. Ophthalmology 
2016;123:1375-1385
e) Lambertus S, Lindner M, Bax NM, et al. Progression of Late-Onset Stargardt Disease. Invest 
Ophthalmol Vis Sci 2016;57:5186-5191.
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Identification, registry and functional 
assessment of ABCA4 variants
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CHAPTER 3.1
In silico functional meta-analysis of 5,962 ABCA4 variants in 
3,928 retinal dystrophy cases.
“The clinical outcome in STGD1 depends on the severity of two ABCA4 variants. 
To provide an accurate prognosis and to select patients for novel treatments, it is 
important to assess the functional significance of non-truncating ABCA4 variants. 
All published ABCA4 variants were collected in a Leiden Open (source) Variant 
Database (LOVD) in this study. In silico meta-analysis of 5,962 variants in 3,928 
ABCA4–associated retinal dystrophy cases was performed, which allowed us 
to predict the functional effects. These studies will facilitate the pathogenicity 
assessment of variants with unknown significance found in diagnostics.”
Stéphanie S. Cornelis
Nathalie M. Bax
Jana Zernant
Rando Allikmets
Lars G. Fritsche
Johan T. den Dunnen
M. Ajmal
Carel B. Hoyng
Frans P.M. Cremers
Human Mutation 2017;38(4):400-408 
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Variants in the ABCA4 gene are associated with a spectrum of inherited retinal 
diseases (IRDs), most prominently with autosomal recessive (ar) Stargardt disease 
(STGD1) and ar cone-rod dystrophy. The clinical outcome to a large degree 
depends on the severity of the variants. To provide an accurate prognosis and 
to select patients for novel treatments, functional significance assessment of 
nontruncating ABCA4 variants is important. We collected all published ABCA4 
variants from 3,928 retinal dystrophy cases in a Leiden Open Variation Database, 
and compared their frequency in 3,270 Caucasian IRD cases with 33,370 non-
Finnish European control individuals. Next to the presence of 270 protein-
truncating variants, 191 nontruncating variants were significantly enriched in 
the patient cohort. Furthermore, 30 variants were deemed benign. Assessing 
the homozygous occurrence of frequent variants in IRD cases based on the allele 
frequencies in control individuals confirmed the mild nature of the p.[Gly863Ala, 
Gly863del] variant and identified three additional mild variants (p.(Ala1038Val), 
c.5714+5G>A, and p.(Arg2030Gln)). The p.(Gly1961Glu) variant was predicted 
to act as a mild variant in most cases. Based on these data, in silico analyses, 
and American College of Medical Genetics and Genomics guidelines, we provide 
pathogenicity classifications on a five-tier scale from benign to pathogenic for all 
variants in the ABCA4-LOVD database.
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Introduction
Variants in ABCA4 (MIM# 601691) are associated with a wide variety of inherited 
retinal diseases (IRDs) [Allikmets et al., 1997b; Cremers et al., 1998; Rozet et al., 
1998; Maugeri et al., 2000]. Homozygous or compound heterozygous variants in 
ABCA4 can cause autosomal recessive (ar) Stargardt disease (STGD1) and a more 
severe phenotype, ar cone-rod dystrophy (CRD). 
Mostly, STGD1 patients present with yellow-white fundus flecks, hence the 
term “fundus flavimaculatus” [Stargardt, 1909]. Furthermore, the disease is 
characterized by retinal pigment epithelium changes and extensive chorioretinal 
atrophy [Fishman et al., 1999]. ABCA4-associated IRDs have a broad phenotypic 
variation, ranging from an early age at onset that mostly results in panretinal 
atrophy [Martinez-Mir et al., 1998; Klevering et al., 2005; Fujinami et al., 2015; 
Lambertus et al., 2015] to a milder foveal sparing phenotype in patients with a 
late age at onset [Westeneng-van Haaften et al., 2012; van Huet et al., 2014]. 
The exact molecular effect of most variants underlying the variety in phenotypes 
is still unknown. ABCA4 encodes the protein ABCA4 (ATP-binding cassette 
transporter, subfamily A, member 4), which is located in the outer segment disk 
membranes of cone and rod photoreceptor cells. ABCA4 is a 2,273 amino acid 
glycoprotein with two tandem halves. Each half contains a single transmembrane 
segment followed by a large exocytoplasmic domain, iterating transmembrane 
segments, and an ATP binding domain [Molday et al., 2009]. 
Previously, a genotype–phenotype model was proposed. According to this model, 
the severity of the functional consequences of the combination of ABCA4 variants 
correlates with the severity of the clinical phenotype [van Driel et al., 1998; 
Maugeri et al., 1999]. Persons with a severe and a mild variant or two moderately 
severe variants are expected to present with STGD1, persons with a severe and 
a moderately severe variant with CRD, and individuals with two severe variants 
with a severe form of CRD. The latter phenotype has been associated with an 
early age at onset (≤10 years) [Simonelli et al., 2005; Lambertus et al., 2015] 
and in a later stage often resembles retinitis pigmentosa (RP) [Cremers et al., 
1998; van Driel et al., 1998; Maugeri et al., 1999]. Furthermore, studies from this 
century confirmed that the disease phenotype correlates with the presence of 
severe variants [Simonelli et al., 2005; Fujinami et al., 2013; Kjellstrom, 2014]. In 
contrast, two “mild” or “hypomorphic” variants are expected not to give rise to 
a disease phenotype [Maugeri et al., 1999]. This model explains that there is an 
unusual high carrier frequency of these mild variants in the general population, 
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which can be as high as 5.5% (c.2588G>C; p.[Gly863Ala, Gly863del] in Sweden 
[Maugeri et al., 2002]) and 11.3% (c.5882G>A; p.(Gly1961Glu) in Somalia [Guymer 
et al., 2001]). 
Sequence analysis of the protein coding exons reveals biallelic variants in 
approximately 75% of the STGD1 cases [Allikmets et al., 1997b; Lewis et al., 1999; 
Maugeri et al., 1999; Rivera et al., 2000; Webster et al., 2001]. The identification 
of one variant only was found more often in patients with a late age at onset 
than in patients with an early onset STGD1 [Utz et al., 2014]. Monoallelic ABCA4 
variants have also been reported in patients with a typical fine granular pattern 
with peripheral punctuate spots and in patients with age-related macular 
degeneration [Allikmets et al., 1997a; Fritsche et al., 2012]. However, it is possible 
that a subset of this latter patient group contains misdiagnosed late-onset STGD1 
patients [Dryja et al., 1998; Souied et al., 2000]. In a subset of STGD1 and arCRD 
cases with initially only one variant, deep-intronic variants were identified later 
that in some instances were shown to result in the insertion of pseudo-exons 
into the mRNA [Braun et al., 2013; Zernant et al., 2014; Bauwens et al., 2015; Bax 
et al., 2015]. 
The ABCA4 gene carries a conspicuously high number of noncanonical splice 
site variants, many of which with an unknown functional effect, such as the 
c.5461-10T>C variant was. By analyzing patient-derived photoreceptor progenitor 
cells, it was recently shown that this apparently benign variant results in the 
skipping of exon 39 or of exons 39 and 40 [Sangermano et al., 2016]. 
Categorizing ABCA4 variants as either benign or pathogenic is important for 
patients to qualify for several therapies. The effect of deep-intronic variants 
potentially can be treated using antisense oligonucleotides [Collin et al., 2012; 
Garanto et al., 2016; Gerard et al., 2016]. STGD1 patients are eligible for therapy 
trials, like gene augmentation (trial number NCT01367444, NCT01736592), 
stem cell therapy (trial number NCT01469832), and small molecule drugs (trial 
number NCT02402660) [Dalkara et al., 2016] (https://clinicaltrials.gov/ct2/show/
NCT01367444), if biallelic disease-causing ABCA4 variants have been identified. 
Additionally, it is important for genetic counseling to know which variants give 
rise to which grade of pathogenicity in the disease phenotype. 
In this study, we therefore gathered all ABCA4 variants published before 
2016 that were associated with STGD1, arCRD and arRP. We uploaded all the 
published variants into the ABCA4 Leiden Open source Variant Database (LOVD) 
and assessed the pathogenicity of all nonprotein-truncating variants based on 
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their prevalence in the ABCA4 patient dataset (below abbreviated as “ABCA4-
LOVD”) versus controls. In addition, we performed in silico predictions, analyzed 
the homozygous occurrence of variants combined with the age of onset of the 
IRD, their presence in patients with an early onset, and their occurrence with 
a frequent mild variant. Based on this information and the American College of 
Medical Genetics and Genomics (ACMG) guidelines, all variants in the ABCA4-
LOVD database were classified according to their pathogenicity. 
Methods
Literature search 
All peer-reviewed publications from before 2016 which reported ABCA4 variants 
(NM_000350.2) in associated retinal dystrophies, such as STGD1, arCRD, and arRP 
patients, were collected by a Pubmed search. We did not collect ABCA4 variants 
reported in patients with age-related macular degeneration. Among others, the 
variant combinations, disease phenotype, and the age of onset were annotated. 
Clear duplicates, for example, persons with the same variants, the same 
identification number, and/or age of onset, were removed. Familial cases with 
the exact same variant combination from the same authors were also removed 
from the dataset, but have been uploaded to the LOVD.
Variant data analysis
For cDNA numbering, we used +1 as the A of the ATG translation initiation codon 
in the reference sequence, with the initiation codon as codon 1. The frequency of 
the variants in the IRD group was compared to the frequency of the variants in the 
Exome Aggregation Consortium (ExAC) database Version 0.3.1, which contains 
exome data from over 60,000 individuals worldwide (http://exac.broadinstitute.
org/). Individuals with severe pediatric diseases are excluded from the ExAC 
database. Therefore, this control dataset does not contain variants of individuals 
with severe early onset IRD, but might contain variants of individuals with a 
later onset or a milder phenotype of IRD. The majority of the published ABCA4 
variants in patients were identified in non-Finnish Caucasian individuals. To have 
reasonable power in the statistical comparisons, we therefore chose to use the 
Caucasian population as a control group and had to exclude non-Caucasian 
patients for statistical comparisons. Fisher’s exact tests were used to analyze 
whether variants were significantly enriched in the Caucasian ABCA4-LOVD 
(ABCA4-LOVD_Cauc) patient group compared to the non-Finnish European (nFE) 
population in ExAC consisting of 33,370 individuals. After this, a correction by 
the false discovery rate (FDR) of Benjamini–Hochberg, classical one stage method 
[Benjamini and Hochberg, 1995] was performed to increase the number of true 
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significant findings allowing an error margin of 5% on the total of the data. These 
tests were performed three times: (1) for all ABCA4-LOVD_Cauc patients, (2) for 
biallelic cases only, and (3) for monoallelic cases only. The latter two tests were 
performed in order to assess if biallelic variants show different significance or 
trends compared to the monoallelic variants. A clear difference could indicate 
that monoallelic patients show a different form of disease or carry ABCA4 variants 
by chance, while the cause of their similar phenotype resides elsewhere. 
When an exonic variant location was absent in ExAC, the allele count of ExAC was 
assumed to be 66,598 for that location as 95% of the known variant locations have 
an allele count of 66,598 or higher. Furthermore, the coverage plots available in 
ExAC were checked for drops in coverage. For those variants that were located in 
a region with low coverage, the coverage of the closest variant in ExAC was taken 
for statistical analysis. Finally, the number of singletons in ExAC was compared 
to the number of singletons in the patient group by using a chi-square test. In 
this way, we investigated if the number of recent de novo variants is found more 
frequent in the patient group, as these are often a cause of disease [Veltman and 
Brunner, 2012]. 
According to the genotype–phenotype model described above, all the variants 
that were found in a homozygous manner in STGD1 cases of any ethnicity were 
annotated to have at least a moderate effect. Variants that were found in a 
homozygous manner in persons with an average age at onset ≤10 years of age 
were annotated to have a severe effect. For all the variants that were present 
in a compound heterozygous manner, the ones that occurred together with the 
mild variant p.[Gly863Ala, Gly863del] or the p.(Gly1961Glu) variant, which in 
the majority of cases was deemed mild (see below), were annotated to be likely 
severe, according to a generally accepted model [Maugeri et al., 1999]. 
In silico analyses
SMART domains and their locations were obtained from http://smart.
embl-heidelberg.de/. Furthermore, 12 transmembrane segments were obtained 
from the Uniprot Web site http://www.uniprot.org/. The number of missense 
variants per domain was compared to the expected amount of missense variants 
per domain with a chi-square test and Bonferroni correction. The expected 
number of missense variants per domain was calculated by dividing the number 
of missense variants per domain in the ExAC database by the total amount of 
missense variants in the protein in the ExAC database, multiplied by the total 
number of variants enriched in the ABCA4-LOVD_Cauc. PhyloP scores, which 
are based on the conservation of nucleotides among multiple organisms, were 
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obtained from the UCSC genome browser tool “Table browser” using the Cons 
46-Way track and the Vertebrate PhyloP conservation table for the February 
2009 genome release GRCh37/hg19 http://genome.ucsc.edu/ (Clade: Mammal, 
Genome: Human, assembly: February 2009 (GRCh37/hg19), Group: Comparative 
Genomics, Track: Conservation) [Karolchik et al., 2004]. Grantham scores were 
obtained from the original paper [Grantham, 1974]. Combined Annotation 
Dependent Depletion (CADD) scores were obtained from the Web site http://
cadd.gs.washington.edu/home [Kircher et al., 2014] and the odds ratios (ORs) 
were calculated for each variant x by the formula: 
AF(x) in ABCA4LOVD_Cauc/ (1– AF(x) ABCA4LOVD_Cauc)
               AF(x) in nFE_ExAC/ (1– AF(x) in nFE_ExAC)
In which AF(x) is the allele frequency of variant x. ORs and their 95% confidence 
intervals were calculated using the Fisher’s exact test for count data as implemented 
in R (http://www.R-project.org). Reported confidence intervals were not adjusted 
for multiple testing. 
Patients in which one allele contained a missense variant and the second allele 
contained a truncating variant, were studied further on the assumption that the 
effect of the truncating allele is always the same. In this way, the type of missense 
variant likely plays a big role in the range of the ages at onset among different 
patients, in which a severe missense variant is likely to lead to an earlier age at 
onset than a mild missense variant. PhyloP, Grantham and CADD scores as well 
as the ORs of these missense variants were plotted against the age of IRD onset 
of corresponding patients to support this hypothesis. Furthermore, Spearman 
correlation tests with Bonferroni correction were performed to assess which of 
the prediction programs and the OR were significantly correlating with the age of 
onset and therefore deemed to be good predictors of the pathogenic nature of 
all the variants.
To assess the splicing scores, we employed the following programmes via the 
Alamut Visual version 2.7.1 (Interactive Biosoftware): SpliceSiteFinder-like, Alamut 
Visual software version 2.7.1: SpliceSiteFinder-like, MaxEntScan, NNSPLICE, 
GeneSplicer, and Human Splicing Finder [Reese, et al., 1997; Pertea, et al., 2001; 
Cartegni, et al., 2003; Yeo and Burge, 2004; Desmet, et al., 2009]. 
Pathogenicity classifications
All the variants in the ABCA4-LOVD dataset were classified into five pathogenicity 
categories: (1) pathogenic, when the variant is truncating; (2) likely pathogenic, 
when the variant is nontruncating and enriched in the ABCA4-LOVD dataset 
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compared to the nFE ExAC control group; (3) uncertain significance, when the 
variant is nontruncating, more frequent in the ABCA4-LOVD dataset than in the 
nFE ExAC control group, but not significantly enriched; (4) likely benign, when 
the variant has a higher frequency in the nFE ExAC population than in the 
ABCA4-LOVD dataset; (5) benign, when the variant has a frequency >0.005 in the 
nFE ExAC population and is not one of the known mild variants p.[Gly863Ala, 
Gly863del] or p.(Gly1961Glu). In addition, all the variants in the ABCA4-LOVD 
dataset were classified according to the ACMG guidelines [Richards et al., 2015]. 
In this classification, the types of evidence for a mutation to be pathogenic are put 
in different categories: 
•	 pathogenic, very strong criterion (PVS), for example, “this variant is truncating”,
•	 pathogenic, strong criterion (PS), for example, “another variant leading to the 
same amino acid change has been associated with disease before”,
•	 pathogenic, moderate criterion (PM), for example, “the variant is located in a 
well-established functional domain”,
•	 pathogenic, supporting criterion (PP), for example, “all in silico prediction 
programs predict pathogenicity.” 
After categorizing the different criterions, the ACMG gives a scoring method of 
how to sum the criteria to come to a final pathogenicity class. For example, a 
variant can be classified as pathogenic if it meets 1 PS, 2 PM, and at least 2 PP 
criteria.
Results
All variants
In total, variants of 4,137 patients were gathered from 148 papers, in which 6,284 
variants were reported. Duplicate removal as well as excluding family members 
led to a total amount of 3,928 patients and 5,962 alleles (Supp. Table S1). The 
total ABCA4-LOVD comprised 303 patients with homozygous variants, 1,869 
patients with compound heterozygous variants, and 1,015 patients carrying one 
variant. Remaining variants most likely occurred in compound heterozygous state, 
although this is unknown because the variants were described per cohort instead 
of per patient. The number of monoallelic cases could be an overestimation 
because in some follow-up studies a second allele was identified and published, 
without mentioning that the patient was already published before. The 5,962 
variants consisted of 913 unique variants, including 64 complex alleles—alleles 
with multiple variants in cis- and 10 deep-intronic variants (Table 1).
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Table 1: Distribution of all variants in the ABCA4- LOVD patient dataset
α Including big deletions and missense variants at the first codon.
After removal of the variants that had a lower frequency in the ABCA4-LOVD 
patient dataset versus the ExAC database, and exclusion of the complex and 
deep-intronic alleles, which are not represented in ExAC, 4,683 alleles and 807 
different variants remained. Of these variants, 316 (3,645 in total; Table 2; Supp. 
Table S2) were significantly enriched in the ABCA4-LOVD_Cauc dataset (Fisher’s 
exact test, P < 0.05, FDR of 5%) compared to the nFE population in ExAC. These 
were composed of 169 truncating variants, which were therefore annotated as 
category 1 (pathogenic) in the LOVD database, and 250 other variants that were 
classified as category 2 (likely pathogenic). Furthermore, there were 347 singleton 
variants unique in the patient group, which usually indicate recent de novo 
events. This is a significantly higher proportion than the occurrence of singletons 
in the ExAC control group (chi-square test, P = 2.3 × 10−189) and therefore most 
likely a significant amount of these singletons are disease causing. Comparing the 
frequency of the subgroup of biallelic variants only with their frequency in the 
ExAC control group, revealed 229 significantly enriched variants (Fisher’s exact 
test, P < 0.05, FDR of 5%). As, strictly speaking, Stargardt patients should have two 
pathogenic variants, these 229 variants might be most informative. Comparing 
the subgroup of monoallelic variants only, which was more than twice as small as 
the biallelic variants subgroup, to the ExAC control group showed 80 significantly 
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 170
170
Chapter 3.1
enriched variants (Fisher’s exact test, P < 0.05, FDR of 5%). Interestingly, six 
variants were enriched in the monoallelic subgroup, which were not enriched 
in the biallelic subgroup. This could indicate that these variants are mere chance 
findings. However, three out of these six variants were truncating variants, 
c.2099G>A; p.(Trp700*), c.4956T>G; p.(Tyr1652*), c.5898+1G>T; p.(?), making it 
unlikely that they are benign. Of note, the three nontruncating variants, c.4610C>T; 
p.(Thr1537Met), c.5914G>A; p.(Gly1972Arg), c.6446G>T; p.(Arg2149Leu), were 
present in the biallelic group as well.
Table 2. Distribution of enriched variants in the ABCA4-LOVD Cauc patient dataset 
α Including big deletions and missense variants at the first codon.
Complex alleles and deep intronic variants were not tested due to the absence 
of these variants in ExAC. The total frequency of significantly enriched variants 
per allele is 0.56 in the patient dataset compared to 0.021 in the ExAC database. 
Therefore, in the ExAC database about one in every 24 persons is a carrier of a 
presumed pathogenic ABCA4 variant.
Frequent ABCA4 variants
The p.(Gly1961Glu) variant is the most frequent variant in the ABCA4-LOVD 
(536/6,670 alleles), followed by p.[Gly863Ala, Gly863del], present in 261 of 
6,670 alleles. In the ExAC nFE population, the p.[Gly863Ala, Gly863del] variant 
is more frequent than p.(Gly1961Glu) (allele frequency 0.0081 for p.[Gly863Ala, 
Gly863del] vs. 0.0047 for p.(Gly1961Glu)) in ExAC. The third most frequent 
variant is c.5461-10T>C (p.[Thr1821Valfs, Thr1821Aspfs]), a noncanonical splice 
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variant that recently was shown to result in the skipping of exon 39 or exon 39/40 
[Sangermano et al., 2016] and is present in 156 of 6,670 alleles in the ABCA4-
LOVD_Cauc vs. 26/66,486 alleles of nFE in ExAC (Supp. Table S1).
Missense variants
For all the missense variants, Grantham, PhyloP, and CADD scores were obtained. 
Furthermore, the OR was determined by comparing the allele count in the ABCA4-
LOVD_Cauc patient dataset with the nFE ExAC control dataset (Supp. Table S3). 
When the in silico scores were compared to the age of onset of cases carrying 
missense variants on one allele as well as a truncating variant on the other allele, 
a significant negative correlation was found for the OR (ρ = –0.34, P < 0.04; Supp. 
Fig. S1) but not for the Grantham (Supp. Fig. S2), CADD (Supp. Fig. S3), and PhyloP 
(Supp. Fig. S4) scores. Of note, Grantham scores >90 were not observed for 
missense variants observed in patients with an onset of disease above 25 years 
of age, indicating that high Grantham scores might be related to an earlier age of 
onset, while variants with a low Grantham score can be found in patients with all 
ages of onset.
Protein-truncating variants
About a quarter of all variants that were associated with disease according to the 
enrichment analysis of the total Caucasian dataset were protein truncating (Supp. 
Table S4), among which is composed of about one-third stop mutations, one-third 
frameshift mutations, and one-third canonical splice site mutations. Only 26 of 
the 313 truncating variants were listed in ExAC, illustrating that most of these 
variants are very rare.
Homozygosity analysis
According to the widely accepted genotype–phenotype correlation model 
mentioned above, patients with a severe variant in a homozygous state are 
expected to present with an early-onset form of STGD1 or arCRD. Furthermore, 
all homozygous variants that cause STGD1 with an onset between 10 and 45 
years of age are expected to have at least a moderate effect. Finally, homozygous 
mild variants are not expected to give rise to a monogenic IRD. Therefore, in this 
analysis, variants were annotated accordingly. In total, 58 nontruncating variants 
were found in a homozygous state (Supp. Table S5).
The two presumed mild variants, p.[Gly863Ala, Gly863del] and p.(Gly1961Glu), 
were found in a homozygous state in 2 and 16 cases, respectively. This is significantly 
less than expected based on their ExAC frequencies and an STGD1 prevalence 
of one in 10,000 individuals (P < < 3.3 × 10−306 and P = 1.8 × 10−172, chi-square 
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test, Bonferroni adjusted) (Table 3). These results confirm that both variants in 
the far majority of IRD cases can be considered as mild alleles. Regarding the 
p.(Gly1961Glu) variant, the Hardy–Weinberg equilibrium was maintained in the 
disease population even though we might expect less homozygous cases due to 
the absence of disease in case of a mild effect on protein function in homozygous 
state. However, if we consider its allele frequency in ExAC (0.005), it is expected 
to occur in a homozygous state in ∼1/40,000 persons in the general population, 
and it thereby would represent ∼25% of STGD1 cases. In the ABCA4-LOVD_Cauc, 
it is only found in a homozygous state in 16/3,335 (0.48%) of cases with one or 
two likely causal ABCA4 variants. From this analysis, we can confer that >95% 
of p.(Gly1961Glu) alleles can be considered to be mild. Furthermore, the three 
variants c.3113C> T (p.(Ala1038Val)), c.5714+5G> A (p.(?)), and c.6089G> A 
(p.(Arg2030Gln)) were deemed mild alleles as they were not found homozygously 
in patients even though this was expected based on their frequency in ExAC (Table 
2). 
Table 3. Variants Occurring Significantly Less in a Homozygous State in the Caucasian ABCA4-LOVD 
than Expected Based on the Frequency in the ExAC Non-Finnish European Population (Chi-Square 
Test, Corrected by FDR).
The number of expected homozygous cases is based on the frequency of the variant in the control 
nFE population and a disease prevalence of one ABCA4-associated macular dystrophy patient in 
10,000 individuals. This means that the ABCA4-LOVD_Cauc cohort represents 32,700,000 individuals 
of a normal population.
In 37 IRD cases carrying homozygous nontruncating variants, the age of disease 
onset was reported (Fig. 1). Thirteen variants led to an early average age of onset, 
which indicates severe pathogenicity of these variants. These included seven 
missense variants, four complex alleles, and two noncanonical splice site changes.
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3Figure 1: Age of disease onset analysis for STGD1 cases carrying homozygous ABCA4 variants. Standard deviations are shown for variants that occurred homozygously more than once.
Compound heterozygosity analysis of mild ABCA4 variants
The variants that were deemed mild by the homozygosity analysis are expected 
to be accompanied by a severe allele when they are found on one allele of 
STGD1 or arCRD patients. In ABCA4-LOVD_Cauc, a second variant was reported 
in 160 cases with p.[Gly863Ala, Gly863del], in 34 cases with p.(Ala1038Val), in 
73 cases with c.5714+5G>A, in 323 cases with p.(Gly1961Glu), and in 24 cases 
with p.(Arg2030Gln) cases. As expected, all of these alleles occurred more often 
with known truncating alleles compared to other nontruncating variants, but this 
was only significant for the p.(Gly1961Glu) variant (P = 0.0076, chi-square test, 
Bonferroni corrected) (Supp. Tables S6 and S7). For the nontruncating variants 
that were found to accompany mild deemed variants in patients, the reported 
age of onset was depicted per variant (Supp. Figs. S5–S9). Of note, in eight cases 
combinations of mild alleles were present in the ABCA4-LOVD dataset with 
reported ages of onset <20 years, indicating that these data should be interpreted 
with caution.
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Early onset analysis
Patients that presented with ABCA4-associated IRD in the first decade of their 
life were expected to harbor two severe mutations. For patients with an early 
age of disease onset mentioned, 20 different missense variants, complex alleles 
with only missense variants, or noncanonical splice site variants were identified, 
which thereby are indicated to be severe alleles (Supp. Table S8). This included 
the p.(Gly1961Glu) variant and interestingly also the complex allele including this 
same variant, namely p.[His1838Asp; Gly1961Glu]. This could indicate that in the 
p.(Gly1961Glu) case the presence of the histidine to aspartic acid change may 
have been missed.
Complex allele p.[Leu541Pro; Ala1038Val]
Among the 285 complex alleles (Supp. Table S8) that have been reported in the 
ABCA4-LOVD, 195 consisted of the p.[Leu541Pro; Ala1038Val] variant. These 
were reported in a homozygous state in 18 patients, indicating that this complex 
allele has a moderate to severe effect on the protein function. Interestingly, both 
variants alone are also enriched in the ABCA4-LOVD_Cauc dataset. Individually, 
the p.(Leu541Pro) and p.(Ala1038Val) variants have allele frequencies of 0.000180 
and 0.00196, respectively, in the nFE ExAC. As mentioned above, the single 
p.(Ala1038Val) variant was defined as a mild variant based on its frequency. The 
p.(Leu541Pro) variant does occur in a homozygous manner in the ABCA4-LOVD 
dataset and is therefore expected to have a moderate to severe effect on its own.
Protein domain variant analysis
To assess the variant distribution over the different protein domains, SMART 
domains and their locations were obtained from http://smart.embl-heidelberg.
de/. Two ATPase domains were present at amino acid positions 955–1145 and 
1964–2148 (Fig. 2). The number of missense variants per ATPase domain and 
the number of missense variants for all transmembrane regions combined were 
compared to the expected amount of variants per domain based on the fraction 
of variants per each domain in the ExAC database. Interestingly, the amount of 
variants in the ATPase domains was significantly higher than expected (P = 1.2−07 
for the first domain, P = 4.7−05 for the second domain, chi-square test, Bonferroni 
corrected), whereas the amount of variants in the transmembrane regions was 
not significantly higher (P = 0.26, chi-square test).
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Benign variants
Thirty variants were published to be disease causing while their frequency in 
the ABCA4-LOVD dataset was lower than in the ExAC database. This makes their 
pathogenicity unlikely, and therefore, these variants were classified as category 
4 (likely benign) in the LOVD database (Supp. Table S9). However, the low 
frequency ratio of some of these variants may result from a reporting bias, if they 
were identified but not published as causative because of their relatively high 
frequency. Ten of these variants have an allele frequency in the nFE population 
that is higher than 0.005. Based on Hardy–Weinberg equations, these variants 
cannot be disease causing in view of the prevalence of the disease and are 
therefore classified as category 5 (benign) (Supp. Table S9). 
Furthermore, five variants that were significantly enriched in the ABCA4-LOVD 
dataset had allele frequencies of >0.005 in a population other than the nFE 
population, which could indicate a mild pathogenic nature of these variants or a 
benign nature. In the latter case, the patients carrying these variants most likely 
descend from a person of a non-nFE ethnicity (comments in Supp. Table S2). 
Finally, 269 variants were found not to be enriched significantly, although their 
frequency was higher in the cohort than it was in the control population. These 
variants were classified as having an uncertain significance (Supp. Table S10). 
Splice site predictions
Among the noncanonical splice site changes (i.e., splice acceptor site variants at 
intronic positions –3 to –14, splice donor site variants at intronic positions +3 
to +8, or the first or last nucleotide of the exon), 30 variants were found to be 
enriched in ABCA4-LOVD_Cauc. Additionally, 10 deep intronic variants and 15 
other noncanonical splice site variants were present in the total ABCA4-LOVD 
dataset. For 34 of the variants close to the exon borders, at least three of five 
splice site prediction programs predicted that the splice site had a reduced splice 
prediction score of at least 10%. Furthermore, seven deep intronic variants were 
predicted to create new splice sites (Supp. Table S11). Splice predictions for 
missense variants led to the identification of 13 missense variants that show a 
decrease in canonical splice site prediction scores of >10% (Supp. Table S12). 
Synonymous variants in the ABCA4-LOVD_Cauc, including polymorphisms, were 
collected and in silico assessed (Supp. Table S13). The c.6342G>A variant has a 
high ratio of ABCA4-LOVD_Cauc frequency/ExAC frequency (>40) and showed 
mild to high predictions for the introduction of a new splice site by all five splice 
site prediction programs (an increase in a predicted splice site ranging between 
1.2 and 72% of the total possible scores). Furthermore, for four additional 
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synonymous variants (i.e., c.618C>T, c.873G>A, c.4128G>A, and c.4773G>C), a 
decrease or increase of >10% of the total possible splice prediction score was 
predicted by at least three out of five programs, indicating a possible pathogenic 
nature of these variants. 
ACMG variant classification
Finally, all the variants from the ABCA4-LOVD dataset were classified according to 
the new guidelines of the ACMG (November, 2015). By the classification mentioned 
in the Methods section, 195 variants were classified as pathogenic, 274 as likely 
pathogenic, 260 as uncertain significance, and 10 as benign. Interestingly, there 
was one variant, c.2948C>T, which was not present in the ABCA4-LOVD_Cauc, but 
was still classified as likely pathogenic due to its location in domain 1, the fact 
that other variants in this codon have been reported to cause disease as well, 
and its high in silico scores (PhyloP 6.41, CADD 25.8, and Grantham 89). Finally, 
21 missense variants had a moderate to high OR and Grantham score, predicting 
them to be of a moderate to severe pathogenicity. Of note, 18 frameshift, stop, 
and canonical splice site variants were classified as “uncertain significance” due 
to the lack of supporting information to classify them as pathogenic.
Leiden Open Source Variant Database
All the recorded published variants with the description of the phenotype, 
including age of onset, phenotype of onset, segregation information, and 
disease definitions, when given, were uploaded to the LOVD (www.LOVD.nl/
ABCA4). Their references can be found in the Suppl. Materials. Furthermore, 
all the variants were categorized as either (1) pathogenic, (2) likely pathogenic, 
(3) uncertain significance, (4) likely benign or (5) benign based on the frequency 
data, enrichment in the ABCA4-LOVD dataset, and whether or not the variant was 
truncating as mentioned above.
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Discussion
We collected ABCA4 variants from 4,137 patients with ABCA4-associated 
phenotypes. Of the 913 different reported variants, the majority comprised 
missense variants (51.6%), followed by protein-truncating variants (34.4%) (Table 
1). 
Severity classification
In this study, 316 variants have been found to be significantly enriched in the ABCA4 
gene of likely Caucasian IRD patients. These include 125 truncating variants, 169 
missense variants, 18 noncanonical variants, and four small insertion/deletions 
(Table 2). We predicted 81 variants to have a moderately severe to severe 
pathogenic nature based on allele combinations, early onset disease analysis, and 
in silico assessments. 
Furthermore, five variants (p.[Gly863Ala, Gly863del], p.(Gly1961Glu), 
p.(Ala1038Val), c.5714+5G>A, p.(Arg2030Gln)) were identified to have a mild 
pathogenic effect in most cases based on their low or absent homozygous 
occurrence, while having a relatively high allele frequency. One interesting finding 
was the homozygous occurrence of p.(Gly1961Glu) in 16 different cases, including 
two cases with an early age at onset. Even though this is still significantly less 
than expected based on the frequency in ExAC (chi-square test, P = 3.5 × 10−173), 
it indicates that in a small percentage of cases the p.(Gly1961Glu) allele can act 
as a moderate to severe variant. In the ABCA4-LOVD dataset, eleven complex 
alleles containing p.(Gly1961Glu) were reported. This could indicate that the 
p.(Gly1961Glu) variant is an old variant next to which multiple other variants have 
arisen over time in cis due to recombination or de novo mutation events, such as 
in the case of p.[His1838Asp; Gly1961Glu]. Alternatively, although deletions are 
very rare in ABCA4 [Yatsenko et al., 2003; Zernant et al., 2014], a small fraction of 
these homozygous cases might be explained by sizeable heterozygous deletions 
overlapping these variants [Maugeri et al., 1999; Rozet et al., 1999]. 
Interestingly, the p.(Asp2177Asn) variant was clearly not enriched in the ABCA4-
LOVD_Cauc dataset, whereas this variant has been associated with age-related 
macular degeneration in a previous study [Zhang et al., 2015]. Furthermore, five 
variants were significantly enriched in the ABCA4-LOVD patient dataset, while 
their frequency in another population was >0.005. This could either indicate a 
mild pathogenic nature of the variants or false positives due to descent from a 
non-Caucasian ancestor. 
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 179
179
Identification, registry and functional assessment of ABCA4 variants
3
Finally, we note that polymorphisms present in more than 25% of persons in 
the general population were frequently reported as causative. Medical doctors 
should, therefore, assess an ABCA4 variant in their patient with caution when it 
has been reported in STGD1/CRD patients, as it might still be a benign variant. 
This paper provides a list of variants that can be used to check if a variant is likely 
pathogenic based on data in a Caucasian population. 
Additional findings
For a genotype–phenotype assessment, we looked at age of onset and variant 
relationships. We identified cases with an unexpected early age of onset based 
on the mild pathogenicity of the variants that were identified. Therefore, the 
assessment of the variants solely based on the age of onset or the occurrence 
with a mild allele is not trustworthy on its own. Similarly, we have found mild 
mutations in a homozygous state, which raises questions about the other variants 
that have been found in a homozygous state. However, due to the low frequency 
of those variants, the chances are very small that their homozygous state occurred 
by chance in a patient with a STGD1/CRD phenotype, without additional variants 
having been identified. Other phenotypic data were not taken up in the analysis, 
because there is too much variation in criteria used for diagnoses of the patients. 
Additionally, we found a significant correlation between ORs of ABCA4 missense 
variants and the age of onset in STGD1 and arCRD patients that presented with 
one of these missense variants on one allele and a truncating variant on the other 
allele, whereas Grantham, PhyloP, and CADD scores did not correlate significantly 
with the age of onset of these patients. 
In the protein domain analysis, we tested if the number of mutations in the 
ABCA4 protein domains was enriched in the ABCA4-LOVD_Cauc dataset to 
investigate whether certain domains are more crucial for normal protein function. 
In the ABCA4-LOVD_Cauc dataset, the number of missense variants in the first 
ATPase domain of the protein is significantly higher compared to what would 
be expected based on the missense variant density in that domain in the nFE 
population (P = 1.2−07, chi-square test, Bonferroni corrected). The same is true 
for the second ATPase domain of the protein, although this is less significant 
(P = 4.7−05, chi-square test, Bonferroni corrected). This could be in line with the 
findings of Ahn et al. [2003], which indicated that the first ATPase domain binds 
ATP better and has more ATPase activity than the second. The same paper shows 
that the combination of both domains has increased ATPase binding and activity 
compared to each of the domains on their own [Ahn et al., 2003]. 
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Confounders
In this study, we used all the published variants in ABCA4 that have been found 
in Stargardt disease and CRD patients. However, the use of different techniques 
to identify variants in ABCA4 may have caused a bias in the data because each of 
the mutation scanning techniques is imperfect. This should be taken into account 
when interpreting the identified enrichment of certain variants in this dataset. 
We deemed five variants to have a mild pathogenicity effect due to their high 
relative frequency and the low or absent amount of patients that are homozygous 
for these mutations. Perhaps not all studies have reported these variants due 
to the possibility that their high frequency has been interpreted as belonging 
to a benign variant. This might especially be the case for the p.(Ala1038Val) 
variant, which often occurs together with the p.(Leu541Pro) variant in cis and 
could therefore have been omitted from publications. Therefore, replication of 
this result in a dataset of patients in which it is known that all the p.(Ala1038Val) 
variants found in the dataset have been taken along in the analysis will be needed 
to confirm this result. 
Low ABCA4 expression levels due to variants in cis- or trans-acting elements could 
explain the high amount of monoallelic cases. Ensembl reports ∼20 enhancer 
regions near ABCA4 [Flicek et al., 2014]. Furthermore, Scheetz et al. found an 
eQTL, a c-Rel binding site, 6.6 kb upstream of the transcription start site in the 
SHRSP rat that correlated with increased Abca4 expression, and which was absent 
in SR/JrHsd rats [Scheetz et al., 2006]. The region 10 kb upstream of the human 
ABCA4 gene contains more than six elements that meet the c-Rel binding site 
motif according to Chen and Ghosh [1999] that might have a similar function. 
In 9.5% of the identified alleles, complex alleles were identified. Our variant 
analyses in persons carrying homozygous or compound heterozygous variants did 
not take into account that additional unknown noncoding variants could similarly 
be in linkage disequilibrium with the studied variants. Furthermore, in particular 
in monoallelic cases, we cannot exclude the possibility that the actual cause of 
disease is situated in other genes [Littink et al., 2010; Zaneveld et al., 2015]. 
One limitation of this study is that the ExAC dataset containing control individuals 
does not match the population of published patients perfectly. Even though both 
datasets contain non-Finnish Caucasian individuals, the ABCA4-LOVD_Cauc dataset 
is obtained from different locations, creating a bias toward benign variants that 
are frequent in ABCA4-LOVD_Cauc. Furthermore, the ExAC database can contain 
STGD1 patients, which were genotyped as healthy controls before presenting with 
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symptoms. However, in view of the prevalence of ABCA4-associated STGD1 and 
arCRD (∼1 in 8,000 individuals) and the large allelic heterogeneity, our assessment 
of individual variants can only be slightly affected by the presence of a few STGD1 
or arCRD cases in ExAC. Another limitation is the fact that the patients present in 
this study over time were diagnosed by different ophthalmologists using different 
criteria and that their genotypes have been revealed by different techniques. 
Therefore, there is no consistency in how many regions of the gene have not been 
tested (accurately) causing an underestimation of the total number of variants 
present in the ABCA4-LOVD group. 
Splice site prediction programs
In our scoring procedure, we gave the results of each prediction program the same 
weight, even though Tang et al. reported that splice prediction programs differ 
in their prediction strength, depending on the variant location affecting splicing 
[Tang et al., 2016]. Of note, when we assessed all the possible noncanonical splice 
site variants, we encountered a small deficiency in the assessment of the Human 
Splicing Finder prediction tool. In some cases, the reference score changed when 
we looked at different variants that were situated close the same splice site (e.g., 
the reference splice site at c.4773 was 86.0 when assessing c.4773+3A>G and 
was 84.6 when assessing c.4773+5G>A). Although no extreme differences were 
encountered, it does decrease the reliability of this version of the tool.
Leiden Open Source Variant Database
All the data that were collected in this study have been merged with a small set 
of previously registered variants and uploaded in the publicly available ABCA4 
LOVD. By combining as many data as possible, we were able to identify many 
variants to be associated with IRDs. We consider our efforts as a first significant 
step toward a comprehensive ABCA4 LOVD as thousands of ABCA4 variants have 
likely been identified in academic and nonacademic diagnostic centers, but have 
not been published. Sharing genetic data of additional patients will increase 
statistical power and can lead to the classification of additional pathogenic and 
benign variants. If scientific journals would make uploading of IRD-associated 
variants in publicly available databases compulsory for the acceptance of papers, 
a growing body of variant data would become available to systematically assess 
the functionalities of IRD-associated variants.
Future research
At the moment, mainly Caucasian patients have been genotyped and often the 
ethnicity of patients is not well annotated. Collecting more accurate data of 
patients of all ethnicities will give a better overview of ABCA4 variants in STGD1 
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patients worldwide. Furthermore, in order to use phenotypic data to investigate 
the direct effect of a variant on the phenotype, it would be very useful if more 
standardized criteria will be used worldwide, such as the Fishman criteria for 
diagnosing different stages of STGD1 [Fishman et al., 1999]. In vivo analysis of 
variants in retinal organoids can finally be used to confirm pathogenicity as well 
as to assess haplotype effects on expression levels.
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Supplementary material
Figures, legends to supplementary tables (Excel file) by references of publications 
1997-2015 listing ABCA4 variants. 
Supplementary Figure 1: 
Age of onset of patients with one null allele and one missense variant plotted against the odds 
ratio of the missense variant. The age of onset correlates with the odds ratio (ρ = -0.34, p <0.03, 
Bonferroni corrected).
Supplementary Figure 2:
 
Age of onset of patients with one null allele and one missense variant plotted against the Grantham 
score of the missense variant. The age of onset does not correlate significantly with the Grantham 
score (ρ = -0.21, p <0.20).
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 188
188
Chapter 3.1
Supplementary Figure 3: 
Age of onset of patients with one null allele and one missense variant plotted against the CADD 
score of the missense variant. The number of patients in this analysis seemed too small to perform 
statistics.
Supplementary Figure 4:
Age of onset of patients with one null allele and one missense variant plotted against the PhyloP 
score of the missense variant. The age of onset does not significantly correlate with the PhyloP score 
(ρ = 0.13, p >0.25, Bonferroni corrected).
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Supplementary Figure 5:
Age of onset analysis for compound heterozygotes carrying one mild c.2588G>C variant. Standard 
deviations are shown for variants that were reported with an age of onset more than once.
Supplementary Figure 6:
Age of onset analysis for compound heterozygotes carrying one mild c.3113C>T variant. Standard 
deviations are shown for variants that were reported with an age of onset more than once.
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Supplementary Figure 7
Age of onset analysis for compound heterozygotes carrying one mild c.5714+5G>A variant. Standard 
deviations are shown for variants that were reported with an age of onset more than once.
Supplementary Figure 8:
Age of onset analysis for compound heterozygotes carrying one mild c.5882G>A variant. Standard 
deviations are shown for variants that were reported with an age of onset more than once.
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Supplementary Figure 9:
Age of onset analysis for compound heterozygotes carrying one mild c.6089G>A variant. Standard 
deviations are shown for variants that were reported with an age of onset more than once
Legends of supplementary tables
The Excel file of supplementary tables is available at https://onlinelibrary.wiley.
com/doi/full/10.1002/humu.23165; section “supporting information” (hu-
mu23165-superior-0002-tableS1-S13.xlsx). 
Table S1. Overview of ABCA4 variants in 3,928 patients with retinal dystrophy. 
References to each variant can be found online at www.LOVD.nl/ABCA4. 
Genomic location, DNA variant, protein variant, ABCA4-LOVD allele count (AC), 
ABCA4-LOVD allele frequency (AF), ExAC allele frequency, the study variant 
severity classification and the ACMG variant severity classification (Richards, 
et al., 2015) are given for each non-complex and non-deep intronic variant. 
Complex and deep-intronic variants are given at the bottom. For the classification 
of this study the following criteria were used. Benign: ExAC allele frequency 
>0.006; Likely benign: (ABCA4-LOVD AF/ExAC non-Finnish Caucasian AF) <1; 
Unknown pathogenicity: (ABCA4-LOVD AF/ExAC non-Finnish Caucasian AF) >1, 
however not significantly enriched; Likely pathogenic: Non-truncating alleles, 
significantly enriched in ABCA4-LOVD or truncating alleles, not significantly 
enriched in ABCA4- LOVD; Pathogenic: Truncating alleles significantly enriched 
in ABCA4-LOVD; Not applicable: variants were identified in patients of a 
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non- Caucasian ethnicity only.Due to low numbers of reported patients of this 
ethnicity, variants could not be statistically compared to a matching control 
group. *Truncating alleles that were not tested in the Fisher Exact test due to 
absence in the Caucasian patient cohort. **Truncating alleles that were not 
significantly enriched in the Caucasian patient cohort.
Table S2. Variants significantly enriched in Caucasian retinal dystrophy patients. 
Variant information, including allele count (AC), allele frequency (AF) and 
total allele number (AN) are given per variant, as well as statistical information, 
including odds ratio, odds ratio confidence intervals (CI) (CIlower; CIupper) and 
a false detection rate corrected p-value (Fisher-exact test).
Table S3. Missense variants identified in patients with retinal dystrophy. Variant 
information is given together with in silico scores and pathogenicity verdict 
based on homozygosity, occurrence with the c.2588G>C variant, occurrence with 
the c.5882G>A variant and occurrence in patients with an early onset.
Table S4. Truncating variants identified in patients with retinal dystrophy. 
Variant information is given together with the odds ratio. *The ABCA4-LOVD 
allele frequency/ExAC allele frequency as well as the odds ratio are based on 
a hypothetical occurrence of one allele in the ExAC database, to estimate a 
minimum.
Table S5. Non-truncating alleles identified in a homozygous state in patients 
with retinal dystrophy. The number of cases with an early age of onset were 
mentioned for each variant.
Table S6. Non-truncating alleles together with the c.2588G>C variant identified in 
patients with retinal dystrophy. 
Table S7. Non-truncating alleles together with the c.5882G>A variant identified in 
patients with retinal dystrophy.
Table S8. Complex ABCA4 alleles identified in retinal dystrophy patients. Allele 
count and allele frequency of all reported complex alleles in the ABCA4 gene.
Table S9. (Likely) benign variants. Variants with an equal or lower allele frequency 
in the LOVD-ABCA4 cohort compared to ExAC. Variants with an allele frequency 
>0.005 are annotated as benign, the remaining variants are annotated as likely 
benign.
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Table S10 Variants of uncertain pathogenicity. Both the variants that were not 
significantly enriched in the ABCA4-LOVD group as well as the variants that 
were found in patients of ethnicities other than Caucasian are given with their 
frequency, odds ratios, odds ratio confidence intervals (CI) (CIlower; CIupper) 
as well as in silico prediction information. 
Table S11. Splice site prediction effects of non-canonical splice site variants. 
Splice site prediction effects are given from SpliceSiteFinder like, MaxEntScan, 
NNSPLICE, Gene Splicer and Human Splicing Finder, which were obtained by 
Alamut Visual, version 2.7. Predictions that differ from the original by >10% are 
marked red.
Table S12. Splice site prediction effects of missense variants. Splice site prediction 
effects are given from SpliceSiteFinder like, MaxEntScan, NNSPLICE, Gene Splicer 
and Human Splicing Finder, which were obtained by Alamut Visual, version 2.7. 
Predictions that differ from the original by >10% are marked red. Only the 
missense variants that showed >10% change by >2 splice prediction programs 
are mentioned. Variants that are substitutions at the first or last nucleotide of 
the exon, are in bold.
Table S13. Splice site prediction effects of synonymous variants. Splice site 
prediction effects are given from SpliceSiteFinder like, MaxEntScan, NNSPLICE, 
Gene Splicer and Human Splicing Finder, which were obtained by Alamut Visual, 
version 2.7, for variants that decrease the canonical splice site predictions 
and variants that increase alternative splice sites. Predictions that differ from the 
original canonical splice site by >10% are marked red. Predictions that occur at 
a non-canonical position are marked in yellow.
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CHAPTER 3.2
Heterozygous deep-intronic variants and deletions in ABCA4 in 
persons with retinal dystrophies and one exonic ABCA4 variant. 
“The most frequently mutated inherited retinal dystrophy gene, ABCA4, shows an 
unusual phenomenon, i.e. in a very high proportion of patients with STGD1, one 
or no ABCA4 variants were found. Braun et al. (2013) identified 5 deep-intronic 
variants in a cohort of STGD1 cases with one ABCA4 variant. We analyzed 45 
retinal dystrophy patients with one ABCA4 variant for the presence of these and 
other deep-intronic variants, and in addition tested these patients for the presence 
of heterozygous deletions. In this way we found six probands with heterozygous 
deep-intronic mutations, two probands with heterozygous deletions, and one 
proband with a heterozygous deep-intronic mutation and an intragenic deletion. 
As antisense oligonucleotide-based therapies are being development, these 
patients are eligible for this novel treatment.” 
Nathalie M. Bax*, Riccardo Sangermano*, Susanne Roosing* 
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Variants in ABCA4 are responsible for autosomal recessive Stargardt disease and 
cone-rod dystrophy. Sequence analysis of ABCA4 exons previously revealed one 
causative variant in each of 45 probands. To identify the ‘missing’ variants in these 
cases we performed multiplex ligation-dependent probe amplification-based 
deletion scanning of ABCA4. In addition, we sequenced the promoter region, 
fragments containing five deep-intronic splice variants and 15 deep-intronic 
regions containing weak splice sites. Heterozygous deletions spanning ABCA4 
exon 5 or exons 20-22 were found in two probands, heterozygous deep-intronic 
variants were identified in six probands, and a deep-intronic variant was found 
together with an exon 20-22 deletion in one proband. Based on ophthalmologic 
findings and characteristics of the identified exonic variants present in trans, the 
deep intronic variants V1 and V4 were predicted to be relatively mild and severe, 
respectively. These findings are important for proper genetic counseling and for 
the development of variant-specific therapies.
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The ATP-binding cassette, subfamily A, member 4 (ABCA4) protein is located at the 
rim of the outer segment discs in rods and in the cell membrane of cones. Variants 
in ABCA4 (MIM #601691) were associated with autosomal-recessive Stargardt 
disease (STGD1) [Allikmets et al., 1997b]. Subsequently, different combinations of 
ABCA4 variants have been linked to a spectrum of phenotypes ranging from mild 
macular dystrophy to severe early-onset panretinal dystrophy [Allikmets et al., 
1997a; Cremers et al., 1998; Maugeri et al., 1999; Klevering et al., 2004]. In the 
proposed genotype–phenotype correlation model, a combination of a mild and 
a severe ABCA4 variant causes STGD1 [Maugeri et al., 1999], the most frequent 
associated disease, whereas a moderate and a severe variant gives rise to a more 
severe phenotype, cone-rod dystrophy (CRD) [Cremers et al., 1998]. Two severe 
variants in ABCA4 result in a panretinal CRD [Cremers et al., 1998; Klevering et al., 
2004]. 
A significant subset of individuals with classic STGD1 however carries only one 
or no ABCA4 variant [Maugeri et al., 1999]. A proportion of these cases may 
be explained by the identification of variants in genes that are associated with 
retinal dystrophies resembling STGD1. ELOVL4 [Edwards et al., 2001] and PRPH2 
[Poloschek et al., 2010] contain variants that are responsible for autosomal-
dominant STGD. Furthermore, the “missing” variants in STGD1 patients may 
be the result of the limitations of the employed molecular genetic analysis. 
Homozygous ABCA4 deletions disrupting the open reading frame are not expected 
to account for the “missing” variants in STGD1 as they would result in a panretinal 
dystrophy. Heterozygous deletions, however, can have been missed as PCR-based 
mutation scanning and Sanger sequencing of ABCA4 exons would not detect small 
heterozygous deletions. Southern blot analysis revealed heterozygous deletions 
of exon 18 [Yatsenko et al., 2003] and exons 20–22 [Maugeri et al., 1999]. 
Deep sequencing of the ABCA4 mRNA of healthy retinal tissues revealed several 
low-expressed alternative transcripts of ABCA4 [Braun et al., 2013]. Sequence 
analysis of rarely used deep-intronic splice sites in STGD1 individuals identified 
variants at five splice junctions (i.e., V1 through V5), causing intron retention or 
premature termination of an exon [Braun et al., 2013]. The variants V6 and V7 
reported in the same study are not deep-intronic and can be identified using 
regular exon analysis. 
Previously, we employed a palette of genotyping methods to scan for exonic 
ABCA4 variants and deletions [Maugeri et al., 1999; Jaakson et al., 2003]. In this 
study, we have expanded our genotyping studies to identify the second variant 
in maculopathy cases with one ABCA4 allele. Forty-five probands with one 
heterozygous ABCA4 variant (33 STGD1, four STGD1/CRD, five arCRD, three ar 
cone dystrophy [CD]; Supp. Table S1), a cohort of 81 STGD1 probands with two 
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ABCA4 variants and nine additional STGD1 probands without ABCA4 variants, 
were ascertained in The Netherlands, the majority of which originates from the 
Southeast. One hundred and sixty-seven ethnically matched healthy control 
samples were collected in The Netherlands. 
Clinical data were collected from the medical records. From the patients with 
an intronic variant, data were collected focused on the age at diagnosis, best 
corrected visual acuity (BCVA) using Snellen visual acuity, ophthalmoscopy, and 
full-field electroretinography (ffERG). FfERG was performed using Dawson–
Trick–Litzkow electrodes and the RETI-port system (Roland Consults, Stasche & 
Finger GmbH, Brandenburg an der Havel, Germany), and the recordings were 
performed in accordance with the guidelines of the International Society for 
Clinical Electrophysiology of Vision (ISCEV) [Marmor et al., 2009]. The inclusion 
criteria for STGD1 were the presence of progressive retinal dystrophy with beaten-
metal appearance and/or yellow-white pisciform flecks and/or autofluorescent 
depositions under the RPE. Inclusion criteria for CRD were a progressive decline of 
visual acuity, and on ERG a reduction of both cone and rod responses, with cone 
responses equally or more severely reduced. Exclusion criteria were an onset 
>40 years, extinguished scotopic or photopic responses on ERG, and congenital 
nystagmus. This study was approved by the local medical ethics committees and 
adhered to the tenets of the Declaration of Helsinki. All participants provided 
signed, informed consent for participation in the study, retrieval of medical 
records, and use of blood and DNA for research. 
Blood samples were obtained of probands, their parents, and when possible, 
affected and unaffected siblings. DNA was isolated from peripheral blood 
lymphocytes by standard procedures. Multiplex ligation-dependent probe 
amplification (MLPA) reagents were obtained according to the manufacturer’s 
instructions (SALSA MLPA kit P151-P152 ABCA4; MRC-Holland, Amsterdam, The 
Netherlands). Primers used to perform Sanger sequencing of all coding regions 
including the intron–exon boundaries and the putative promoter region (hg19 
chr1:94,587,564–94,586,601; c.-963>c.1) of ABCA4 are described in Supp. Table 
S2. Supp. Table S3 lists the primers employed to perform Sanger sequencing 
of the deep-intronic variants (V1–V5). Sanger sequencing of the 15 regions 
encompassing rarely used splice sites was performed using previously described 
primers [Braun et al., 2013]. The variants reported in this study were submitted to 
the locus-specific database for ABCA4 at http://www.lovd.nl/ABCA4. 
An overview of the genetic analyses performed previously and in this study is 
provided in Supp. Table S1. Sequence analysis of the promoter region did not 
yield any variants. An in-frame deletion of exons 20–22 (c.2919-?_3328+?del; 
p.S974Qfs*64) was identified previously by Southern blotting [Maugeri et al., 
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1999]. As part of a diagnostic deletion scanning protocol, DNAs of 27 patients 
with retinal dystrophies and one heterozygous ABCA4 variant were fully analyzed 
for heterozygous ABCA4 deletions using MLPA, which yielded two probands 
carrying the exon 20–22 deletion in a heterozygous state (A-IV:2 and F-II:1; 
Fig. 1; Table 1). A-IV:2 is a member of a previously described multiplex family 
segregating several monogenic and multifactorial retinal dystrophies [Klevering 
et al., 2004]. She was diagnosed with STGD1/CRD and carried the c.768G>T 
variant on the other allele, which is a frequent causative ABCA4 variant [Maugeri 
et al., 1999]. The exon 20–22 deletion was also found in a second cousin (A-IV:1) 
who carried the c.5461–10T>C variant in a heterozygous state. Finally, another 
family member with STGD1 (A-III:3) carried this deletion, but no second ABCA4 
variant was detected. As described previously, III:1 and III:3 also carry the same 
maternal haplotype containing ABCA4 [Klevering et al., 2004]. Ophthalmological 
investigations were not carried out for III:1. In Family F, this deletion was found 
together with a heterozygous missense variant (p.C1488R) and a heterozygous 
deep-intronic splice variant (see below). 
Table 1: Retinal dystrophies-associated variants identified in ABCA4
Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in NM_000350.2, 
with the initiation codon as codon 1. To determine the correct mutation nomenclature,
http://www.LOVD.nl/mutalyzer, Alamut Visual version 2.4 (Interactive Biosoftware, Rouen, France), 
and http://www.hgvs.org/mutnomen/ were employed.
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Figure 1: Pedigrees with retinal dystrophies and ABCA4 variants. A–B: Families with retinal 
dystrophies due to compound heterozygous exonic ABCA4 variants and intragenic deletions. Family 
A is adapted from Klevering et al. (2004), and contains several monogenic and multifactorial retinal 
dystrophies. A heterozygous deletion of exons 20–22 was found in A-IV:1, A-IV:2, and A-III:3. The 
latter patient does not carry a second ABCA4 variant. In Family B, a heterozygous deletion spanning 
exon 5 was identified. C–I: Families with retinal dystrophies due to combinations of exonic ABCA4 
variants and deep-intronic variants. The exception is proband F-II:1, who carried a deletion spanning 
exon 20–22, together with a missense mutation, and a deep-intronic variant V1. Segregation 
analysis was not possible for Families B–F. ABCA4 variants: M1: c.768G>T; M2: c.5461–10T>C; 
M3: p.(S974Qfs*64); M4: p.(G148Vfs*89); M5: c.4539+2001G>A (V4); M6: c.5584+6T>C; M7: 
p.(A1794D); M8: c.5196+1137G>A (V1); M9: p.(C1488R); M10: p.(L1631P); M11: p.(Q1292*); M12: 
p.(G1961E).
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Using MLPA probes spanning exon 5, a novel heterozygous deletion with 
unknown boundaries (c.443-?_570+?del), resulting in a predicted truncated 
protein (p.G148Vfs*89), was detected in a STGD1 proband and an affected sibling 
of Family B (Fig. 1). Both also carried the c.768G>T variant in a heterozygous state. 
The identification of heterozygous ABCA4 deletions of exon 5 and exons 20–22 
explained six cases of three families (Fig. 1). 
The 45 probands with one heterozygous ABCA4 allele, as well as a group of nine 
STGD individuals without any pathogenic ABCA4 variant, were analyzed for the 
presence of five deep-intronic variants (V1 through V5) and analyzed for sequence 
variants at the splice sites of 15 additional cryptic exons [Braun et al., 2013]. 
The deep-intronic variant c.5196+1137G>A (V1) was detected in isolated cases 
of two families (Families F and H; Fig. 1; Table 1). In Family F, the proband also 
carried a heterozygous missense variant (p.C1488R) and a heterozygous deletion 
of exons 20–22, but segregation analysis was not possible due to unavailability 
of parental DNAs. The second deep-intronic variant identified in our cohort was 
c.4539+2001G>A (V4), which was found in a heterozygous state in five probands 
(Families C–E, G, and I; Fig. 1; Table 1). In two STGD1 siblings of family C, V4 was 
found together with the heterozygous splice site variant c.5584+6T>C. The CRD 
phenotype in the sporadic patient in Family D is very likely caused by heterozygous 
variant V4 together with a heterozygous variant that is in linkage disequilibrium 
with the splice-site variant c.5461–10T>C. Individual II:1 of Family E carries the 
severe heterozygous missense variant p.A1794D and V4, together causing STGD1/
CRD. Two siblings of Family G with STGD1/CRD carry the heterozygous missense 
variant p.L1631P, together with the heterozygous variant V4. The bull’s eye 
phenotype in a sporadic case of Family I is caused by the heterozygous variant V4 
and the heterozygous missense variant p.G1961E. The analysis of the remainder 
of the variants or alternatively spliced exons did not yield additional variants in 
our cohort. None of the deep-intronic variants were identified in the nine STGD 
cases without exonic ABCA4 variants. 
Using Sanger sequencing, we did not identify variants V1 and V4 in 167 ethnically 
matched controls. In the 45 retinal disease probands with one heterozygous 
exonic ABCA4 allele and in nine STGD cases with no ABCA4 variant, we did not 
find the deep-intronic variants V2, V3, and V5, nor any variants in the 15 regions 
encompassing weak splice sites [Braun et al., 2013]. For STGD cases with no 
ABCA4 variant, we should bear in mind that the genetic defects can very well 
reside in other genes. 
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The clinical characteristics of five unrelated patients with intronic variants from 
Families E through I are shown in Supp. Table S4. They are all of Caucasian descent. 
These patients were diagnosed between the age of 12 and 23 years (mean: 18.4 
years). The mean follow-up of disease was 25 years (range: 12–49 years). Patients 
from Families F and H showed the intronic variant V1. The proband from Family 
F carried an exon 20–22 deletion in trans, a protein-truncating (severe) allele 
[Maugeri et al., 1999]. She shows a STGD1 phenotype with a CRD pattern and 
a BCVA at last visit (age 35 years) of 20/600. The patient from Family H carried 
a nonsense variant in trans, and showed a typical STGD1 phenotype. His BCVA 
at last visit was 20/400 (age 32 years). Based on these results, V1 is deemed 
to have a mild effect on the function of ABCA4. Employing RNA extracted from 
keratinocytes derived from a STGD1 proband carrying V1 and p.T1526M (E.M.S., 
personal communication), Braun et al. (2013) identified intronic RNA insertions 
due to V1 in a significant fraction of RNA. Assuming that the ABCA4 RNA splicing 
in keratinocytes is similar to that in the retina, this argues for a severe effect of V1, 
which is in contradiction with our assessment. V1 was very recently found as the 
most frequent deep-intronic variant (10/233) in STGD1 probands with one ABCA4 
variant [Zernant et al., 2014] and not present in 368 European controls. It was 
deemed nonpathogenic as it was present in 8/200 (4%) African-American controls 
and only found in 1/46 (2%) African-American STGD1 cases with one ABCA4 
variant. However, the c.2588G>C variant in ABCA4, previously shown to be a mild 
allele, was found in a heterozygous state in 3% and 6% of Dutch and Swedish 
STGD1 cases, respectively [Maugeri et al., 1999; Maugeri et al., 2002]. The V1 
variant c.5196+1137G>A is present at an orthologous position in Macaca mulatta 
as the major allele, and shown not to affect exon 36/exon 37 splicing [Zernant 
et al., 2014]. This result does not rule out pathogenicity of V1 in humans, however, 
as differences in RNA splicing have been reported between, for example, human 
patients and a “humanized” knock-in mouse that carries the same segment of 
human CEP290 with a deep-intronic variant [Garanto et al., 2013]. 
Patients from Families E, G, and I showed the intronic variant V4. Patients from 
Families E and I carried the p.A1794D and p.G1961E variants in trans, respectively, 
both of which were deemed to be mild variants in previous studies as they were 
identified in typical STGD1 cases that carried protein-truncating variants on the 
other allele [Maugeri et al., 1999; Burke et al., 2012]. The proband from Family E 
at her last visit had a BCVA of 20/1200 (age 67 years) and showed a STGD1/CRD 
picture. The proband from Family I showed a CD phenotype. Based on these data, 
it is proposed that V4 has a severe effect on ABCA4 function. 
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As reverse-transcription polymerase chain reaction analysis using lymphoblast 
RNA from patients carrying V4 did not yield consistent results (data not shown), 
there is no experimental proof for this assumption. In the absence of detailed 
RNA analysis, we cannot be sure that V4 is disease-causing, and it is still possible 
that the causative variant is in linkage disequilibrium with V4. Although we did 
not perform haplotype analysis for V4, it is plausible that all probands carrying 
this variant share a common haplotype. Our findings, together with the frequent 
occurrence of V4 in trans with exonic ABCA4 variants in a Belgian STGD1 cohort 
(E. de Baere, personal communication), strongly suggest that V4 is a founder 
mutation. 
In contrast to the cohort from Iowa, the remaining deep-intronic splice variants 
V2, V3, and V5 were not identified in our cohort. We also did not identify variants 
in the 15 additional regions containing infrequently used deep-intronic splice 
sites as described elsewhere [Braun et al., 2013]. From the initial cohort of 127 
probands with STGD or STGD/CRD, 88 cases (69%) are currently solved with two 
ABCA4 alleles, which is a remarkable difference to the Iowa cohort in which 91.8% 
of the cases were explained. 
Identification of a second ABCA4 variant is of high significance for the relevant 
patients as this clearly implicates ABCA4 as the underlying gene, and thereby 
autosomal-recessive inheritance of the gene defects. In view of the high frequency 
of heterozygous ABCA4 variants in healthy individuals, that is, up to 1/20 individuals 
[Maugeri et al., 1999], the presence of one allele can be coincidental and the 
genetic cause situated in another gene. Affected persons with two ABCA4 variants 
are also eligible for experimental treatments based on gene augmentation. 
Moreover, the nine persons from families C through I carrying heterozygous deep-
intronic variants V1 or V4 in principle are eligible for a novel type of treatment 
based on correcting erroneously spliced RNAs, using antisense oligonucleotides. 
In fibroblasts and immortalized lymphocytes of patients with Leber congenital 
amaurosis, the potential of this approach was shown by reversing the effect of 
a deep-intronic splice defect in CEP290 [Collin et al., 2012]. The “correction” of 
one of two alleles may be beneficial and the added advantage of this approach 
versus ABCA4 gene augmentation is that overexpression of the ABCA4 gene is not 
possible. 
In conclusion, in this study we identified previously “hidden” ABCA4 alleles in nine 
of 45 (20%) families with retinal dystrophies, leaving 36 of the 45 (80%) probands 
with one heterozygous exonic ABCA4 allele unexplained. To identify additional 
putative intronic ABCA4 variants in the remaining monoallelic cases, intronic DNA 
sequencing can be combined with mRNA analysis of differentiated retinal-like 
cells derived from patient’s somatic cells. 
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Supplemental material
Supplemental Table S1. Genotyping studies in retinal dystrophy patients with one ABCA4 variant
DGGE, denaturing gradient gel electrophoresis; MLPA, multiplex ligation-dependent probe 
amplification; NGS, fluidigm-based next generation sequencing; SSCP, single strand conformation 
polymorphism.
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Supplemental Table S2. Primers for Sanger sequencing of ABCA4
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Supplemental Table S3. Primers for Sanger sequencing of deep intronic variants (V1-V5) in 
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A
aD
, A
ge at diagnosis; A
lV, age at last visit; BCVA
, best corrected visual acuity (Snellen); CD
, cone dystrophy; CRD
, cone-rod dystrophy; STG
D
1, Stargardt 
disease type 1; ff
ERG
, full-field electroreti
nogram
; F, fem
ale; M
, m
ale; LE, left
 eye; RE, right eye. *The abbreviati
ons reflect the am
plitude: N
, norm
al (equal 
to or above the low
er 5%
 of the range for a norm
al populati
on: photopic ≥78uV, scotopic ≥263uV
); M
R, m
oderately reduced (1-5%
 of norm
al range: photopic 
≥69 uV
 and <78 uV, scotopic ≥195 uV
 and <263 uV
); SR, severely reduced (<1%
 of norm
al range: photopic <69 uV, scotopic <195uV
). N
D
, not detectable; N
P, 
not perform
Supplem
ental Table S4. Clinical characteristi
cs of the pati
ents included in this study at findings at first diagnosis and m
ost recent visit
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Photoreceptor progenitor mRNA analysis reveals exon skipping 
resulting from the ABCA4 c.5461-10T à C mutation in Stargardt 
disease
“We investigated the effect of the c.5461-10T>C variant on splicing by analyzing 
mRNA from photoreceptor progenitor cells (PPCs) derived from persons with 
STGD1 who carry this variant in a homozygous or heterozygous state. In addition, 
we performed in vitro minigene splicing studies to show that this variant results in 
truncation of the predicted ABCA4 protein.”
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PURPOSE: To elucidate the functional effect of the ABCA4 variant c.5461-10T→C, 
one of the most frequent variants associated with Stargardt disease (STGD1).
DESIGN: Case series.
PARTICIPANTS: Seventeen persons with STGD1 carrying ABCA4 variants and 1 
control participant.
METHODS: Haplotype analysis of 4 homozygotes and 11 heterozygotes for 
c.5461-10T→C and sequence analysis of the ABCA4 gene for a homozygous 
proband. Fibroblasts were reprogrammed from 3 persons with STGD1 into 
induced pluripotent stem cells, which were differentiated into photoreceptor 
progenitor cells (PPCs). The effect of the c.5461-10T→C variant on RNA splicing by 
reverse-transcription polymerase chain reaction was analyzed using PPC mRNA. 
In vitro assays were performed with minigene constructs containing ABCA4 exon 
39. We analyzed the natural history and ophthalmologic characteristics of 4 
persons homozygous for c.5461-10T→C.
MAIN OUTCOME MEASURES: Haplotype and rare variant data for ABCA4, RNA 
splice defects, age at diagnosis, visual acuity, fundus appearance, visual field, 
electroretinography (ERG) results, fluorescein angiography results, and fundus 
autofluorescence findings.
RESULTS: The frequent ABCA4 variant c.5461-10T→C has a subtle effect on splicing 
based on prediction programs. A founder haplotype containing c.5461-10T→C 
was found to span approximately 96 kb of ABCA4 and did not contain other rare 
sequence variants. Patient-derived PPCs showed skipping of exon 39 or exons 39 
and 40 in the mRNA. HEK293T cell transduction with minigenes carrying exon 39 
showed that the splice defects were the result of the c.5461-10T→C variant. All 
4 subjects carrying the c.5461-10T→C variant in a homozygous state showed a 
young age of STGD1 onset, with low visual acuity at presentation and abnormal 
cone ERG results. All 4 demonstrated severe cone–rod dystrophy before 20 years 
of age and were legally blind by 25 years of age.
CONCLUSIONS: The ABCA4 variant c.5461-10T→C is located on a founder 
haplotype lacking other disease-causing rare sequence variants. In vitro studies 
revealed that it leads to mRNA exon skipping and ABCA4 protein truncation. Given 
the severe phenotype in persons homozygous for this variant, we conclude that 
this variant results in the absence of ABCA4 activity.
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Introduction
Biallelic variants in the gene encoding the ATP-binding cassette transporter type 
A4 (ABCA4) have been identified in approximately 75% of cases with autosomal 
recessive Stargardt disease (STGD1) 1, 2, 3, 4, 5 and in approximately 30% of patients 
with autosomal recessive cone–rod dystrophy (CRD).6 In severe CRD cases, 
the phenotype can resemble retinitis pigmentosa. More recently, late-onset 
STGD17 and STGD1 cases with a fine granular pattern with peripheral spots on 
autofluorescence examination8 have been associated with the presence of 1 or 
2 ABCA4 variants. The clinical variability observed in ABCA4-associated cases can 
be explained by a genotype–phenotype correlation model in which the residual 
activity of the mutant ABCA4 protein determines the clinical phenotype.2, 9 Persons 
with severe CRD carry 2 ABCA4 null alleles, whereas persons with STGD1 carry 2 
moderately severe variants or a combination of a mild and a severe variant. 2, 9 
The ABCA4 protein has been proposed to act as a flippase for 11-cis and all-trans 
isomers of N-retinylidene-phosphatidylethanolamine across disc membranes, 
thereby facilitating the removal of retinal products from the disc membranes and 
preventing the accumulation of potentially toxic bisretinoid compounds (e.g., 
A2E) in photoreceptor and retinal pigment epithelial cells.10, 11
To provide an accurate prognosis for persons with ABCA4 variants, it is important 
to assess the functional consequences of the approximately 1000 ABCA4 variants 
that have been reported to date. This is straightforward for protein-truncating 
variants (i.e., stop mutations, frameshift mutations, canonical splice-site 
mutations), but much more difficult for rare missense mutations (i.e., amino acid 
substitutions) and noncanonical splice variants (i.e., RNA splice variants outside 
the conserved intronic dinucleotides at the ends of introns) with an unclear 
functional effect. The pathogenicity of selected amino acid substitutions has been 
studied by assessing mutant ABCA4 protein stability, ATP-binding properties, 
ATPase activity, and mislocalization. 12, 13, 14, 15
An unusually high proportion of STGD1 cases from northern Europe and the United 
States (approximately 30%) shows only 1 ABCA4 variant, despite comprehensive 
Sanger sequencing and deletion analysis of the 50 protein coding exons. 1, 2, 3, 4, 16, 
17 Very recently, deep-intronic variants (i.e., variants not located near the coding 
exons) have been identified that can explain a proportion of these so-called missing 
mutations. 16, 17, 18, 19 The identification of both ABCA4 alleles and experimental proof 
that they have an effect on ABCA4 function also are crucial for the selection of 
persons with STGD1 for upcoming gene-specific trials, such as gene augmentation 
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(i.e., https://clinicaltrials.gov/ct2/show/NCT01367444?term=ABCA4&rank=8 and 
https://clinicaltrials.gov/ct2/show/NCT01736592?term=ABCA4&rank=12) or 
other types of treatment.
The identification of mRNA abnormalities is hampered by the photoreceptor-specific 
expression of ABCA4.5 This is particularly important for noncanonical splice 
variants with unknown effects on splicing. The third most frequent ABCA4 
variant, c.5461-10T→C (previously denoted as IVS38-10T→C; Cornelis S, Cremers 
FPM, unpublished data, 2015), on the basis of prediction programs has a very 
small effect on splicing efficiency. In our classical STGD1 patients, it is found very 
often together with the mild c.2588G→C (p.Gly863Ala)/(p.Gly863del) variant, 
suggesting that c.5461-10T→C represents a severe ABCA4 variant.
In this study, we investigated the effect of the c.5461-10T→C variant on splicing 
by analyzing mRNA from photoreceptor progenitor cells (PPCs) derived from 
persons with STGD1 who carry this variant in a homozygous or heterozygous 
state. In addition, we performed in vitro minigene splicing studies to show that 
this variant results in truncation of the predicted ABCA4 protein.
Methods
Subjects and Clinical Evaluation 
We ascertained 15 persons with STGD1 carrying the c.5461-10T→C variant in a 
homozygous state (patients 1–4) or compound heterozygous state (patients 5–15) 
from the Netherlands and Germany. In addition, we studied 2 individuals with 
STGD1 with a single ABCA4 allele (patients 16 and 17) and a control. Genotype 
data for patients 1 through 17 can be found in Supplemental Table 1. This study 
was approved by the institutional review board and adhered to the tenets of the 
Declaration of Helsinki. We studied all recent and available retrospective data of 
patients 1 through 4. This included history on initial symptoms, age at diagnosis, 
regression of Snellen best-corrected visual acuity (converted in Fig 1 to equivalent 
logarithm of the minimum angle of resolution visual acuity), and description of the 
fundus abnormalities. Thereafter, we also examined available color vision testing 
results, visual fields (Goldmann), fundus photography, fluorescein angiography, 
fundus autofluorescence imaging (confocal scanning laser ophthalmoscope 
[Spectralis; Heidelberg Engineering, Heidelberg, Germany]), spectral-domain 
optical coherence tomography (Spectralis), and full-field electroretinography 
(ffERG). 
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Molecular Genetic Analysis
In silico analysis of the ABCA4 c.5461-10TàC variant on splicing
The possible effect of the noncanonical splice variant c.5461-10T→C in ABCA4 on 
splicing was assessed by the use of 5 algorithms (SpliceSiteFinder, MaxEntScan, 
NNSPLICE, GeneSplicer, and Human Splicing Finder) via Alamut Visual software 
version 2.7 (Interactive Biosoftware, Rouen, France; www.interactive-biosoftware.
com).
Figure 1: Graph showing visual acuity in 
4 persons with Stargardt disease with 
the homozygous c.5461-10T→C ABCA4 
mutation. Snellen best-corrected 
visual acuity (BCVA) was converted to 
equivalent logarithm of the minimum 
angle of resolution (logMAR) visual 
acuity: logMAR 0.5 = 20/60 Snellen; 
logMAR 1.0 = 20/200 Snellen; logMAR 
1.4 = 20/500 Snellen = blindness 
(World Health Organization criteria). 
Age at diagnosis for these persons 
was between 6 and 14 years; legal 
blindness was observed in all 4 patients 
before the age of 25 years. P = patient.
Haplotype analysis
Eighteen single nucleotide polymorphisms (SNPs) were selected from within 
the ABCA4 gene and flanking sequences on the basis of their high degree of 
heterozygosity in the Dutch population (average minor allele frequency, 0.39; 
Genome of the Netherlands; http://www.nlgenome.nl/). Polymerase chain 
reaction (PCR) primers were designed to analyze amplicons of approximately 270 
bp containing these SNPs. Reaction mixtures (25 μl) contained Taq DNA polymerase, 
1 U/μl (catalog no., 11647679001; Roche, Basel, Switzerland), 10X PCR buffer 
containing MgCl2, 25 mM MgCl2, 10 mM dNTPs (deoxynucleotide triphosphates), 
and 10 μM of each primer pair and of 50 ng genomic DNA. Polymerase chain 
reaction analyses were performed by using the Veriti Thermal Cycler (Thermo 
Fisher Scientific, Waltham, MA), and PCR conditions were a first denaturation step 
of 95° C for 5 minutes followed by 35 cycles of melting (95° C for 30 seconds), 
annealing (58° C for 30 seconds), and extension (72° C for 45 seconds) steps, with 
a final elongation of 72° C for 5 minutes. Polymerase chain reaction products were 
Sanger sequenced in a 3100 or 3730 DNA Analyzer (Thermo Fisher Scientific). 
Primer details are given in Supplemental Table 2 .
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Haloplex targeted ABCA4 enrichment and sequence analysis
For patient 1, the ABCA4 locus was enriched by using a custom Haloplex Target 
Enrichment kit (Agilent, Santa Clara, CA). Probes were designed with SureDesign 
(Agilent) to target a 365-kb region (chr1:94337885–94703604, GRCh37/hg19 
assembly) encompassing the entire ABCA4 gene and flanking regulatory elements 
that have been conserved in different species.20 This study used multispecies 
comparison to map cis-regulatory domains of genes assuming they are located 
in regions of synteny. The 365-kb region corresponds to a region of synteny. The 
probes covered more than 98% of the targeted regions, and gaps in coverage 
corresponded to repeat-rich regions. Subsequently, samples were sequenced by 
using Illumina sequencing technology (MiSeq; Illumina, San Diego, CA) to obtain 
2×250-bp reads. Data analysis was performed with CLC Bio Software (CLC Bio 
Genomics Workbench; Qiagen, Hilden, Germany). Reads were aligned against a 
reference genome (GRCh37/hg 19 assembly), and variants were identified and 
annotated by a custom-designed workflow. Variants were considered for further 
filtering only if they were present in at least 1 forward and 1 reverse read, in 
a minimum of 20% of all reads, and with a minimum coverage of 5 reads. The 
variants were annotated further by Alamut Batch (Interactive Biosoftware) and 
RegulomeDB (http://www.regulomedb.org). Variants were filtered on the basis of 
population frequency, as determined by Genome of the Netherlands, a database 
containing genomic sequences from approximately 500 control individuals from 
the Netherlands,21 and Exome Aggregation Consortium (Cambridge, MA), a dataset 
of 60706 unrelated individuals sequenced as part of various disease-specific and 
population genetic studies (available at: http://exac.broadinstitute.org; accessed 
November 10, 2015).
Patient-derived fibroblast reprogramming
Skin biopsy samples from 3 persons with STGD1 and from 1 control were collected, 
washed in phosphate-buffered saline (catalog no., P5493; Sigma Aldrich, St. 
Louis, MO), dissected, and processed as described in the Supplemental Materials 
(available at www.aaojournal.org). After approximately 1 month, a pure culture 
of fibroblasts was reprogrammed by following the protocol described in the 
Supplemental Materials (available at www.aaojournal.org). Briefly, fibroblasts 
were transduced with 4 lentiviral vectors containing the stemness-related genes 
OCT3/4, NANOG, KLF4, and c-MYC and cultured in stem cell-specific medium 
for 1 month. Subsequently, induced pluripotent stem cell (iPSC) colonies were 
picked and expanded on Vitronectin-coated plates (catalog no., A14700; Thermo 
Fisher Scientific) in Essential E8 medium (catalog no., A1517001; Thermo Fisher 
Scientific).
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Induced pluripotent stem cell differentiation into photoreceptor progenitor cells
Induced pluripotent stem cell clumps were cut with the StemPro Ez-passage 
disposable stem cell passaging tool (catalog no., 23181-010; Thermo Fisher 
Scientific) and cultured in ultralow-attachment 24-well plates (catalog no., 
corn3473; VWR, Amsterdam, the Netherlands) to form embryoid bodies for 4 
days. Embryoid body medium consisted of DMEM/F-12 (Dulbecco’s Modified 
Eagle Medium: Nutrient Mixture F-12) containing 10% (volume/volume), 
knockout serum replacement (catalog no., 10828-028; Thermo Fisher Scientific) 
supplemented with nonessential amino acids (catalog no., M7145; Sigma Aldrich), 
L-glutamine (catalog no., G8541; Sigma Aldrich), B27 supplements (catalog no., 
12587010; Thermo Fisher Scientific), N2 supplements (catalog no., 17502048; 
Thermo Fisher Scientific), 5 ng/ml insulin-like growth factor-1 (catalog no., I3769; 
Sigma Aldrich), 1 ng/ml Dickkopf-related protein-1 (catalog no., SRP3258; Sigma 
Aldrich), and 1 ng/ml Noggin (catalog no., SRP3227; Sigma Aldrich). Embryoid 
bodies then were transferred to attachment culture conditions on Matrigel 
(catalog no., corn354230; VWR)-coated plates and cultivated for 2 weeks in 
PPC intermediate medium consisting of DMEM/F-12 containing L-glutamine, 
nonessential amino acids, B27 supplements, N2 supplements, 10 ng/ml insulin-like 
growth factor-1, 5 ng/ml recombinant fibroblast growth factor basic (catalog no., 
F0291; Sigma Aldrich), 10 ng/ml Dickkopf-related protein-1, and 10 ng/ml Noggin. 
Two weeks after the start of the differentiation, the PPC final medium, consisting 
of PPC intermediate medium, with 40 ng/ml 3,3,′5-Triiodo-L-thyronine sodium 
salt (catalog no., T6397; Sigma Aldrich), 20 mM Taurine (catalog no., T0625; Sigma 
Aldrich), 2 ng/ml recombinant FGF acidic (catalog no., 231-BC-025; R&D Systems, 
McKinley Place, MN), and 10 μM DAPT (catalog no., D5942; Sigma Aldrich) was 
added.
RNA isolation and cDNA synthesis
All RNA isolations and cDNA synthesis were performed as follows. Total RNA 
was isolated by using the NucleoSpin RNA Clean-up Kit (catalog no., 740955-50; 
Macherey-Nagel, Düren, Germany) according to the manufacturer’s protocol. 
RNA was quantified and cDNA was synthesized from 1 μg RNA by using the iScript 
cDNA synthesis kit (catalog no., 1708891; Bio-Rad, Hercules, CA) following the 
manufacturer’s instructions.
Induced pluripotent stem cell and photoreceptor progenitor cells characterization 
by quantitative polymerase chain reaction and immunofluorescence
RNA isolation and cDNA synthesis were performed as described above. Primers 
for the quantitative PCR analysis are listed in Supplemental Table 3 (available at 
www.aaojournal.org). Quantitative PCR was performed with the GoTaq Real-Time 
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qPCR Master Kit (catalog no., A6002; Promega, Madison, WI). Samples were 
processed in an Applied Biosystem 7900HT fast real-time PCR system (Thermo 
Fisher Scientific). Each sample was assayed in triplicate and normalized against 
the expression of the housekeeping gene GUSB. Relative quantification was based 
on the 2−(ΔΔCt) method, with fibroblasts and undifferentiated iPSCs as calibrators for 
the characterization of iPSCs and PPCs, respectively.
For immunofluorescence, cells cultivated in slide flasks (catalog no., 10439672; 
Thermo Fisher Scientific) were fixed for 20 minutes in 4% (weight/volume) 
paraformaldehyde at room temperature. Antigen retrieval was required for all 
experiments, and donkey serum (6% [volume/volume] in Tris-buffered saline and 
0.5% [volume/volume] Triton X-100) was used during the blocking and for the 
dilution of the antibodies. Primary and secondary antibodies used for both iPSC 
and PPC characterization are listed in Supplemental Table 4 (available at www.
aaojournal.org). The slides were incubated with the primary antibody overnight 
at 4° C. The sections were washed 3 times for 5 minutes with Tris-buffered saline 
and incubated for 2 hours at 37° C with the secondary antibody. This was followed 
by 3 further washes of 5 minutes in Tris-buffered saline, and then the slides were 
mounted with Vectashield-containing DAPI (4′,6-diamidino-2-phenylindole) 
mounting medium (catalog no., H-1200; Vector Laboratories, Inc, Burlingame, 
CA) and observed in a Zeiss Imager Z2 microscope (Zeiss, Oberkochen, Germany). 
Images were captured with the software Zen Pro 2012 (Carl Zeiss, Sliedrecht, the 
Netherlands).
ABCA4 transcript analysis
Photoreceptor progenitor cells were harvested from patients 1, 16, and 17 and 
1 healthy control after 45 days of differentiation. Reverse-transcription (RT) 
PCR was performed by using a forward primer located in ABCA4 exon 36 (5′-
CCACCTACTGGGTGACCAAC-3′) and a reverse primer located in ABCA4 exon 41 (5′-
AACAATGGGCTCCTTAGTGG-3′). All reaction mixtures (50 μl) contained 10 μM of 
each primer pair, Taq DNA polymerase, 1 U/μl (catalog no., 11647679001; Roche), 
10X PCR buffer without MgCl2, 25 mM MgCl2, 10 mM dNTPs, and 50 ng cDNA. 
Polymerase chain reaction analysis was performed by using the Veriti Thermal 
Cycler (Thermo Fisher Scientific), and PCR conditions were a first denaturation 
step of 94° C for 5 minutes followed by 35 cycles of melting (94° C for 30 seconds), 
annealing (58° C for 30 seconds), and extension (72° C for 1 minute) steps, with 
a final elongation step of 72° C for 5 minutes. The RT-PCR products were run on 
a 1.5% (weight/volume) agarose gel, and the resulting bands were excised and 
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purified with the NucleoSpin Gel & PCR cleanup kit (catalog no., 740609.250; 
Macherey-Nagel) according to the manufacturer’s protocol. Finally, 100 ng of the 
purified nucleic acid was analyzed by Sanger sequencing in a 3100 or 3730 DNA 
Analyzer (Thermo Fisher Scientific).
Generation of minigenes and in vitro splice assays
To amplify 2 segments of the genomic region encompassing exon 39 of the ABCA4 
gene, we designed PCR primers located in introns 38 (forward) and 40 (reverse), 
as described in Supplemental Table 5 (available at www.aaojournal.org). The 
primers were designed with Primer3 software (available at: http://bioinfo.ut.ee/
primer3-0.4.0). The PCR reaction mixtures (50 μl) contained 10 μM of each primer 
pair, a high-fidelity Taq polymerase AccuPrime Taq DNA Polymerase System 
(catalog no., 12339-016; Invitrogen, Carlsbad, CA), 10X AccuPrime PCR buffer II, 
and 200 ng genomic DNA from patient 1 and 1 healthy control. The resulting PCR 
products were run on a 1% (weight/volume) agarose gel, their bands were excised, 
and the nucleic acid was purified with the NucleoSpin Gel and PCR cleanup kit 
(catalog no., 740609.250; Macherey-Nagel), according to the manufacturer’s 
protocol. One hundred fifty nanograms of each purified insert were cloned into 
the pDONR201 vector by using the Gateway BP Clonase Enzyme Mix (catalog no., 
11789021; Thermo Fisher Scientific).
A plasmid containing the genomic region encompassing exons 3 through 5 of RHO 
inserted at the EcoRI/SalI sites in the pCI-NEO vector23 was adapted to the Gateway 
cloning system and used for in vivo splicing assays. The plasmid was digested 
with EcoNI and PflMI (catalog no., R0521S; New England Biolabs, Ipswich, MA), 
resulting in the removal of exon 4 and part of the flanking intronic sequences, 
and was blunted using large (Klenow) fragment DNA polymerase I (catalog 
no., M0210S; New England Biolabs) according to manufacturer’s instructions. 
Subsequently, a blunt-end Gateway cloning cassette containing attR1 and attR2 
sites and the pCI-neo vector was ligated by using the Rapid DNA Ligation Kit 
(catalog no., 11635379001; Roche) to generate pCI-NEO-RHO exon3,5/DEST. The 
different pDONR cloned constructs were validated by Sanger sequencing, and 150 
ng of each were cloned into the destination vector pCI-NEO-RHO exon3,5/DEST by 
using the Gateway LR Clonase enzyme mix (catalog no., 11791043; Thermo Fisher 
Scientific). Four minigene constructs were generated, 2 with the wild-type and 2 
with the c.5461-10T→C variant.
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HEK293T cells (ATCC CRL-3216; American Type Culture Collection [ATCC], Wesel, 
Germany) were grown in DMEM supplemented with 10% (volume/volume) fetal 
calf serum (catalog no., F7524; Sigma Aldrich), 1% (volume/volume) Na pyruvate 
(catalog no., S8636; Sigma Aldrich), and penicillin/streptomycin (catalog no., 
P4333; Sigma Aldrich). Cells were seeded in 12-well plates at a density of 2.5×105 
cells/well and transfected the day after with 1 μg of each minigene plus FuGENE 
HD Transfection Reagent (catalog no., E2311; Promega) with a DNA-to-liposome 
ratio of 1 μg:3 μl, according to the manufacturer’s instructions. Medium was 
replaced after 24 hours, and cells were harvested 48 hours after transfection. 
Total RNA isolation and cDNA production was performed as described before. 
All RT-PCR reactions were performed as described above, and PCR conditions 
were an initial denaturation step of 94° C for 5 minutes followed by 35 cycles of 
melting (94° C for 30 seconds), annealing (58° C for 30 seconds), and extension 
(72° C for 1 minute) steps, with a final elongation step of 72° C for 5 minutes. The 
splicing efficiency of exons of interest was determined by RT-PCR with forward 
and reverse primers residing in exons 3 and 5 of RHO (Supplemental Table 5, 
available at www.aaojournal.org). The RT-PCR products were resolved on a 2% 
(weight/volume) agarose gel, the resulting bands were excised, and the nucleic 
acid was purified by using NucleoSpin Gel & PCR cleanup (Macherey-Nagel), and 
Sanger sequencing was performed on 100 ng of each purified band by using the 
same primers used in the PCR reaction.
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Results
Clinical characteristics of patients carrying the homozygous c.5461-10 TàC 
ABCA4 mutation
Clinical characteristics of patients with the homozygous c.5461-10T→C variant 
are shown in Table 1. All patients had loss of central vision early in life and were 
diagnosed with STGD1 between 6 and 14 years of age. On follow-up, visual 
acuity showed a sharp decline to severe visual impairment within 2 or 3 years 
from first symptoms (Fig 1), leading to legal blindness (visual acuity, 20/500 or 
lower) in early adulthood. Figure 2 depicts fundus, fundus angiography, fundus 
autofluorescence, and optical coherence tomography images in several disease 
stages of patient 2, as well fundus photographs of patients 3 and 4 after 30 
years of follow-up. Funduscopy at diagnosis revealed a maculopathy in all 4 
patients with perimacular lipofuscin deposits extending toward the midperiphery 
(fundus flavimaculatus; especially in patients 1 and 3, data not shown). Through 
the years, the central lesions evolved into atrophy of the retinal layers, retinal 
pigment epithelium, and choriocapillaries (Fig 2G-I). In the mid periphery, retinal 
pigment epithelium mottling occurred followed by atrophy in all 4 patients, with 
hyperpigmentation in patient 1 (data not shown) and patient 3 (Fig 2H).We could 
retrieve the BCVA at the first ophthalmic visit in 21 out of 31 patients; the median 
BCVA  at that time was 20/32 Snellen (20/20 - 20/400). The median interval and 
95% confidence interval (CI) between the age at onset and decline in BCVA to 
mild, moderate, severe visual impairment and blindness was 1 year (95% CI, 0.0 
- 2.25), 4 years (95% CI, 3.1 - 4.9) and 12 years (CI 95% 7.8 – 16.2). One patient 
reached blindness 34 years after the first symptoms of onset at age 9. In many 
patients, the visual acuity findings were quite variable early in the course of the 
disease as shown in Figure 1. 
At presentation, ERG cone responses were reduced in all 4 patients, suggesting 
early generalized cone disease. On follow-up, cone dysfunction developed into 
progressive loss of cone and rod responses, leading to a nondetectable ERG 
response in patients 1, 2, and 3. Color vision defects varied from normal to 
defects in the red–green or blue–yellow axis at the first visit. Later color vision 
disturbances became more diffuse. Goldmann perimetry performed in patients 1 
and 3 revealed large central scotomas.
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Table 1: Clinical characteristi
cs of pati
ents hom
ozygous for c.5461-10 Tà
C
B-Y = blue-yellow
 color defect; CF = counti
ng fingers; D
 = diopter; F = fem
ale; H
RR = H
ardy-Rand and Ritt
ler; M
 = m
ale; N
 = norm
al; N
P = not perform
ed; N
R = 
nonrecordable; RPE = reti
nal pigm
ent epithelium
.
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Figure 2. Chorioretinal images for 3 Stargardt patients with the homozygous c.5461-10T→C 
ABCA4 mutation: (A–F) patient 2 (P2), (G,H) patient 3 (P3), and (I) patient 4 (P4). A, Fluorescein 
angiogram of the left eye at 8 years of age showing a dark choroid sign. B, Fundus photograph 
of the left eye obtained at 10 years of age showing a hypopigmented macula and no flecks. C, 
Autofluorescence image of the left eye obtained at 14 years of age showing an atrophic macula and 
hypoautofluorescence up to the arcades and peripapillary. D, Optical coherence tomography scan of 
the left eye obtained at 14 years of age showing loss of the retinal pigment epithelium (RPE) layer. E, 
Autofluorescence image of the left eye obtained at 17 years of age showing an atrophic macula and 
hypoautofluorescence up to the periphery. F, Fundus photograph of the left eye obtained at 17 years 
of age showing central to mid-peripheral atrophy. G, Autofluorescence image of the left eye obtained 
at 42 years of age showing central and peripheral large atrophic lesions. H, Fundus photograph of 
the left eye obtained at 42 years of age showing large atrophic lesions with hyperpigmentation. I, 
Fundus photograph mosaic obtained at 40 years of age showing pronounced atrophy posterior pole, 
atrophic lesions, and RPE alterations in the periphery. y = years.
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Haplotype and sequence analysis
To investigate whether 4 persons with c.5461-10T→C homozygous STGD1 and 
11 heterozygous persons with STGD1 shared an identical genomic segment, 
we performed haplotype analysis by using 18 SNPs located in and outside the 
ABCA4 gene (Supplemental Fig 1, available at www.aaojournal.org). Eight SNPs 
were present in a homozygous state in the 4 c.5461-10T→C homozygotes, and 
the corresponding haplotype also was found in a heterozygous state in the 11 
patients carrying c.5461-10T→C. Therefore, we defined the minimal shared 
haplotype between rs548122 (g.94,565,430) and rs35270729 (g.94,469,543) of 
chromosome 1, spanning 95.9 kb. These data suggest that the c.5461-10C→T 
variant resides on a so-called founder haplotype spanning exons 6 to 44 of the 
ABCA4 gene. To investigate further if c.5461-10T→C was the only rare variant 
present in the shared haplotype, we performed targeted next-generation 
sequencing of the entire ABCA4 genomic locus for patient 1 at an average depth 
of coverage of 62X, which did not identify additional rare variants. None of these 
variants, except c.5461-10T→C, was present at an allele frequency of less than 
0.01 in Genome of the Netherlands and Exome Aggregation Consortium data, 
strongly suggesting that the c.5461-10T→C variant is the only rare variant in the 
shared haplotype.
Generation of induced pluripotent stem cells and photoreceptor progenitor cells
Control and patient fibroblast lines were reprogrammed successfully into iPSCs. 
Quantitative PCR analysis on all cell lines confirmed the expression of the 
pluripotency markers LIN28, NANOG, OCT3/4, and SOX2 normalized against 
GUSB expression (Supplemental Fig 2, available at www.aaojournal.org), which 
was comparable between control and patient cell lines. ABCA4 was used as 
negative control. To corroborate the gene expression results, we performed 
immunofluorescence staining that showed expression of OCT3/4, NANOG, SSEA4, 
and TRA-1-81 (Supplemental Fig 3, available at www.aaojournal.org).
Control and patient iPSC lines were differentiated successfully into 
photoreceptor-like cells by a 60-day protocol in which cells cultured on 
Matrigel-coated dishes were kept in PPC-specific medium until the end of the 
experiment. Samples for quantitative PCR were obtained before the differentiation 
(iPSCs) and at 1 and 2 months of differentiation. Adult neural retina cDNA was 
used for comparison of gene expression. The expression of neural (PAX6) and 
photoreceptor progenitor (CRX and CHX10) markers in the cell line derived from 
patient 1 increased after 1 month of differentiation and remained constant up 
to 2 months of the differentiation (Fig 3B). In the control line, the expression of 
the same genes was much lower than in the patient, and after 2 months, their 
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expression decreased (Fig 3A, B). In both cell lines, the expression of the blue and 
red–green cone markers (OPN1SW and OPN1M/LW, respectively) and rod markers 
(RHO, NRL, and RCV1) increased after 1 and 2 months, except for OPN1SW, which 
in the control decreased in the second month (Fig 3A, B). ABCA4 expression was 
very low in fibroblasts and iPSCs and increased considerably on differentiation into 
PPCs, where it remained constant until the second month (Supplemental Fig 4, 
available at www.aaojournal.org). The expression of ABCA4 increased consistently 
in both patient-derived cell lines after 1 month of differentiation. In patient 1, the 
moderately high ABCA4 expression was comparable with the high CRX, CHX10, 
and OPN1SW expression (Fig 3B). OPN1M/LW and RCV1 expression also was 
confirmed by immunofluorescence staining (Fig 3C, D). Fig 3E clearly shows the 
different densities of progenitor (PAX6 positive, in green) and photoreceptor 
(ABCA4 positive, in red) cells in the culture after 2 months of differentiation.
ABCA4 transcript analysis
The 5 algorithms used to assess the effect of c.5461-10T→C on splicing consistently 
predicted a very subtle weakening of the splice acceptor site of ABCA4 exon 39 
(Supplemental Fig 5A, available at www.aaojournal.org). To investigate the role 
of the c.5461-10T→C variant on RNA splicing, we analyzed total RNA derived 
from 30-day differentiated PPCs of persons with STGD1 who carried this variant 
in a homozygous or heterozygous state. Because the variant is located in ABCA4 
intron 38, we performed RT-PCR analysis of ABCA4 exons 36 to 41. We found the 
expected wild-type 584-bp fragment in a control PPC line, adult human neural 
retina, a PPC generated from patient 16, who carried the c.5461-10T→C variant 
and an unknown second ABCA4 variant, and a PPC established from patient 17, 
who carried the c.1822T→A (p.Phe608Ile) allele and an unknown second ABCA4 
allele (Fig 4A). Patients 1 and 16 showed bands of 460 bp and 330 bp, which on 
Sanger sequence analysis revealed deletions of exon 39 and of exons 39 and 40 
(Fig 4B). ABCA4 exons 39 and 40 consist of 124 and 130 nucleotides, respectively, 
and therefore the loss of exon 39 and the loss of exons 39 and 40 are predicted 
to result in shifts of the open reading frame and premature stop codons, that is, 
p.Thr1821Valfs*13 and p.Thr1821Aspfs*6, respectively.
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Figure 3.
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Figure 3. Retinal gene expression profiles and immunofluorescence of patient-derived photoreceptor 
progenitor cells (PPCs). Gene expression profile of (A) control-derived and (B) patient-derived PPCs 
after 1 and 2 months of differentiation compared with induced pluripotent stem cells (iPSCs) and 
adult neural retina. The appearance of PPCs can be deduced by the increase in expression of 
PAX6, CRX, and CHX10. The differentiation into photoreceptor-like cells is shown by the increased 
expression of ABCA4, NRL, OPN1SW, OPN1M/LW, RCV1, and RHO after 1 month of differentiation. 
In the control, the expression of the genes CRX, CHX10, ABCA4, and OPN1SW increased after 1 
month, but it decreased in the second month of differentiation. However, expression of genes for 
green–red cones (OPN1M/LW) and rods (RCV1, NRL, and RHO) consistently increased in the second 
month. In the patient sample, the expression remained constant during the differentiation, with the 
exception of CRX and RCV1, for which the expression decreased, and NRL, OPN1M/LW, and RHO 
for which expression increased. Immunofluorescence staining of patient cells showed (C) cone cells 
expressing OPN1M/LW and (D) rods expressing RCV1. E, Coexpression of PAX6 and ABCA4 showed 
the different density of PPCs (PAX6 positive) and photoreceptor-like cells (ABCA4 positive). The 
dotted box represents the magnified area of the figures on the left side. DAPI was used to nuclear 
staining (blue). Scale bars = 50 μm.
Figure 4. The c.5461-10T→C variant results in skipping of exons 39 or of exons 39 and 40 in mRNA 
of photoreceptor progenitor cells (PPCs). A, Reverse-transcription polymerase chain reaction (PCR) 
results of ABCA4 exons (e) 36 to 41 showing a single expected 584-bp fragment in a control PPC (C), 
adult neural retina (R), patient 16 (P16), who was heterozygous for c.5461-10T→C and an unknown 
second allele, and patient 17 (P17), who carried c.1822T→A (p.Phe608Ile) and an unknown second 
allele. Patients 1 (P1) and 16, who carried the variant in homozygous and heterozygous states, 
respectively, show fragments of 460 bp and 330 bp, suggesting deletions of exon 39 or of exon 39 
and 40 (black arrowheads). Reverse-transcription PCR analysis of GUSB was performed as a control. 
B, Sanger sequence analysis of the mutant fragments showing the exon 39 (upper panel) or exons 39 
and 40 (lower panel) skipping events. bp = base pairs; WT = wild-type.
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In vitro splice assays using ABCA4 minigenes
To investigate the splicing defect observed in the PPCs in more detail, we generated 
2 minigenes by PCR using control and patient 1 genomic DNAs: MG1 and MG2 (Fig 
5A). The minigenes contain exon 39 and were designated -10C for the mutant and 
-10T for the control sequences. Sanger sequencing revealed no de novo variants 
in these constructs resulting from the PCR-based cloning procedure. To assess 
whether the minigene constructs recapitulated the splice defects observed in PPCs 
and whether we could pinpoint the genetic defect, HEK293T were transfected with 
mutant and control minigenes. Both control minigenes MG1-10T and MG2-10T 
showed partial skipping of exon 39 (Fig 5B, C); the mutant minigenes MG2-10C 
and MG2-10C showed 100% skipping of ABCA4 exon 39 (Fig 5B, C).
Figure 5. In vitro splice studies revealing that the c.5461-10T→C variant underlies exon (e) 39 
skipping. A, Schematic representation of the ABCA4 genomic region of patient 1 (from exons 38 to 
41) and of the structure of the minigenes generated in this study (MG1 and MG2). The c.5461-10T→C 
variant is highlighted in the black box. The 19 additional variants in introns 38, 39, and 40 were 
found after Sanger sequence analysis (data not shown). B, Reverse-transcription polymerase chain 
reaction (RT-PCR) of RHO exons 3 through 5 in HEK293T cells 48 hours after transfection. The 
mutant MG1-10C and MG2-10C were transfected in parallel with 2 control minigenes (MG1-10T 
and MG2-10T). MG1-10T and MG2-10T show fragments of approximately 410 bp, corresponding 
to normal splicing (RHO exon 3–ABCA4 exon 39–RHO exon 5) and a fragment of approximately 290 
bp, corresponding to the size of the RHO exons spliced together without ABCA4 exon 39. The mutant 
minigenes MG1-10C and MG2-10C showed 100% skipping of ABCA4 exon 39. C, Sanger sequence 
analysis of the RT-PCR fragments confirmed the exon 39 skipping. WT = wild-type.
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Discussion
By using stem cell technology and in vitro splice assays, we showed that the 
frequent ABCA4 c.5461-10T→C variant is associated with exon 39 or exons 39 and 
40 skipping, which results in truncated ABCA4 proteins. Haplotype and sequence 
analysis in 15 persons with STGD1 strongly suggested that this variant is part 
of a shared founder haplotype spanning a sizeable part of the ABCA4 gene. In 
addition, no other rare single nucleotide variants were detected in this shared 
haplotype, which could explain the observed splice defects. The c.5461-10T→C 
variant is found almost exclusively in the European population (26/33243 persons 
vs. 1/27272 persons in non-Europeans; Exome Aggregation Consortium, available 
at: http://exac.broadinstitute.org; accessed November 10, 2015). Importantly, 
STGD1 or CRD patients carrying 2 c.5461-10T→C variants or 1 c.5461-10T→C 
variant and another causal ABCA4 variant are now eligible for new treatments.
The clinical data of 4 homozygotes for c.5461-10T→C corroborate that this variant 
results in the absence of ABCA4 activity, because all patients showed a young age 
of onset of STGD1 with rapid deterioration of central vision and progressive cone–
rod loss of ERG responses leading to legal blindness before the age of 25 years. 
Moreover, in a recent study of 34 bi-allelic ABCA4 cases with early-onset STGD1,24 
the c.5461-10T→C variant was found in 17 of 68 alleles (25%), and thereby was 
the most frequent ABCA4 variant. The second most frequent variant in this group 
was c.768G→T (p.?) identified in 9 of 68 (13.2%) of alleles, which also has been 
deemed to have a severe effect.2
In silico predictions indicate that the c.5461-10T→C variant had a small effect 
on splicing (Supplemental Fig 5, available at www.aaojournal.org). However, a 
strong effect of a thymine-to-cytosine change in the thymine–cytosine stretch of 
splice acceptor sites on splicing is not unprecedented, as shown for the VCAN 
c.4004-5T→C (p.?) variant, which has been found previously to result in exon 8 
skipping in persons with autosomal dominant Wagner disease in the Netherlands.25
To explain the strong effect of the c.5461-10T→C variant, we checked for 
other sequence elements in or near exon 39. At position c.5461-51, the at-risk 
haplotype carries an adenine deletion, which is situated 5 nt downstream of the 
predicted branch point sequence at -56. We cannot exclude the possibility that it 
has a subtle effect on the strength of the exon 39 splice acceptor site. Likewise, 
other upstream variants could influence splicing. As depicted in Supplemental Fig 
6 (available at www.aaojournal.org), significant levels of exon 39 skipping (see 
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 242
242
Chapter 3.3
Fig 5B) in constructs with the wild-type T nucleotide suggest that RHO exon 3 
to 5 splicing is at least as efficient as RHO exon 3 to ABCA4 exon 39 to RHO exon 
5 splicing. The splice donor site of exon 39 is predicted to be relatively strong, 
but it does carry a conspicuously large number of alternative splice donor sites. 
As shown in Supplemental Fig 5B (available at www.aaojournal.org), 3 additional 
splice donor sites are predicted very near the canonical splice donor site of 
exon 39. The presence of 3 alternative splice donor sites at the exon 39–intron 
39 junction may render exon 39 susceptible to exon skipping. None of the other 
48 splice donor sites in ABCA4 carries more than 1 alternative splice donor site, 
and only 5 exons (exons 10, 15, 23, 26, and 42) contain 1 extra splice donor site 
residing in the last 10 nucleotides of the exons or the first 11 nucleotides of the 
adjacent introns. Sanger sequence analysis of introns 38, 39, and 40 in patient 
1 ruled out the presence of other single nucleotide variants and deletions that 
could have an effect on splicing, but we cannot exclude the existence of other rare 
copy-number variants inside and outside of the exon 38 through exon 41 region 
that were missed in the Sanger and Haloplex-based sequencing.
The c.5461-10T→C variant previously was tested for its effect on splicing using 
the pSPL3b exon-trapping vector,3 but no effect on splicing was observed. The 
reason may be that only 69 nt of upstream and 52 nt of downstream sequences 
of exon 39 were cloned into the minigene construct. Although less plausible, it is 
also possible that there are species-specific or cell line–specific differences in the 
splicing machineries, as shown for other intronic mutations.26 We used HEK293T 
cells, derived from human embryonic kidney, whereas Rivera et al3 used COS9 
cells, derived from monkey kidney fibroblasts.
Finally, in the ABCA4 cDNA of PPCs derived from patient 1, we also found exon 
40 to be spliced out from part of the mRNA. This possibly can be attributed to 
the order of splicing. Intron 39 is relatively small and possibly is spliced out at an 
early stage.27 Therefore, exons 39 and 40 skipping may be considered a so-called 
bystander effect.
ABCA4 is a transmembrane protein situated at the rim of the photoreceptor outer 
segment discs and in the cell membranes. 28, 29 Therefore, during in vitro iPSC 
differentiation into PPCs, its high peak of expression is expected when the outer 
segments of photoreceptor cells are formed. It is interesting to note that the peak 
of ABCA4 expression in iPSC-differentiated PPC cultures appeared after 1 month 
of differentiation. The quantitative PCR analysis after 1 month of differentiation 
clearly showed the expression of genes that typically are upregulated in PPCs and 
cone photoreceptors, indicating the presence of only these 2 types of cells. The 
same analysis performed after 2 months of differentiation showed an increase 
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of rod photoreceptor cells and a decrease of PPCs. These data suggest that 
ABCA4 is produced mainly by progenitor and blue cone photoreceptor cells. In 
the control PPCs, ABCA4 expression seemed to be derived from PPCs rather than 
photoreceptors (Fig 3A).
In conclusion, we found that the frequent ABCA4 c.5461-10T→C variant results in 
the skipping of exon 39 or exons 39 and 40. Because both splicing events result 
in the absence of significant parts of ABCA4 protein, the c.5461-10T→C variant 
can be considered to result in the absence of functional ABCA4. Accordingly, 
persons carrying this variant in both gene copies show an early age-of-onset form 
of STGD1, with a rapid progression and a poor visual prognosis in the second and 
third decades of life.
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Supplementary Material
Supplemental methods: Patient-derived fibroblast reprogramming
Skin biopsies from two persons with STGD1, one homozygous (P1) and one 
heterozygous (P16) for c.5461-10T>C, as well as one control, were collected, 
washed in PBS (cat. no. P5493, Sigma Aldrich, St. Louis, MO, USA), dissected 
with a scalpel and incubated for 1-3 h at 37˚C in a solution of 1000 U/ml 
Collagenase type II (cat. no. LS004176, Worthington Biochemical Corporation, 
Lakewood, NJ, USA) and Penicillin/streptomycin (cat. no. P4333, Sigma Aldrich) 
in DMEM (cat. no. D0819, Sigma Aldrich). The digestion was then stopped by 
the addition of 20% (v/v) fetal calf serum (FCS, cat. no. F7524, Sigma Aldrich) and 
the cell suspension was incubated in a medium containing DMEM and 20% FCS for 
7 days at 37˚C and 5% (v/v) CO2.
After about one month, a pure culture of fibroblasts was reprogrammed as 
follows. Fibroblasts were transduced at 80% confluence with four lentiviral 
vectors containing the pluripotency genes OCT3/4, NANOG, KLF4 and c-MYC. 
Transduced cells were incubated for 24 h at 37˚C, the lentiviruses were removed 
and cells washed three times with PBS. The following day, the transduced 
cells were transferred onto murine embryonic fibroblast (MEF)-coated plates 
and cultured for one month at 37˚C and 5% CO2 in a stem cell medium containing 
DMEM/Ham’s F-12 (cat. no. 1445C, Sigma Aldrich), 20% (v/v) Knock-out serum 
replacement (KOSR, cat. no. 10828-028, Thermo Fisher Scientific), MEM 
Non-essential amino acids (NEAA, cat. no. M7145, Sigma Aldrich), L-glutamine 
(cat. no. G8541, Sigma Aldrich), β-mercaptoethanol (cat. no. M3148 Sigma 
Aldrich), β-FGF (cat. no. F0291, Sigma Aldrich). One month after transduction, 
iPSC colonies were picked and expanded on Vitronectin-coated plates (cat. no. 
A14700, Thermo Fisher Scientific) in Essential E8 medium (cat. no. A1517001, 
Thermo Fisher Scientific).
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Supplemental Table 1: ABCA4 variants in persons P1-P17
Supplemental Table 2: SNP analysis primer details 
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Supplemental Table 3: qPCR primers
Supplemental Table 4: Primary and secondary antibodies
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Supplemental Table 5: Primers for minigene generation and in vitro splice assay
Supplemental Figure 1
The c.5461-10T>C variant resides on an ancestral ‘founder’ haplotype spanning a large part of the 
ABCA4 gene. Haplotype analysis was performed in four homozygous and 11 heterozygous persons 
with Stargardt disease for c.5461-10T>C. All the subjects were investigated for 18 single nucleotide 
polymorphisms (SNPs), which are frequent variants in the Dutch population, in and outside the 
ABCA4 gene. Eight SNPs were present in a homozygous state in the four c.5461- 10T>C homozygotes 
and this shared haplotype was also found in a heterozygous state in the 11 cases heterozygous for 
c.5461-10T>C, defining a minimal shared region of 95.9 kb between the SNPs rs35270729 and 
rs548122 (highlighted with black boxes). The maximum shared region, spanning
128.2 kb, was defined between the SNPs rs12121974 and rs4147804 (highlighted with grey boxes).
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Supplemental Figure 2
Quantitative PCR (q-PCR) analysis of cDNA derived from induced pluripotent stem cells (iPSCs). The 
expression of the pluripotency genes LIN28, NANOG, OCT3/4 and SOX2 (normalized against GUSB) 
in iPSCs was clearly increased compared with the patient fibroblasts. ABCA4 was used as a 
negative control of the reprogramming and its expression remained very low during the whole 
experiment.
Supplemental Figure 3
Induced pluripotent stem cells (iPSCs) show expression of pluripotency markers. Expression was 
observed for A. OCT3/4 (red) and NANOG (green), B. TRA-1-81 (green), C. SSEA4 (green). The 
dotted box represents the magnified area of the figures on the left side. DAPI was used for nuclear 
staining (blue). Scale bars 50 µm.
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Supplemental Figure 4
ABCA4 expression levels in fibroblasts, induced pluripotent stem cells (iPSCs) and photoreceptor 
progenitor cells (PPCs). In comparison with GUSB (expression set at 1), ABCA4 expression is very 
low in fibroblasts and iPSCs and consistently increased after one month (PPCs 1 m) of differentiation 
into PPCs. The expression slightly decreased after two months (PPCs 2 m).
Supplemental Figure 5
In silico splice predictions of the strength of ABCA4 exon 39 splice sites. The five algorithms employed 
to assess the effect on splicing are depicted in green for the splice acceptor site and in blue for the 
splice donor site. A. The predicted effect of c.5461-10T>C on splicing is a very subtle weakening of 
the canonical splice acceptor site of ABCA4 exon 39. B. The canonical splice donor site of ABCA4 
exon 39 and three alternative splice donor sites (aSDS 1-3).
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Supplemental Figure 6
In silico splice prediction of the strength of ABCA4 exon 39 splice sites and RHO exon 3 donor 
and exon 5 acceptor splice sites. The five algorithms employed to assess the effect on splicing are 
depicted in green for the splice acceptor site and in blue for the splice donor site. The canonical splice 
donor site of RHO exon 3 is predicted to be slightly stronger than that of exon 39; the reason might 
be the presence of alternative splice donor sites (Supplemental Figure 5B). The splice acceptor site 
of RHO exon 5 is not predicted to be stronger than that of exon 39.
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CHAPTER 4
Quality of life in Stargardt patients
“To date, quality of life studies which assess visual impairment are mainly focused 
on elderly patients, and many are not specified for retinal dystrophies. Knowledge 
of quality of life in Stargardt disease (STGD1) patients can gain insight about the 
impact of the disease on daily functioning. These data are important to provide 
outcome measures and indicators of cost effectiveness for emerging clinical trials. 
In this study, we provide a detailed description of our findings in social, demographic, 
and disease-specific characteristics, as well as general and vision-specific quality 
of life in patients with STGD1. The results were compared with norm groups. In 
general, STGD1 patients, as presented in our study, perceive good general quality 
of life with serious, vision-related impairments suggesting a large potential of 
health gain by innovative interventions to treat vision-related impairments.”
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PURPOSE: This study evaluates social, demographic, and disease-specific 
characteristics, as well as general and vision-specific quality of life (QoL) in patients 
with Stargardt disease (STGD1).
METHODS: Our database (Department of Ophthalmology, Radboudumc, Nijmegen, 
the Netherlands) contains 448 patients with a clinical diagnosis of STGD1. Genetic 
analysis was performed in 270 patients, 260 of whom carried ≥1 ABCA4 mutations. 
To those patients who had a follow-up visit between May 2013 and March 2015, 
we asked to participate in this study. 106 STGD1 patients participated in this 
study. We used three questionnaires: a patient-characteristics questionnaire, the 
RAND-sf36 and the VFQ-25 to evaluate the general and vision-specific QoL to 
obtain social, demographic, and disease-specific characteristics, as well as general 
and vision-specific QoL of STGD1 patients compared with norm groups. 
RESULTS: Low vision aids were used in 86% of the patients. All patients completed 
education, and 43% had a part-time or full-time job. 
General QoL: comparisons with norm groups revealed similar physical, social, 
and emotional role functioning. STGD1 patients showed better scores on mental 
health (t=5.108 p<=.001), vitality (t=2.980 p=.004), and general health perception 
(t=2.398 p=.019) than the norm group.
Vision-specific QoL: STGD1 patients perceive less favorable vision-related QoL 
compared with other eye disease patients for nearly all aspects of vision-related 
QoL, except for general health.
CONCLUSIONS: STGD1 patients perceive good general QoL, but with serious, 
vision-related impairments suggesting a large potential of health gain by 
innovative interventions to treat vision-related impairments.
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Introduction
Stargardt disease type 1 (STGD1) is arguably the most common retinal dystrophy 
caused by a defect in a single gene, which affects 1:10,000 people worldwide 
[1]. This disease is caused by mutations in the ABCA4 transporter gene and is 
inherited in an autosomal recessive fashion [2]. In general, patients present with 
progressive bilateral central vision loss, the majority of them presenting within 
their first two decades of life [3, 4]. Peripheral vision usually remains unaffected, 
but progression to peripheral loss of vision can occur, especially in patients with 
an early age at onset [5, 6]. 
The clinical heterogeneity in STGD1 is considerable with a wide variation in the 
age at onset and the level of visual impairment [4, 6-8]. Patients with an early age 
at onset show rapid retinal degeneration resulting in severe visual impairment 
(≤20/200) before adulthood, and functional blindness between their fourth and 
fifth decade of life [6]. Patients with a disease onset between adolescence and 
middle adulthood progress slower to severe visual impairment at a median of 22 
years after onset [4]. Late-onset STGD1 patients relatively preserve their visual 
function with only mild visual impairment (≥20/40 Snellen) up to nine years 
after diagnosis, due to sparing of the central macular structures [7, 9]. To date, 
no treatment is available, but clinical trials are ongoing, like; gene augmentation 
(trial number NCT01367444, NCT01736592), and small molecule drugs (trial 
number NCT02402660) [10, 11]. 
Currently, quality of life (QoL) is determined as a significant outcome for 
measuring the impact of disease, and for estimating the efficacy of treatment. 
In general, visual impairment is related to loss in QoL [12-16]; visually impaired 
patients frequently have high levels of anxiety and periods of depression [14, 
17, 18]. These patients are also at increased risk of accidental injuries, which can 
worsen existing chronic health conditions [19, 20]. Moreover, blindness is feared 
third most of all chronic disorders after cancer and AIDS/HIV by Americans [21]. 
To date, QoL studies which assess visual impairment are mainly focused on elderly 
patients [13, 22-25], and many are not specified for retinal dystrophies. To our 
knowledge, besides from retinitis pigmentosa in general, we know little about the 
QoL in patients with retinal dystrophies, for example STGD1. 
Knowledge of QoL in STGD1 patients can gain insight about the impact of the 
disease on daily functioning. These data are important to provide outcome 
measures and indicators of cost effectiveness for emerging clinical trials [26].
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This study aims to investigate general and vision-related QoL in patients with 
STGD1 and their relation to demographic aspects (like age and gender) and 
disease-specific features including disease onset and duration, and degree of 
visual impairment. Additionally, we provide a detailed overview of our STGD1 
cohort, e.g. to obtain information about education and workability. We will 
present the results as explorative data. 
Methods
Patients
The database of the Department of Ophthalmology at Radboud university medical 
center (Nijmegen, the Netherlands) contains 448 patients with a clinical diagnosis 
of STGD1. Genetic analyses was performed in 270 patients, and 260 patients were 
proven with one or more ABCA4 mutations. Of these patients, which visited the 
outdoor clinic because of follow-up in the period from May 2013 to March 2015, 
we asked to participate in this study. A total of 106 STGD1 patients were willing 
to participate in this study. For studies on inherited retinal disease we have the 
certificate of approval from the central committee on Ethics and Human research 
(IRB).Informed consent of the research was obtained from all patients, and the 
study was in adherence to the tenets of the Declaration of Helsinki.
Questionnaires
In this study, we used three questionnaires: one questionnaire to collect patient 
characteristics, and two standardized questionnaires to evaluate the general and 
vision-specific QoL. In the period from May 2013 to March 2015, the patients 
were interviewed individually by a trained researcher (N.M.B., S.L., L.Y.).
     1. Demographics and vision-related characteristics
We designed a questionnaire to acquire patient characteristics including 
demographics, general health (e.g., consultation of other specialists, use of 
medication, and presence of other diseases), life style (e.g., smoking, outdoor 
activities, sports, and diet), social aspects (e.g., education, work, and having a 
family), and vision-related characteristics (e.g., age at onset, and first complaints). 
We can correlate some of the social aspects to the general Dutch population 
(www.CBS.nl). 
The disease impact on QoL can be measured from a general perspective or from a 
disease-specific perspective. An assessment from a general perspective describes 
the perceived quality of general aspects of life, which includes physical and 
emotional health, and the impact of general health problems in daily life. Such an 
assessment enables a direct comparison of a specific patient group with healthy 
controls. In contrast, disease-specific QoL addresses issues related to specific 
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aspects of the disease. This assessment enables a comparison between one 
patient and another within the group of patients with the same disease. Therefore, 
we choose two different questionnaires to obtain general and disease-specific 
information: 
     2. General quality of life
General QoL was assessed with the validated 36-Item Short Form Health Survey 
(RAND-sf36) [24,25], of which norm scores are available. The questionnaire 
consists of eight subscales: physical and social functioning, role limitations 
due to physical health problems, role limitations due to personal or emotional 
problems, general mental health, energy/ fatigue, bodily pain, and general health 
perceptions [27, 28]. 
     3. Vision-related quality of life
The Visual Function Questionnaire-25 (VFQ-25) is generally used to investigate the 
vision-related QoL [29]. The VFQ-25 is a 25-item version of the 51-item National 
Eye Visual Function questionnaire (NEI-VFQ) [30]. Norm scores are available, as 
well as scores from other eye diseases to compare with. The questionnaire consists 
of twelve subscales: overall health, overall vision, difficulty with near vision, 
difficulty with distance vision, driving difficulties, peripheral vision, color vision, 
pain and discomfort around the eyes, role limitations due to vision, dependency 
on others due to vision, limitations in social functioning due to vision, and mental 
health symptoms due to vision [29].
Interpretation and analyses
Vision-related characteristics were described and defined as follows: age at onset 
was defined as the age at which the patient noticed first symptoms. When we could 
not identify the age of first symptoms occurred, we used the age at diagnosis. We 
classified clinical subtypes based on the age at onset: (1) early-onset, as described 
by Lambertus et al [6] (≤10 years); (2) intermediate-onset (11-44 years); and (3) 
late-onset (≥45 years), as described by Westeneng- Van Haaften et al [7]. We 
defined disease duration as the difference between the age at onset and the age 
at interview. We grouped disease duration as follows: 0-10 years, 11–20 years, 
21-30 years, 31-40 years and >40 years. We measured visual acuity using an Early 
Treatment Diabetic Retinopathy Study (ETDRS) or Snellen chart. Disease severity 
was then categorized by World Health Organization (WHO) criteria as follows: mild 
or no visual impairment (≥20/60), moderate visual impairment (20/60 - 20/200), 
severe visual impairment (20/200 – 20/500), and blindness (≥20/500).
We compared the scores from the RAND-sf36 and the VFQ-25 questionnaires 
of our STGD1 population with the available norm scores and with patients with 
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other eye diseases (e.g., diabetic retinopathy, age-related macular degeneration, 
glaucoma, cataract, cytomegalovirus retinitis, and low vision in general). Detailed 
information of these norm groups from other eye diseases was not available. We 
also compared the norm scores between each subgroup (age of onset, gender, 
disease duration, and visual impairment) as mentioned above.
We analyzed data with SPSS version 22.0 (IBM Corp, Armonk, NY), using descriptive 
statistics by mean and standard deviation (SD) for continuous variables, and 
percentages for categorical variables. We compared two groups with independent 
t-tests and three or more groups with a one-way ANOVA and continuous variables 
in mean and SD. Comparisons with norm scores (RAND-SF36) and norm and 
comparison scores (VFQ-25) were assessed by an one sample t-test.
Results
From the included 106 STGD1 patients, 60% were female. We conducted 
all three questionnaires in 99 patients. In the remaining seven patients, not 
all questionnaires could be completed, because of tiredness. The patient 
characteristics questionnaire was completed in 105 cases, the RAND-sf36 and the 
VFQ-25 both in 100 cases.
Demographic and vision-related characteristics
An overview of the results is presented in Table 1. The median age at onset was 
16 years (range: 1-71). The median disease duration was 21 years (range: 2-57). 
105 STGD1 patients were interviewed at a median age of 45 years (range: 16-86). 
The median BCVA was 20/200 Snellen (range: hand movement - 20/16). Clinical 
subtypes based on age at onset contained 27 (25.7%) early-onset (median 8 years), 
54 (51.4%) intermediate-onset (median 17.5 years), and 24 (22.9%) late-onset 
(median 51.5 years) STGD1 patients. The median disease duration was 27 years 
(range: 7-57), 22.5 years (range: 3-51), and 9.5 years (2-31), respectively. The 
median BCVA in different age of onset groups was 20/600 Snellen (range: 20/6000 
– 20/120) in the early onset group, 20/200 Snellen (range: 20/6000- 20/20) in the 
intermediate onset, and 20/50 Snellen (range: 20/600 – 20/16) in the late-onset 
STGD1 patients.
Patients experienced most problems with reading (95%). Reading problems 
occurred at a median age of 24 years (range: 6-62). Low vision aids in the broad 
sense, varying from a loupe to a guide dog, were used in 86% of the patients. All 
patients completed some kind of education, 43% of whom had finished University, 
and 43% had a part-time or full-time job. The majority of the patients (61%) had 
children. 
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Table 1: O
verview
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General quality of life (RAND-sf36)
Results from the general QoL questionnaire RAND-sf36 are summarized in Table 
2. The norm scores were estimated from a Dutch population (mean age 44.1 
years, range 18-89, 65% women) and had a comparable distribution of age and 
gender to our study cohort. Comparisons with norm groups revealed similar 
physical functioning, social functioning, physical role functioning and emotional 
role functioning compared to norms (t-values not shown). STGD1 patients showed 
better scores on mental health (t=5.108 p<=.001), vitality (t=2.980 p=.004), pain 
(t=4.241 p <=.001), and general health perception (t=2.398 p=.019) than the norm 
group. 
Differences in aspects of QoL regarding demographic factors revealed worse 
mental health (F=9.458; p=.003) and vitality (F=6.576; p=.012) in women compared 
to men. Regarding disease characteristics, we found differences in physical 
functioning between groups with different ages at onset (F=3.622; p=.031) with 
less favorable perceived physical health in patients with later disease onset. In 
addition, we indentified difference in general perceived health in patients with 
different duration of complaints (F=2.913; p=.026) with worst perceived health in 
patients with shorter duration of complaints. Patients also indicated differences 
in disease severity (F=5.713; p=.001) with no linear relationship between disease 
severity and perceived health. 
Vision-specific quality of life (VFQ-25)
The results on vision-related QoL as indicated by the VFQ-25 are reported in 
Table 3. No differences in vision-related QoL were observed between different 
demographic characteristics, except for gender and mental health, indicates 
more mental health problems in women (F=4.419; p=0.38) compared to men. 
Differences regarding several disease characteristics were as follows: patients 
with a later age at onset indicated better overall vision (F=6.822; p=.002), distance 
activity (F=4.541; p=.013) and social functioning (F=7.606; p=.001) compared to 
those with earlier disease onset. Regarding severity of visual impairment, it was 
indicated that overall vision (F=12.164; p<.001), near vision (F=10.360; p=<.001), 
distance vision (F=10.432; p=<.001), driving (F=3.801; p=.017), role limitation due 
to vision (F=4.438; p=.006), color vision (F=2.771; p=.046), and social functioning 
(F=7.767; p<0.001) differed significantly regarding severity of visual impairment, 
with less favorable vision-related QoL in patients with more severe impairment. 
Concerning duration of disease, longer duration of disease, was related to a better 
vision-related QoL on every subscale (p<.001 to p=0.02), except for overall vision, 
ocular pain, and mental health. 
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Table 4 presents the scores of our STGD1 cohort compared to norm groups and 
other eye diseases, such as diabetic retinopathy, age-related macular degeneration, 
glaucoma, cataract, cytomegalovirus retinitis and low vision in general [29]. 
Results indicate that STGD1 patients perceive less favorable vision-related QoL 
compared to other patients with eye diseases, except for the group of patients 
with “low vision in general”. This is true for nearly all aspects of vision-related QoL 
except for general health which is perceived as more favorable by STGD1 patients 
compared to other patient groups. 
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Table 4: Results of the V
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Discussion
Overall, the general QoL (RAND-sf36) in this cohort of STGD1 patients was 
good and comparable to norm groups. On the other hand, the vision-specific 
QoL as represented by the VFQ-25 reports a considerable impact of disease in 
vision-specific QoL. This is most obvious in the subgroup of STGD1 patients with 
an early age at onset, generally low visual acuity and long disease duration. 
Study cohort
In general, our study cohort has a healthy lifestyle according to diet, performing 
sport, not using drugs, and just a small percentage of smokers. Although, we are 
not able to differ the lifestyle before STGD1 was diagnosed; maybe they have 
altered their lifestyle after diagnosis. 
According to demographics, like marital status and having children, the numbers 
are comparable to the general population of the Netherlands (www.CBS.nl). 
Likely, these demographics are not influenced by visual impairment. 
A remarkable number of cases of our cohort has finished university (43%) 
compared to the general Dutch population (29%). Unfortunately, we are unable 
to provide any explanation on this issue. 
There seems to be a contrast between the education level and work participation 
in the labor market of our cohort. Despite that a large number of patients 
completed (higher) education, they did not have an equal representation on the 
labor market compared to the general population. A rough calculation present a 
harsh reality; 93% of the general population (capable for work) has a part-time 
or full-time job, compared to only approximately half of our STGD1 population 
(www.CBS.nl). Moreover, the incidence of disqualification from work in STGD1 
patients is much higher than the general Dutch population (www.CBS.nl). Visual 
impairment seems to have no influence in finishing a study, but certainly gives 
problems in finding a job. We are not able to answer whether STGD1 patients with 
a part-time or full-time job were capable to find a job in the same direction of 
their study. To our knowledge, no registration or numbers are known for visually 
impaired persons and their work situation. A study of Sainohira et al indicates a 
strong relationship between being employed and the degree of depression in a 
group of visual impaired patients due to retinitis pigmentosa [31]. Therefore, we 
recommend better registration, counseling and guidance of institutions to help 
visual impaired persons to find their way on the labor market, so they could use 
their full capabilities. 
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General quality of life
Our cohort perceive a good general health, although they have serious and 
persistent disabilities. An important issue explaining the good QoL in this 
patient group is the differences between a disability and a disease [32]. The 
International Classification of Functioning, Disability and Health (ICF) represents 
the conceptualization of disability, function, and health and indicates a significant 
shift from the previous image where disability was assumed to be related with 
miserable health [33]. This opinion nuances health from disability, and suggest 
that patients can be disabled as well as healthy [34]. A disease has a relationship 
with an illness or with feeling sick. This study shows that patients with STGD1 
perceive their health as good, despite the important impairment as the result 
of STGD1. The impact of these limitations is better reflected in disease-specific 
QoL instruments, as is shown in this paper by the VFQ-25. So one could conclude 
that STGD1 patients, in this study, are presented as a group of patients generally 
perceive their health as good, with important impairments in daily life because 
of their visual disability. This could be explained by the flexibility to integrate 
these impairments in daily functioning resulting in a favourable perceived health. 
Several studies discuss the difficulties in interpreting health related QoL scores in 
people with disabilities due to the confounding between health, functioning and 
disability [35]. 
Another explanation of the good general health perception of our cohort can be 
related to the phenomenon that people tend to change their perception of QoL 
to their circumstances, also called “response shift” [36, 37]. This is a psychological 
mechanism of adjustment to life changing circumstances resulting in a reappraisal 
of new circumstances, a reappraisal of life with a disability, in this case, visual 
impairment [38, 39]. This is seen in cancer patients, showing QoL comparable to 
norm groups, and even better, explained by adjustment to and reappraisal of new 
life with cancer with adjusted goals resulting in a new life balance [40]. 
Studies on QoL in people with visual impairment predominantly focus on older 
people having to deal with impaired vision. These studies present less favourable 
QoL compared to age matched norms. This could be clarified by the important 
impact of visual impairment, especially in the elderly where possibilities to adjust 
to new life circumstances are more problematic as general functioning is normally 
challenged too. 
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Average duration of complaints in our cohort was 22 years, implicating a very long 
period of opportunity to adjust to disease impairments. This is also supported by 
the positive relationship between QoL and duration of complaints. In addition, the 
RAND questionnaire focuses on items related to physical condition which is not 
impaired in these patients. This is in line with QoL scores in patients with specific 
hearing as well as vision impairment: in Usher syndrome, patients also had no 
differences in their QoL compared to norms [41]. The patients in our sample 
have an average age of 46 years and nearly no co-morbidity, which could also 
explain the favorable scores on general QoL assessment. This imply that the vision 
impairment interfere with specific aspects of QoL. This, however, is reflected in 
the problems indicated in the vision-specific QoL assessment. 
Vision-specific quality of life
On the contrary, the vision-specific QoL indicates severe restriction on almost 
every subscale. This indicates that STGD1 patients suffer in their daily life, because 
of their visual impairment. In comparison with patients with other eye-disease, 
such as diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, 
cataract, and low vision in general [29], STGD1 patients belong to the group of 
patients with the lowest scores, comparable to AMD and low vision patients. 
From a general health perspective, STGD1 patients experience no limitation in 
social function or mental health. The subscales “social function” and “mental 
health” are represented in both questionnaires. From a disease-specific point of 
view, as assessed by the VFQ-25, these subscales indicate more discomforts. This 
discrepancy suggests concerns regarding social and mental health related to, and 
focused on their visual impairment, but not to their life in general. So patients 
indicating concerns regarding their vision related health, but do not indicate 
concerns regarding their health in general. That indicates that visual impairment 
has a significant impact on social function and mental health. 
Overall, the vision-specific QoL pointed out the impact of disease that specifically 
arises from a low visual acuity, long disease duration and a younger age at onset.
These results are comparable with results in other studies. A better visual acuity, 
suggesting a better reading ability, gives a better QoL as presented in the study 
from Murro et al. in a group of Stargardt patients [42]. In other retinal dystrophies, 
such as retinitis pigmentosa, there is a relationship between QoL and the severity 
of visual impairment [43, 44]. 
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Utilization of questionnaires
Given that STGD1 patients perceive no problems in general health, a decreased 
score of the RAND-sf36 could suggest general problems related to well-being. This 
information will be helpful in tailor-made counseling beyond the scope of the 
direct ophthalmic care.  
The VFQ-25 presents a better overview of the QoL in STGD1 patients, as it is 
specified to the effect of their visual impairment on their QoL. Therefore, the 
VFQ-25 questionnaire could be valuable as an outcome measure in clinical trials. 
The scale is already included in other clinical trials [45-47]. 
However, both Rand-sf36 and VFQ-25 questionnaires could be used to predict 
utility health scores. Utility health scores could be used in economic and health 
policy analyses and evaluations [48]. The Rand-sf36 was revised into a six 
dimensional health state classification called the SF-6D. This SF-6D responses 
could be even translated into quality-adjusted life year (QALY; i.e. one year of life 
in optimal health)[49]. Six items from the VFQ-25 were used to develop the visual 
function questionnaire – utility index health state classification, which defines 
visual function health states [50, 51]. Although these questionnaires may resemble 
useful outcome measures, the change of these outcomes doesn’t always reflect 
the true change that clinicians need to measure. The interpretation of these 
subjective measurements can differ not only between patients, but also within 
a patient over time due to their response shift. These changes in the perception 
of QoL influencing the outcome of measurements present methodological 
challenges to reliably measure a true QoL change.
In general, STGD1 patients, as presented in our study, perceive good general QoL 
with serious, vision-related impairments suggesting a large potential of health 
gain by innovative interventions to treat vision-related impairments.
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General discussion
Stargardt disease (STGD1) is the most prevalent inherited disease that causes visual 
impairment in childhood and young adults [1]. STGD1 was originally considered 
a juvenile-onset macular degeneration, however, more recent research has 
shown that initial abnormalities may develop at early childhood until old age, 
and includes a wide range of clinical, psychophysical and imaging findings [2-5]. In 
recent years, considerable advances have been made in our understanding of the 
clinical phenotypes, natural history and molecular genetics of STGD1 and have led 
to the first steps in developing therapies [6-14].
This thesis provides an overview of the different clinical characteristics of STGD1, 
works towards unraveling genetic causes and offers detailed information about 
general and vision-specific quality of life in STGD1 patients.
The main goal of the studies in this thesis is to provide a better understanding of 
the natural course and staging of disease in order to perform better counseling, 
to provide an accurate diagnosis and perspective for the STGD1 patient. A STGD1 
patient may potentially receive a multitude of descriptive diagnoses throughout life 
based on phenotypic or ERG classifications. Moreover, the present classifications 
offer a diagnosis at that moment, instead of a single diagnosis that is informative 
with respect to clinical course, which may help the patient to answer important 
questions like: “Am I able to continue my present work for the next 10 years?”, 
or “Am I able to see my children growing up?” Currently, the ophthalmologist 
identifies a variety of STGD1 phenotypes, and it can be difficult to provide good 
counseling. The main challenges in diagnosing STGD1 lie in the early-onset and 
late-onset spectrum. Therefore, I will discuss these cohorts in more detail. 
Clinical characteristics
Early-Onset Stargardt Disease (Chapters 2.1 and 2.2)
The arbitrary cut-off point of early-onset was defined as ≤ 10 years of age to avoid 
including patients with a more typical STGD1 phenotype. 
Visual acuity
In all patients a fast decline in visual acuity was noted, either by the patients 
themselves, their parents or school physicians. Visual acuity varied greatly during 
the first 5 years after first ophthalmic consultation. In other studies, a wide range 
of BCVA at first visit was observed and in most cases visual acuity was good 
(20/20), suggesting that BCVA is not a proper parameter to diagnose STGD1 or to 
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use as an outcome measurement in therapeutic trials [4, 15]. A study of Kong et 
al (ClinicalTrials.gov NCT01977846), states that BCVA is not a sufficiently sensitive 
outcome measure for STGD1 treatment trials with 1 year follow-up [16]. 
Retinal features and retinal imaging
Retinal features in early-onset STGD1 patients may include: macular atrophy 
with macular or peripheral flecks, macular atrophy without flecks, flecks without 
macular atrophy, or a normal fundus appearance [4, 17]. The prevalence of a 
normal fundus appearance ranges from 2.5% [4] to 24% [3] in early-onset STGD1 
cohorts. The absence of fundus abnormalities may leave an alarming number 
of patients without a correct diagnosis and can mean years of inappropriate 
treatment (this thesis). To minimize delay in diagnosis, I suggest that these 
children are screened using FAF, SD-OCT and a color vision test. Thickening of 
the external limiting membrane (ELM) on SD-OCT has been suggested as an early 
sign in the absence of other functional and structural changes to the retina [18, 
19]. It may reflect a gliotic response to cellular stress at the photoreceptor level. 
Edges of the inner segment ellipsoid band appear to recede earlier than the ELM 
band in active lesions. On FA, atrophic foveal changes (sometimes appearing as 
a bull’s eye lesion) present as hypo-autofluorescent lesions, surrounded by a 
hyperautofluorescent perifoveal ring and/or very subtle hyperautofluorescent 
flecks/dots. Hyperautofluorescence may precede the apparent atrophic changes. 
Abnormalities in color vision test could suggest an early-sign of a cone dysfunction. 
Other studies have suggested that adaptive optics imaging could be used to 
study early signs in STGD1 [20-22]. Song et al. reported increased photoreceptor 
spacing in STGD1 patients in otherwise normal appearing areas on OCT and FAF 
imaging [20]. Adaptive optics imaging derived cone-density has been shown to 
correlate well with OCT measurements of ONL thickness and retinal sensitivity, 
demonstrating a valuable structure-function association, even though the extent 
of atrophic changes was not in correspondence with visual acuity [21]. Tanna et 
al. investigated the reliability and reproducibility of cone counting with adaptive 
optics in STGD1 patients (confocal and (nonconfocal) split-detector adaptive 
optics scanning light ophthalmoscopy (AOSLO) imaging), and concluded that this 
imaging technique is valuable for natural history studies and clinical trials [22]. 
This suggest that adaptive optics could be informative and a reliable follow-up 
measurement. 
FA and ERG may be less helpful in the diagnostic phase. The rate of the dark 
choroid sign as seen on FA is relatively low (26%, this thesis) and full-field ERG 
may not be informative, as this may suggest normal retinal function. In addition, 
it should be realized that these are invasive tests. 
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If no yellow-white flecks are seen by ophthalmoscopy, patterns on full-field ERG 
may be helpful and can point to an isolated cone dystrophy, cone-rod dystrophy or 
even rod-cone dystrophy. In the early phase, optic disc pallor, hyperpigmentations, 
and arteriolar attenuation indicate a cone(-rod) dystrophy, but these signs 
may also manifest themselves not until later stages of early-onset STGD1. The 
progressive retinal degeneration eventually results in profound chorioretinal 
atrophy with retinal pigmentations. At this stage, traces of yellow-white flecks 
may only be seen in the far periphery. This rapid and severe retinal degeneration 
results in a severe visual impairment (20/200), which is usually reached before 
adulthood and eventually a visual acuity of about 20/500 or lower is expected at 
the age of about 40 years. An early-onset STGD1 patient at the age of 60 years 
may have the same phenotype as a retinitis pigmentosa or cone-rod dystrophy 
patient of the same age. Although STGD1 is due to variants in only one gene, RP 
and CRD can be due to variants in more than a hundred genes. These disorders 
are characterized by visual loss, abnormalities of color vision, visual field loss, 
and variable degrees of nystagmus, photophobia and night blindness. Specific 
genetic testing for mutations in ABCA4 is therefore the only approach to confirm 
the diagnosis of STGD1.
ABCA4
The majority of the early-onset STGD1 patients carry two predicted severe ABCA4 
mutations suggesting that expression and residual activity of ABCA4 play a major 
role in determining the disease severity [4, 23, 24]. A comprehensive discussion 
of ABCA4 is given later. 
However, it is a challenge to diagnose STGD1 in young children and further research 
like retinal imaging and genetic screening is necessary. Therefore, I suggest to refer 
children with unexplained visual complaints to a specialized ophthalmic center.
Late-Onset Stargardt Disease (Chapters 2.3, 2.4 and 2.5)
The arbitrary cut-off point of late-onset STGD1 was defined as ≥ 45 years of 
age. Patients generally present with either a mild decrease in visual acuity, 
metamorphopsia, oscillopsia or visual field defects. Patients can even be 
asymptomatic and signs of late-onset STGD1 can coincidentally be found during 
ophthalmologic screening for other diseases, like diabetes mellitus. A distinctive 
characteristic of late-onset STGD1 is so-called ‘foveal sparing’ as described in 
Chapter 2.3 and by Fujinami et al [5]. Although numerous yellow-white flecks can 
be found throughout the retina, the fovea is somehow not affected by atrophic 
lesions. In contrast to early-onset patients, in late-onset STGD1 foveal structure 
and function are relatively preserved, until the fovea eventually becomes affected 
by the increasing RPE atrophy. When foveal sparing is observed, visual acuity is 
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preserved for a long time. Due to the extensive surrounding RPE atrophy, patients 
switch between central fixation with a good visual acuity, and far eccentric 
fixation. However, they may experience a “jack-in–the-box” effect due to large 
paracentral scotomas. Eventually, loss of foveal sparing will result in a sudden 
decrease in visual acuity. 
Notably, the clinical phenotype of foveal sparing is not exclusively found in late-onset 
STGD1 (Chapter 2.4). Geographic atrophy in AMD, mitochondrial retinal dystrophy 
(MRD) associated with the m.3243A>G mutation, central areolar choroidal 
dystrophy (CACD), and pseudo-Stargardt pattern dystrophy (PSPD) should also be 
considered and differentiated by genetic testing. The presence of foveal sparing 
in retinal dystrophies with distinctly different underlying mechanisms suggests a 
disease-independent mechanism that prolongs the survival of the fovea. Given 
the development of therapies for slowing down progressive chorioretinal atrophy 
in IRDs, the presence of foveal sparing has implications for the design of future 
clinical trials, and there is a need for longitudinal studies of foveal sparing. New 
imaging methods like adaptive optics and OCT-angiography could be helpful. 
In a study of Chen et al. confocal adaptive optics demonstrated abnormal and 
decreased cone spacing in regions corresponding to areas of reduced and irregular 
FAF, in predominantly late-onset patients with foveal sparing [25]. 
In some recent studies, another relatively new imaging method, OCT- angiography 
(OCT-A), has been employed in STGD1 patients [26, 27]. OCT-A may help to 
understand the development of atrophy, and study disease patterns to distinguish 
between different entities. Guduru et al. analysed the choriocapillaris layer 
on OCT-A and assessed RPE changes on FAF. Areas of choriocapillaris and RPE 
impairment were quantified and correlated. The study presents that RPE damage 
on FAF appears to be significantly larger than choriocapillaris layer vessel loss on 
OCT-A, which suggests that RPE damage might precede choriocapillaris defects 
[27]. Müller et al. investigated the choroidal blood flow in areas within and 
adjacent to RPE atrophy secondary to late-onset STGD1 and AMD. Using OCT-A, 
comparison of choroidal flow signal within and outside the area of RPE atrophy 
revealed distinct differences between STGD1 and AMD, potentially implicating a 
differential role of the choroid in the pathogenesis of RPE atrophy in these two 
diseases [26].
Contrary to early-onset STGD1 patients, the late-onset phenotype is at the 
mild end of the STGD1 spectrum. Mainly, patients with late-onset STGD1 are 
diagnosed with one severe and one mild ABCA4 variant. Mild variants described 
in late-onset cases often include c.5603A>T (p.Asn1868Ile), c.[2588G>C; 5603A>T] 
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(p.[Gly863Ala, Gly863del; Asn1868Ile]) or other mild coding or intronic variants 
such as c.5882G>A (p.Gly1961Glu) and c.4253+43G>A (p.[=, Ile1377Hisfs*3]), 
respectively [11, 28-30].
The misunderstanding persists that patients with an age at onset of 50 years 
or above could not develop an inherited retinal dystrophy, and are thus usually 
diagnosed with age-related macular degeneration (AMD). Therefore, knowledge 
on these phenotypes is essential in order to have well diagnosed cohorts for 
therapeutic trials, both for AMD and STGD1. In addition, ABCA4 mutation 
screening may be essential, as Vitamin A supplements are recommended for AMD 
patients, but are contra-indicated in STGD1 patients. 
In upcoming and ongoing trials: profound inter-eye differences in disease 
progression has impact on the statistical power of clinical trials; treated and 
untreated eyes must demonstrate a larger difference than do the inter-eye 
differences by their natural course. However, lower inter-eye correlations are 
more likely found in late-onset STGD1 patients carrying combinations of variants 
that more often show a large difference in disease expression between siblings 
(Chapter 2.5). Therefore, in therapeutical trials, inter-eye discordance may be an 
exclusion criterion. 
Towards a useful classification of Stargardt disease. 
Already in 1909, Duane described the necessity of a useful classification in (eye) 
diseases [31]. In general, from many points of view it is of great importance to 
have a correct and uniform arrangement, classification, and nomenclature of 
diseases. The arrangement and classification of diseases is crucial in the selection 
of statistics on morbidity (causes of illness) and mortality (causes of death). If the 
nomenclature is not uniform, the consequence may be that medical doctors use 
different terms to denote the same condition. To develop a classification that will 
be universally acceptable is a difficult task. A classification which is suitable for the 
purposes of a general practitioner is not usually the best for a medical specialist 
[31]. 
Classification of a specific disease has the same challenges. In our opinion a 
good classification needs first of all a good understanding of the natural course 
of disease. There is a need for clarifying staging of disease and understanding 
the natural course of STGD1 in order to obtain an widely accepted, useful and 
correct classification. In addition, the classification must be manageable and 
understandable for clinicians worldwide, to obtain a better counseling, to provide 
a more accurate diagnosis and prognosis for the patient. Consequently, for STGD1 
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patients it will be better to understand their disease and future perspectives. 
Additionally, a widely accepted classification will be helpful to evaluate efficacy 
of upcoming treatments.
Several classifications of STGD1 have been proposed, however, they include just 
a small aspect of the disease. Van Driel et al. and Maugeri et al. introduced a 
classification based on the expected residual function of the ABCA4 protein by the 
severity of mutations [32, 33]. However, this classification will only work when the 
genetics of STGD1 are totally elucidated and we have accurate quantitative data 
on the effect of mutations on ABCA4 protein function. Additionally, information 
about phenotype and course of disease is lacking. Especially the course of disease 
represents important information for the patient. 
Fishman et al. differentiated three clinical phenotypes based on flecks and 
atrophic lesions [34]. Still, the phenotypes of STGD1 are numerous. Furthermore, 
genotyping and functional assessment are missing and the patients may be 
diagnosed with several stages of diseases during life; this will be confusing. 
Lois et al. recognized three patterns based on electrophysiological attributes [35]. 
Based on this classification, patients may get the diagnosis “cone dystrophy” 
which during life can develop into a “cone-rod dystrophy”. Besides, the present 
classifications lack information about clinical course. Also it is time consuming and 
burdensome for the patients to undergo ERG measurements. Nowadays, more 
efficient and patient-friendly imaging is available to evaluate the progression and 
stage of STGD1. 
Therefore, this thesis proposes a more useful classification to provide a better 
understanding and perspective of natural course of disease, which includes 
ABCA4 function, clinical presentation and functional assessment. 
What kind of “work-flow” do we advise? First, refer a patient with unexplained 
visual loss to a specialized ophthalmic center. Second, ask patients for family 
history, initial symptoms, age of onset, medical history and use of medication. Third, 
perform clinical examination of best-corrected visual acuity, ophthalmoscopy, 
fundus photography, fundus autofluorescence, and spectral-domain optical 
coherence tomography. Color vision tests could be helpful in children. All these 
examinations are non-invasive and a good baseline for further follow-up. Fourth, 
when any abnormalities and/or a positive family history are noted, we advise to 
perform genetic testing. When no abnormalities are seen and a negative family 
history exists, but the patient has still complaints of vision loss, we advise to make 
an appointment for follow-up. 
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Based on results from earlier studies and studies described in this thesis, we 
roughly classify STGD1 based on age-at-onset, which is now divided in three main 
subtypes: 
1. Early-onset STGD1 (disease onset ≤10 years, Chapters 2.1, 2.2). STGD1 
patients with an early-onset of disease are at the most severe spectrum 
of STGD1 phenotypes. They have a fast decline of visual acuity and in 
most cases are legally blind around the age of 20 years.
2. The “classic” or intermediate STGD1 as typically described in literature 
with fishtail flecks and age of onset between 11-44 years.
3. Late-onset STGD1 with an age of onset ≥45 years (Chapters 2.3, 2.4 and 
2.5). STGD1 patients with a late-onset are at the mild spectrum of STGD1 
disease. Typically, patients present with a foveal sparing phenotype and 
consequently a good visual acuity. However, due to atrophic lesions 
surrounding the fovea, they experience a “jack-in-the-box” effect, which 
can give problems in daily life.
In addition, whenever a spectrum of disease contains overlapping phenotypes 
as the rule rather than the exception, any cut-off point used to define a 
particular disease within that spectrum will be arbitrary. Natural history studies 
in combination with statistical analyses, like multinomial logistic regression 
calculation may be necessary to determine a more exact cut-off point. 
Table 1 gives an overview of the three subtypes, including typical fundus 
abnormalities at presentation of disease at the ophthalmologist, acceleration of 
visual decline, end stage of visual acuity, ERG abnormalities and combination of 
ABCA4 mutations. Examples of clinical presentation of the classification based on 
age-at onset, is demonstrated in Figure 1. [36]
Table 1 Overview of types of STGD1. *The definition of mild variants is currently not well established 
as they can have an effect on the mRNA and protein or both. In addition, non-ABCA4 factors may 
play a role. 
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Figure 1. O
verview
 of disease progression in subtypes of STG
D
1. Subtypes have disti
ncti
ve disease onsets, indicati
ng the severity 
of disease. The visual acuity decline is fast in early-onset STG
D
1, w
hereas in late-onset STG
D
1, visual acuity is aff
ected only several 
years aft
er disease onset.
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Identification, registry and functional assessment of ABCA4 variants
Until recently, approximately 25% of STGD1 patients were missing a complete 
genetic diagnosis [33, 37-39]. Identification, registry and functional assessment 
of reported variants is essential to elucidate the missing heritability in STGD1. Van 
Driel et al. [32] and Maugeri et al. [33] first proposed a classification based on the 
expected residual function of the ABCA4 protein by the severity of mutations. 
In this model, patients showed a spectrum of clinical phenotypes, from classical 
STGD1 when carrying a severe and mild (or two moderately severe) variant, to 
more severe phenotypes such as CRD (when carrying a severe and moderately 
severe variant), and RP (when carrying two severe ABCA4 variants). To better 
understand the impact of individual variants and to elucidate the missing 
heritability in STGD1, we provided several studies in this thesis. 
Identification and registry of ABCA4 variants (Chapter 3.1)
Till date, 7,447 ABCA4 variants are described in the Leiden Open (source) Variation 
Database (LOVD). We collected all up to 2016 published ABCA4 variants from 
3,928 retinal dystrophy cases, which included 5,962 ABCA4 variants (this thesis). 
This was the first comprehensive collection of ABCA4 variants AND STGD1 cases. 
In rare diseases, like STGD1, combining genetic data is important to increase 
statistical power which can aid in the classification of variants, whether they are 
pathogenic or benign. Allele frequencies were compared between the STGD1 
patient cohort and ~33,370 non-Finnish European controls in ExAC, because 
till now this is the best comparison as no other sizeable validated database is 
available. The assumed effect of the missense variants was verified by PhyloP, 
Grantham and CADD scores. The odds ratio contributes to support the hypothesis 
of the classification of a variant. 
The study also proposes five variants (p.[Gly863Ala, Gly863del], p.(Gly1961Glu), 
p.(Ala1038Val), c.5714+5G>A, p.(Arg2030Gln)) to have a mild pathogenic effect in 
most cases based on their low or absent homozygous occurrence in STGD1 cases, 
while having a relatively high allele frequency. It was also proposed that in a small 
percentage of cases the p.(Gly1961Glu) allele can act as a moderate to severe 
variant. Recently, it was proposed that only ~10% of p.[Gly863Ala, Gly863del] 
alleles present in the general population result in STGD1 when found in trans with 
a severe variant, i.e. when p.[Gly863Ala, Gly863del] is in cis with p.(Asn1868Ile) 
[28, 29]. The p.(Asn1868Ile) variant, despite its unprecedented high allele 
frequency (i.e. 7%) in the normal population for an automal recessive variant, in 
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other studies was also found as a single mutation in trans with loss-of-function 
mutations, in ~10% of STGD1 cases [28, 29]. It was strongly associated with late 
onset STGD1, often due to foveal sparing. The mean ages at onset for STGD1 cases 
carrying p.(Asn1868Ile) and a severe variant in trans were 42 years [29] and 36.3 
years [28]. Runhart et al. also found 3/10 bi-allelic siblings to be unaffected and 
calculated that a combination of p.(Asn1868Ile) with a loss-of-function variant in 
trans is penetrant in ~2% of individuals [29]. Although this finding was challenged 
[40], Cremers and colleagues strengthened earlier findings by using ABCA4 variant 
allele frequency data from ~21,559 Dutch control persons [41]. Their conservative 
estimate is that the penetrance of p.(Asn1868Ile), when in trans with a severe 
variant, is ~5%. These findings suggest an important role for environmental or 
genetic modifiers in STGD1. 
What is clearly lacking in these genotype-phenotype studies is a trustworthy 
functional classification of protein and RNA defects. “In vivo” analysis of variants 
in more suitable models, e.g. patient-derived retinal organoids, may be used to 
confirm pathogenicity as well as to assess expression levels. 
Functional assessment of ABCA4 variants (Chapter 3.2 and 3.3)
In Chapter 3.2, we elucidated the functional effect of one of the most frequent 
ABCA4 variants associated with STGD1, i.e. c.5461-10T>C. Based on splice strength 
prediction algorithms this variant was predicted to have a very small effect on 
the strength of the splice acceptor site of exon 39. However, mRNA analysis of 
patient-derived PPCs revealed full exon(s) 39 or 39/40 skipping, which essentially 
means no ABCA4 function. Our hypothesis was that a “weak” splice donor site of 
exon 39, probably explains the large effect of this predicted mild splice acceptor 
site variant. Follow-up studies have proven this to be true: strengthening of the 
splice donor site by mutagenesis of the c.5584+4 position from G>A nullifies 
the splice defect due to c.5461-10>C (S.S. Cornelis, M. Khan, F.P.M. Cremers, 
unpublished data). 
We investigated the presence of the first five identified deep-intronic ABCA4 
variants [42] in 45 (monoallelic) genetically unsolved STGD1 cases, as described 
in Chapter 3.3. We identified c.5196+1137G>A (a.k.a. V1) and c.4539+2001G>A 
(a.k.a. V4), in two and five probands of 45 cases (this thesis) [43]. The V4 variant 
also was very frequent in Belgian STGD1 cases as it explained 18/70 monoallelic 
probands [44]. For three of the five deep-intronic variants, i.e. V1-V3, it was 
shown that they resulted in aberrant mRNA in patient-derived keratinocytes, due 
to the insertion of pseudoexons [42]. Pseudoexons are small intronic segments 
that in the normal genome are not recognized by the splicing machinery as exons. 
STGD1-associated deep-intronic variants often strengthen the splice acceptor 
or donor site, and thereby result in the definition of a pseudoexon which will 
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subsequently be inserted in the mRNA. Almost invariably, pseudoexon insertions 
result in the introduction of a stopcodon or a frameshift into the reading frame. 
These will lead to nonsense-mediated decay of the mRNA and/or to ABCA4 protein 
truncation, thereby leading to the absence of ABCA4 activity, if the splicing defect 
affects 100% of the mRNA.
Two neighboring intron 30 variants, c.4539+2001G>A (V4) and c.4539+2028C>T 
(V5), were not functionally tested previously. In a recent study by Albert et al. 
[45], the effect of these variants could not be shown in vitro, using a splice assay, 
nor in patient-derived fibroblasts. Fibroblasts therefore were reprogrammed 
into induced pluripotent stem cells, which were subsequently differentiated 
into photoreceptor progenitor cells (PPCs). RNA analysis of PPCs revealed partial 
insertion of a 345-nt pseudoexon for V4 and V5. Both variants do not affect 
the splice acceptor or donor site of this pseudoexon, but create exonic splice 
enhancers that apparently act in a retina-specific manner.
Variants V1 to V5 were identified after a targeted search for intronic variants 
located in or close to predicted ultralow expressed pseudoexons [42]. In follow-up 
studies, the complete 128-kb ABCA4 gene was sequenced in mono-allelic STGD1 
cases, which revealed another 13 causal deep-intronic variants. Together with 
copy number variants and the above-mentioned low-penetrant p.Asn1868Ile 
variant, these non-coding variants currently explain ~84% (Bauwens et al. 2019) 
and ~95% (Sangermano et al. 2019) of STGD1 probands [11, 30]. The relatively high 
occurrence of deep-intronic ABCA4 variants partially can be explained by the fact 
that many of them have a mild effect as only a proportion of mRNA is defective. 
Intermediate and late-onset STGD1 in most cases are due to a combination of a 
severe with a mild variant, explaining why intronic variants are relatively abundant 
in STGD1. 
Quality of life
Therapeutic trials for STGD1 are ongoing and new therapies are emerging. 
Currently, quality of life (QoL) is considered a significant outcome to measure 
the impact of disease, to estimate the efficacy of treatment, and an indicator 
of cost effectiveness for emerging clinical trials [46]. Additionally, knowledge of 
QoL in STGD1 patients can provide insight into the impact of the disease on daily 
functioning. But at the same time, we know little about the QoL in patients with 
STGD1. Therefore we performed a study on general and disease specific QoL in 
STGD1 in Chapter 4.
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Remarkably, the general QoL was even better for STGD1 patients than for norm 
groups. We discussed a good general health, “response shift”, and the difference 
between “disability” and “disease” as possible explanation. However, will this 
help us determine a significant outcome to measure the impact of disease? In my 
opinion: no. The results are just to confirm if a patient is generally healthy. It does 
not measure the burden or limitations of being visually impaired. In other words: 
it does not measure the visual disease impact, so it is not suitable as an outcome 
measurement in trials.
The vision-specific QoL was reduced in STGD1 patients. The vision-specific QoL 
was comparable or even worse than in patients with AMD or diabetic retinopathy. 
Studies of QoL in AMD patients reflect high levels of anxiety and depression. In 
our study we did not measure these aspects. In follow-up or future studies, this 
needs more attention to demonstrate if these psychological problems are present 
in STGD1 patients.
In general, STGD1 patients, as presented in our study, perceive good general QoL 
with serious, vision-related impairments suggesting a large potential of health 
gain by innovative interventions to treat vision-related impairments. Although 
treatments are currently lacking, there is a need for health improvement 
illustrated by the fact that only 43% of the STGD1 patients has a part-time or 
fulltime job, despite the fact that 100% of the STDG1 patients received a high 
school education. 
What questionnaires do I recommend for ongoing and upcoming trials? Both 
Rand-sf36 and VFQ-25 outcomes could be used to predict utility health scores. 
Utility health scores could be used in economic and health policy analyses 
and evaluations [47]. The Rand-sf36 was revised into a six dimensional health 
state classification called the SF-6D. The SF-6D responses can be translated into 
quality-adjusted life year (QALY; i.e. one year of life in optimal health) [48]. Six 
items from the VFQ-25 were used to develop the visual function questionnaire – 
utility index health state classification, which defines visual function health states 
[49, 50]. Although these questionnaires may seem like useful outcome measures, 
a change in these outcomes does not always reflect a true change in the clinical 
condition. A questionnaire to evaluate the capabilities of a patient may be a better 
outcome measure, than the questionnaires I discussed.
In my opinion, counseling and capabilities of STGD1 patients needs more attention 
and further research. For example, we need to evaluate why STGD1 patients are 
less likely to be employed, even though they obtained a proper education and to 
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investigate whether they are depressed or anxious, as shown in other studies on 
visually impaired patients [51-53]. Better counseling and finding the bottleneck of 
unused capabilities may be beneficial for better quality of life in STGD1 patients.
Future perspectives
Phenotyping STGD1
STGD1 is not only a disease which starts in adolescence and young adulthood, 
but could appear from early childhood to old age. Good classification is essential 
to understand the wide clinical spectrum of STGD1. The classification must be 
manageable and understandable for all clinicians worldwide, to obtain a better 
counseling, to provide a more accurate diagnosis and prognosis for the patient. 
Consequently, for STGD1 patients it will be better to understand their disease and 
future perspectives. Additionally, universal accepted classification will be helpful 
to evaluate efficacy of upcoming treatments. Therefore, further studies on the 
natural course of disease are mandatory. 
Elucidating the missing heritability in STGD1
Identification, registry and functional assessment is essential to elucidate the 
missing heritability in STGD1. A worldwide variant and patient database, like 
LOVD-ABCA4, will help to identify and register all published ABCA4 variants and 
cases. The next challenge will be to also include unpublished ABCA4 variants 
and STGD1 cases known in diagnostic centers. Sharing genetic data is important 
to increase statistical power and can aid in the classification of pathogenic and 
benign variants. 
New techniques, like mRNA analysis of patient-derived PPCs or fibroblasts, could 
study the functional effect of ABCA4 variants. To investigate the effect of a variant, 
in vivo analysis of variants in more suitable models, e.g. patient-derived retinal 
organoids, can be used to confirm pathogenicity as well as to assess expression 
levels.
 
Eventually to expand the collection of ABCA4 variants we must combine these 
with cases, in order to understand the genotype-phenotype correlation and 
prediction of disease outcome. 
Quality of life
Less is known about QoL in STGD1 patients. The standardized available 
questionnaires to measure visual impairment and QoL do not specify the exact 
problems STGD1 patients face in daily life. These questionnaires need to be 
improved and specify the reason WHY someone needs help and not IF someone 
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needs help. Counseling and capability of STGD1 patients needs more attention 
and further research. Better counseling and finding the bottleneck of unused 
capabilities may be beneficial for better QoL in STGD1 patients.
Upcoming therapies
Since the first description of Stargardt disease in 1917 by Karl Stargardt [54], 
more than a century has passed and we still have no cure. Trials are ongoing, but 
for STGD1 patients who are visiting our clinic at this moment, we still have no 
treatment to offer. Although frustrating, there is some perspective. 
Currently, gene therapy, stem cell therapy, and pharmacotherapy with visual cycle 
modulators and complement inhibitors are being studied as potential treatments. 
Figure 2 presents the working mechanisms of the potential treatments for STGD1 
in the visual cycle: 
Figure 2: After Sears AE, Bernstein PS, Cideciyan AV, et al.[55]
Gene therapy aims to augment the mutated ABCA4 gene, nevertheless the 
outcomes of a phase I/II trial are pending (SAR422459; ClinicalTrials.gov, 
Identifier: NCT01367444). However gene therapy is rapidly developing and more 
targeted techniques like CRISPR/CAS9-facilitated DNA editing and antisense 
oligonucleotides (AON)-based RNA modulation are potentially effective strategies 
targeting specific mutated regions of the ABCA4 gene or RNA.
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Stem cell therapy has been explored as an option to regenerate or replace 
damaged RPE cells. Stem cells can be derived from human embryonic stem cells 
(hESCs), induced pluripotent stem cells (iPSCs), and adult stem cells. Currently, 
stem cell therapy suggests potential biologic plausibility in a phase I/II trial. 
ClinicalTrials.gov Identifier: NCT01469832. 
Drug treatments for STGD1 aim to reduce toxic bisretinoids and lipofuscin in the 
retina and retinal pigment epithelium (RPE). These agents include C20-D3-vitamin 
A (ALK-001), isotretinoin, VM200, emixustat, and A1120 [14, 56-63]. Avacincaptad 
pegol is a C5 complement inhibitor that may reduce inflammation-related RPE 
damage. Animal models of STGD1 show promising data for these treatments, 
although proof of efficacy in humans is lacking. Fenretinide and emixustat are 
visual cycle modulators for dry AMD and STGD1 that failed to halt geographic 
atrophy progression or improve vision in trials for AMD. A1120 prevents retinol 
transport into RPE and may spare side effects typically seen with VCMs (night 
blindness and chromatopsia). 
All these treatment options offer biologically plausible treatments for STGD1. 
Further trials are warranted to assess efficacy and safety in humans.
My thoughts for the near future
Investigation of knowledge of the metabolic dimensions critical to the pathogenesis 
of retinal dystrophies in general, is crucial. Further research of this topic needs 
attention. Suitable human eye-models may help, because most studies are now 
performed on rodents, that do not possess a macula. For instance primates, 
like Marmosets, or human donor eyes. Another future perspective on human 
eye-models might be in vitro retina models.
New imaging techniques, like adaptive optics and OCT-A may help to understand 
etiologic features like foveal sparing, all in order to elucidate the disease. 
Multimodal imaging studies are necessary to study the natural history and provide 
biomarkers to monitor the efficacy of treatment(s).
To determine efficacy of treatments, international cooperation is necessary to 
obtain cohorts of sufficient subjects. In the Netherlands the RD5000 database 
contains all clinical and essential genetic data of Dutch STGD1 cases [64]. In this 
system detailed standardized phenotyping is essential. 
We have to be aware that STGD1 (but also other retinal dystrophies), is a rare 
disease. Collecting cohorts and information is essential to obtain detailed 
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information about e.g. the course of disease. However, selecting patients for 
therapeutical trials may be a problem. A well phenotyped study cohort is crucial 
to determine the effect of a treatment, but candidates are rare. Most of them are 
not eligible for clinical trials, because the disease is already too far progressed to 
measure any treatment effect. On the other hand, considering lots of upcoming 
and ongoing therapeutical trials, we have to be very selective which trial we select 
STGD1 patients for. 
Hopefully, treatment will be available for STGD1 patients within 10 years, based 
on the latest developments. In the meantime, good counseling of STGD1 patients 
is crucial. Finally, it is also important to support patients to function optimally in 
their daily life.
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Chapter 6
SUMMARY
This thesis contains studies on clinical, genetic and psychological characteristics 
of Stargardt disease (STGD1). The general introduction in Chapter 1 provides 
information about the retina, retinal dystrophies, and an overview of all aspects 
of STGD1. At the end of the introduction, I summarize the aims of this thesis. 
Clinical characteristics of STGD1 are described in Chapter 2. This chapter contains 
several studies on different subtypes of STGD1: 
Chapter 2.1 gives a detailed description of early-onset STGD1 patients. In its 
natural course, early-onset STGD1 initially presents with variable full-field 
electro-retinographic abnormalities and funduscopic findings. As this retinal 
degeneration progresses, the spectrum of phenotypes eventually converges, 
causing profound chorioretinal atrophy and severe vision loss. Thus, early-onset 
STGD1 lies at the severe end of the spectrum of ABCA4-associated retinal 
phenotypes.
We notice in early-onset STGD1 patients a delay of diagnosis, because they 
initially present without fundus abnormalities. Therefore, we analyzed this group 
of patients in Chapter 2.2. A lack of obvious fundus abnormalities left an alarming 
number of children with STGD1 without the correct diagnosis. We propose that 
greater awareness of this subtype avoids misdiagnosis and years of inappropriate 
treatment. 
In Chapter 2.3 I switch to late-onset STGD1. A typical phenotype in late-onset 
STGD1 patients is called “foveal sparing”. In this chapter, we provide a detailed 
description of our clinical findings in this interesting vision-preserving retinal 
phenomenon, which mainly occurs in patients with late-onset STGD1 and 
characterizes the mild end of the clinical variations in STGD1. Long-term follow-up 
data provided insights in the natural course of foveal sparing. Although the 
etiology is unclear, we hypothesize on possible underlying factors. 
The intriguing phenomenon of foveal sparing is not only a feature in late-onset 
STGD1. In several other retinal dystrophies, like central areolar choroidal dystrophy 
(CACD), mitochondrial retinal dystrophy (MRD), and pseudo-Stargardt pattern 
dystrophy (PSPD), foveal sparing is noticed.
In Chapter 2.4, we provide a detailed description of our clinical findings in these 
distinct retinal dystrophy patients with a clearly recognizable foveal sparing 
533987-L-sub01-bw-Bax
Processed on: 7-8-2019 PDF page: 301
301
Epilogue
6
phenotype. Long-term follow-up data provided insights into the natural course of 
foveal sparing. The presence of foveal sparing in retinal dystrophies with distinctly 
different underlying mechanisms suggests a disease-independent mechanism 
that prolongs the survival of the fovea. The associated preservation of visual 
acuity is important for the individual prognosis and has implications for the design 
of future therapeutic trials for inherited retinal disease.
Chapter 2.5 presents the results of our study in asymmetry in disease progression 
between left and right eyes in STGD1 patients. Asymmetric inter-eye progression 
in STGD1 is most likely observed in patients with a later disease onset and patients 
carrying combinations of ABCA4 variants that only partially affect ABCA4 function. 
This needs to be considered in novel therapeutic trials with a fellow-eye paired 
controlled design to optimize the power of a study.
Studies on identification, registry and functional assessment of ABCA4 variants 
are provided in Chapter 3. The clinical outcome in STGD1 depends on the severity 
of two ABCA4 variants. To provide an accurate prognosis and to select patients 
for novel treatments, it is important to assess the functional significance of 
non-truncating ABCA4 variants. All published ABCA4 variants were collected 
in a Leiden Open (source) Variant Database (LOVD) in Chapter 3.1. In silico 
meta-analysis of 5,962 variants in 3,928 ABCA4–associated retinal dystrophy cases 
was performed, which allowed us to predict the functional effects. Based on their 
prevalence in patients vs controls, we hypothesized that five variants (c.2588G>C; 
p.[Gly863Ala, Gly863del], c.5882G>A; p.(Gly1961Glu), c.3113C>T; p.(Ala1038Val), 
c.5714+5G>A; p.[=, Glu1863Leufs*33] (Cornelis et al 2016, Sangermano et al 
2017), and c.6089G>A; p.(Arg2030Gln)) act as mild alleles. These studies will 
facilitate the pathogenicity assessment of variants with unknown significance 
found in diagnostics.
In Chapter 3.2 we investigated the presence of five deep-intronic ABCA4 variants 
identified previously by Braun et al. (2013). We analyzed 45 maculopathy cases 
with one causal ABCA4 variant for the presence of these deep-intronic variants, 
and in addition tested a subset of these patients for the presence of heterozygous 
deletions encompassing one or several exons. In this way we found six probands 
with heterozygous deep-intronic mutations, two probands with sizeable 
heterozygous deletions, and one proband with a heterozygous deep-intronic 
mutation and a sizeable deletion. As antisense oligonucleotide-based therapies 
are being development, patients with deep-intronic variants are eligible for this 
novel treatment.
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Furthermore, Chapter 3.3 aimed to elucidate the functional effect of the ABCA4 
variant c.5461-10T>C, one of the most frequent variants associated with STGD1. 
Splice site strength prediction programs predicted a very small effect of this 
variant on the splicing of exon 39. This variant is located on a ‘founder’ haplotype 
lacking other disease-causing rare sequence variants. Employing patient-derived 
photoreceptor progenitor cells, we found mRNA exon(s) 39 or 39/40 skipping and 
predicted ABCA4 protein truncation if the mutant RNA escapes nonsense-mediated 
decay. Given the severe phenotype in persons homozygous for this variant, we 
concluded that this variant results in the absence of ABCA4 activity. This work not 
only sheds light on the significance of this frequent variant, but also serves as an 
excellent example for the study and classification of similar non-canonical splice 
site variants with unknown effects on splicing.
Currently, quality of life is determined as a significant outcome for measuring 
the impact of disease, and for estimating the efficacy of treatment. With 
upcoming therapies in STGD1, we provide in Chapter 4 a research of quality of 
life in STGD1 patients. We used three questionnaires to provide information on 
demographics, general quality of life, and vision-specific quality of life. In general, 
STGD1 patients, as present in our study, perceive good general quality of life, but 
serious vision-related impairments. This suggest a large potential of health gain 
by innovative interventions to treat STGD1 patients.
A general discussion on clinical, genetics and psychological characteristics in 
patients with STGD1 is given in Chapter 5. 
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SAMENVATTING
Dit proefschrift bevat onderzoek naar de klinische, genetische en psychologische 
aspecten van de ziekte van Stargardt (STGD1). Het eerste hoofdstuk bevat de 
inleiding van het proefschrift. Het beschrijft de bouw en functie van het netvlies, 
erfelijke netvlies aandoeningen, en de klinische, genetische en psychologische 
aspecten van STGD1. Tenslotte worden de leerdoelen van dit werk benoemd. Het 
proefschrift is opgedeeld in drie delen (Hoofdstukken 2, 3 en 4) met ieder zijn 
eigen aandachtsgebied.
Hoofdstuk 2 bevat verschillende studies naar de verschillende subtypen binnen 
STGD1:
Hoofdstuk 2.1 geeft een uitgebreide beschrijving van het vroeg optredende STGD1 
type. Er is een groot verschil in fundoscopische afwijkingen tussen kinderen bij 
eerste klinische presentatie. Maar als de ziekte verder vordert, dan vormt het 
zich meer een duidelijk fenotype dat zich presenteert als centrale chorioretinale 
atrofie leidend tot ernstig visus verlies. Wij scharen daarom het vroeg optredende 
fenotype tot een ernstige vorm binnen het ABCA4-geassocieerde spectrum.
STGD1 patiënten waarbij de ziekte zich al vroeg openbaart krijgen vaak de diagnose 
pas laat gesteld, ondanks dat zij soms al jaren visuele klachten hadden. Bij hen 
werden in eerste instantie geen fundoscopische afwijkingen waargenomen. 
Daarom hebben wij deze groep patiënten bestudeerd en de resultaten zijn te 
vinden in Hoofdstuk 2.2. Wij hopen dat door middel van een groter bewustzijn 
van dit subtype binnen STGD1 het aantal verkeerde diagnoses en jaren van 
inadequate behandeling kan worden vermeden.
In Hoofdstuk 2.3 maak ik de switch naar laat optredende STGD1. Een typisch 
kenmerk binnen de laat optredende STGD1 patiënten is “foveal sparing”. In dit 
hoofdstuk worden de klinische bevindingen en natuurlijk beloop beschreven 
van dit interessante fenomeen. Ondanks dat de etiologie van foveal sparing 
(nog) onbekend is, doen wij hierin wel een aantal hypotheses over mogelijke 
onderliggende factoren.
Het fenomeen foveal sparing wordt niet alleen in (laat optredende) STGD1 
gezien, maar ook in een aantal andere retinale dystrofieën, zoals: centrale 
areolaire choroidale dystrofie (CACD), mitochondriële retinale dystrofie (MRD) en 
pseudo-Stargardt patroon dystrofie (PSPD).
In Hoofdstuk 2.4 beschrijven wij uitgebreid de overeenkomsten en verschillen 
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tussen de verscheidene  aandoeningen met foveal sparing om zo een beter beeld 
te krijgen van het natuurlijk beloop van de aandoening. Aangezien foveal sparing in 
verschillende retinale dystrofieën voor komt suggereert dat er een onafhankelijke 
onderliggende factor of mechanisme is, welke er voor zorgt dat juist de fovea 
gespaard blijft. Het daarmee samenhangende resterend gezichtsvermogen is 
belangrijk voor de patiënt, maar kan mogelijk ook een rol spelen in toekomstige 
mogelijkheden voor therapie bij retinale dystrofieën.
In Hoofdstuk 2.5 wordt onze studie ten aanzien van asymmetrie in ziekte 
progressie tussen het linker en rechter oog van de STGD1 patiënten beschreven. 
Asymmetrie van ogen zien we met name bij patiënten die STGD1 op een latere 
leeftijd ontwikkelen, of bij degenen die een combinatie van ABCA4 varianten 
dragen die maar deels de ABCA4 functie beïnvloeden. Dat er asymmetrie tussen 
ogen is van eenzelfde patiënt is een belangrijk gegeven bij mogelijke therapieën 
die in trials worden geëvalueerd, want dit kan de uitkomsten beïnvloeden, dus 
een goede selectie van patiënten in trials is essentieel en asymmetrie tussen ogen 
kan dus een exclusie criteria zijn.
Studies ten aanzien van het identificeren, registeren en functioneel testen van 
ABCA4 varianten worden weergegeven in Hoofdstuk 3. De ernst van de aandoening 
correleert met de ernst van de twee ABCA4 varianten. Om een juiste prognose te 
kunnen stellen en om patiënten te kunnen selecteren voor klinische trials, is het 
belangrijk om de functionele significantie van ABCA4 varianten te bepalen die 
niet leiden tot een premature translatie stop. Alle gepubliceerde ABCA4 varianten 
werden verzameld en ingevoerd en de “Leiden Open (source) Variant Database 
(LOVD)”. De resultaten zijn te lezen in Hoofdstuk 3.1. In silico meta-analyse van 
5,962 varianten in 3,928 ABCA4–geassocieerde retinale dystrofie patiënten werd 
verricht, waardoor wij het functionele effect konden voorspellen. Wij konden 
hieruit afleiden dat 5 varianten (c.2588G>C; p.[Gly863Ala, Gly863del], c.5882G>A; 
p.(Gly1961Glu), c.3113C>T; p.(Ala1038Val), c.5714+5G>A; p.[=, Glu1863Leufs*33] 
(Cornelis e.a. 2016, Sangermano e.a. 2017) en c.6089G>A; p.(Arg2030Gln)) zich als 
een milde variant voordoen, gebaseerd op de prevalentie van deze varianten in 
STGD1 patiënten ten opzichte van niet-aangedane personen. Deze studies geven 
handvaten om de geschatte pathogeniciteit te voorspellen van ABCA4 varianten 
die in DNA diagnostiek gevonden worden met een onduidelijke betekenis.
In Hoofdstuk 3.2 onderzochten wij de aanwezigheid van vijf diep-intronische ABCA4 
varianten, die eerder werden beschreven door Braun e.a. (2013) bij 45 patiënten 
met een maculopathie waarbij maar één oorzakelijke ABCA4 variant bekend was. 
Tevens werd gekeken naar de aanwezigheid van heterozygote deleties die één 
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of meerdere exonen omvatten. Op deze manier vonden wij zes probanden met 
een heterozygote diep-intronische mutatie, twee probanden met heterozygote 
deleties en één proband met een heterozygote diep-intronische mutatie en 
een heterozygote deletie. Wanneer op antisense oligonucleotide gebaseerde 
therapieën beschikbaar komen, dan zijn de patiënten met diep-intronische 
varianten zeer geschikt voor deze therapie.
In Hoofdstuk 3.3 wordt het functionele effect van c.5461-10T>C, één van de meest 
voorkomende ABCA4 varianten, beschreven. Predictie programma’s voorspelden 
een klein effect op de inclusie van exon 39 in het mRNA. Door de toepassing van 
‘patient-derived photoreceptor progenitor cells’ vonden we dat exon(en) 39 of 
39/40 in het mRNA werden overgeslagen, waardoor er een korter voorspeld 
ABCA4 eiwit wordt gemaakt, vooropgesteld dat het mutante mRNA niet wordt 
afgebroken door ‘nonsense-mediated decay’. De patiënten bij wie deze variant 
homozygoot aanwezig was, hadden een zeer ernstig fenotype. Wij concludeerden 
dat deze variant resulteert in de afwezigheid van ABCA4 activiteit. Deze studie 
beschrijft niet alleen de significantie van deze veelvoorkomende variant, maar is 
ook een goed voorbeeld voor het onderzoeken en classificeren van vergelijkbare 
varianten in de splice site consensus sequenties met een nog onbekend effect op 
de splicing.
In Hoofdstuk 4 stappen wij over van de genetica naar de kwaliteit van leven 
van STGD1 patiënten. Momenteel wordt kwaliteit van leven als een significante 
parameter gebruikt om de impact van de ziekte en de effectiviteit van een 
mogelijke therapie te meten. Wij hebben drie vragenlijsten gebruikt om de 
algemene patiënt karakteristieken, de algemene kwaliteit van leven en de ziekte 
specifieke kwaliteit van leven te meten. In het algemeen ervaren STGD1 patiënten 
een goede algemene kwaliteit van leven, maar ondervinden zij wel veel hinder 
van hun visuele handicap. Deze uitkomst geeft aan dat er veel gezondheidswinst 
te behalen is als STGD1 patiënten kunnen worden behandeld voor hun visuele 
handicap.
Het manuscript wordt afgesloten met een algemene discussie, waarin klinische, 
genetische en psychologische aspecten bij STGD1 uiteengezet worden in 
Hoofdstuk 5.
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“Coornhert Gymnasium” in Gouda, and started 
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in Rotterdam. 
Her interest in research and foreign countries 
was combined when writing her master thesis. 
For her thesis entitled ‘Genotype and phenotype 
correlation studies in epilepsy syndromes in 
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at the Department of Pediatrics in Siena, Italy.  
After finishing her medical study in 2010, she worked for 2 years as a resident at 
the Intensive Care Unit of the Albert Schweitzer hospital in Dordrecht, followed by 
a residency in Surgery and Orthopedics at the “Havenziekenhuis” in Rotterdam.
 
In May 2013, she joined the research group of prof. dr. C.B. Hoyng and started 
her PhD project on Stargardt disease at the Department of Ophthalmology in the 
Radboudumc in Nijmegen. Her research results are presented in this thesis. 
In September 2016, she started her residency in Ophthalmology at the same 
institute under the supervision of prof. dr. J.E.E. Keunen and prof. dr. B.J. Klevering.
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ACKNOWLEDGEMENTS/ DANKWOORD
Toen ik een jaar of 8 was, won ik mijn eerste zwemwedstrijd. Ik keek erg uit naar 
de prijsuitreiking: Wat zou mijn prijs zijn? Een beker, of een gouden medaille? 
Ik hoopte op een mooie kampioensbeker. Helaas voor mij had men dat jaar wat 
anders verzonnen. Het waren de jaren ‘90 en “de smiley” vierde zijn hoogtijdagen. 
Ik kreeg dan ook een grote kartonnen smiley met daarop de tekst “nummer één 
word je nooit alleen”. Destijds was ik teleurgesteld dat ik geen gouden medaille 
of beker won, maar een rond, geel karton. En waarom had ik het niet alleen 
gedaan? Wie had mij dan geholpen tijdens het zwemmen? Nooit gedacht dat ik 
als volwassen vrouw aan juist dit moment terug heb moeten denken tijdens mijn 
promotie. Want ondertussen weet ik: je doet het niet alleen en je kan het niet 
alleen. En daarin spelen sommige mensen een grote rol, sommigen een bijrol 
en/of ondersteunende rol, maar ieder met een aandeel. Daarom wil ik hier de 
personen bedanken zonder wie ik dit werk niet had kunnen doen en volbrengen. 
Allereerst de grote groep zonder wie dit proefschrift en onderzoek naar de ziekte 
van Stargardt in het algemeen niet mogelijk was geweest: “de patiënten”. Voor 
mij zijn velen bekenden geworden, maar in dit boek anoniem en als nummers 
weergegeven. Nu de eerste klinische trial in het Radboudumc van start is gegaan, 
komt er dan hopelijk toch zicht op een behandeling. Dank voor uw onzelfzuchtige 
medewerking, want voor de meesten zal een therapie te laat zijn. Door uw 
medewerking kan het hopelijk wel snel mogelijk worden voor de volgende 
generatie. 
Dan de man zonder wie ik dit werk niet had kunnen doen; Prof. dr. Hoyng, Beste 
Carel, of ook wel gekscherend “De Grote Nul”. Dankjewel voor jouw vertrouwen in 
mij, al heeft het ons beider afgelopen jaren wat grijze haren gekost. Ik bewonder 
jouw enthousiasme, jouw oprechtheid om daadwerkelijk een therapie te vinden 
voor oogaandoeningen, en dat je mensen probeert te verbinden. Om jouw doel 
te bereiken wals je soms over zaken heen of merk je wat er op de achtergrond 
gebeurd niet altijd op, maar je hart zit meer dan op de goede plek. Jouw humor 
werkt soms aanstekelijk. Er zijn weinigen met wie (en ook om…) je zo kan lachen 
als met jou: de trip naar Moorfields, de vergadering over gentherapie bij ARVO, in 
jouw Porsche naar Bonn, en dat je gewoon in je gympak met witte sportsokken de 
afdeling opkomt, et cetera. Je kan trots zijn op de onderzoeksgroep en het werk 
dat je hebt neergezet. Zonder jou was er nu geen trial in Nederland gaande voor 
een therapie voor de ziekte van Stargardt. Nogmaals, dank. 
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En natuurlijk mijn andere promotor: prof. dr. Cremers, beste Frans. Mijn dank 
dat je mijn tweede promotor wilde zijn. Jij kan de ingewikkeldste nieuwste 
ontwikkelingen in genetica-land in 30 seconden uitleggen, alsof het niets is. Je bent 
echt briljant op genetica vlak, maar desondanks ben je nooit naast je schoenen 
gaan lopen en erg bescheiden. Erg leuk dat je ook interesse hebt getoond in het 
klinisch werk en samen met mij de polikliniek oogheelkunde bent rond geweest. 
Je hebt mij veel geleerd over genetica, ABCA4 (cursief!!), maar ook dat je soms 
gewoon moet doorpakken. Ik waardeer het erg dat ik altijd bij je terecht kon voor 
advies of gewoon een kleine peptalk. Ook jij hebt een onderzoeksgroep neergezet 
waar je trots op kan zijn, en waar ik je nog veel succes mee wens.
Prof. dr. Klevering, Beste Jeroen, of “gewoon” BJ: jou zie ik toch een beetje als mijn 
onofficiële derde promotor. Niet alleen door het onderwerp van destijds jouw 
promotie waar ik toch grotendeels op verder heb geborduurd, maar met name 
door je betrokkenheid tijdens mijn PhD en “laatste loodjes”. Dankjewel voor 
je eerlijkheid, maar vooral ook je sturing, kennis, helderheid en pragmatische 
instelling. Soms heb ik wel eens gedacht dat je een klein extra X-chromosoom 
hebt, want je hebt een geheugen waar een vrouw jaloers op kan zijn. Je vergeet 
echt niets en je houdt ook tig ballen tegelijk in de lucht (spreekwoordelijk). 
Dankjewel voor je altijd goedbedoelde bemoeienis, uiteindelijk heb ik het altijd 
gewaardeerd.   
Prof. dr. Klaver, Beste Caroline: Rotterdam vs Nijmegen, wij kennen het beiden. 
Dank dat je destijds mij getipt hebt bij Carel. Ik vind het erg leuk dat je nu ook 
grotendeels in het Radboudumc werkt en deelneemt in mijn corona. Ik heb 
ontzettend veel bewondering voor je hoe je alles combineert, van top onderzoek 
tot je gezin, en dat met alle reisafstanden. Tevens sta je als vrouw meer je mannetje 
dan de meeste mannen. Chapeau!
Dr. Lambertus, Beste Stanley, Stargardt-maatje: onze (grote) verschillen hebben 
wij optimaal benut door elkaar juist aan te vullen in het Stargardt onderzoek. 
Daardoor hebben wij een grote database weten op te bouwen om het Stargardt 
onderzoek zo veel mogelijk van de grond te krijgen en mooie projecten kunnen 
doen. Ook de vele congressen en reizen die wij hebben gemaakt waren 
onvergetelijk. Nu wij beiden weer wat extra tijd hebben, kunnen wij eindelijk 
BBQ’en in onze tuinen. Terima kasih banyak!
De vele co-auteurs van alle artikelen: dank u allen wel! Dear co-authors: thank 
you all!
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In het bijzonder:
Leden van het RD5000 consortium: een goede landelijke samenwerking om alle 
retinale dystrofieën in Nederland in kaart te brengen en daardoor ook betere 
samenwerking op onderzoeksgebied.
Dear German colleagues from the Universitäts-Augenklinik Bonn, especially prof. 
dr. Frank Holz, prof. dr. Monika Fleckenstein, prof. dr. Schmitz-Valckenberg and of 
course Moritz. I think we all appreciate that Carel was overruled in the brainstorm 
session about the name of our consortium “FAST”. Thank you all for the great and 
pleasant teamwork! 
Many thanks to our collaborators at the Moorfields Eye Hospital in London for our 
successful collaboration: prof. dr. Webster, prof. dr. Moore, prof. dr. Michaelides, 
and Ana.
Also many thanks to other international collaborators: prof. dr. Stone, prof. dr. 
Braun, prof. dr. Fritsche, prof. dr. Alikmets, and dr. Zernant.
Tevens dank voor de “genetische” samenwerking met prof. dr. De Baere en Miriam 
Bauwens van het Universitair Ziekenhuis Gent.  
Dr. Oomen, Beste Clasien, dank voor al jouw inzet op het Stargardt project, van 
aanvragen schrijven tot overleggen met de ethische commissie. Je bent een 
onmisbaar manusje-van-alles geweest! Daarnaast kon ik altijd even bij je terecht 
voor een praatje en loop je over van tips over flora en fauna. Sinds kort heb je een 
nieuwe baan, ik wens je veel plezier en succes. Dat gaan we nog vieren met de al 
lang geplande BBQ, die er nu echt van gaat komen. 
Prof. Boon, Beste Camiel, dank voor je samenwerking op verschillende projecten. 
Wat ga jij als een speer! Helaas heb je Nijmegen verlaten voor een mooie carrière 
in het Westen van het land. Gelukkig houd je door de samenwerkingen nog wel 
goed contact met Nijmegen. Zo bewijst je deelname in mijn corona dan ook. 
Ik wens je veel succes (al lijk je dat bijna niet nodig te hebben) met je verdere 
carrière en hoop dat je het plezier in je werk weet vast te houden. 
Dr. Van Huet, Beste Ramon, over “als een speer gaan” gesproken… dat kan ik 
ook over jou zeggen! Dank voor het inwerken in het Stargardt onderzoek waar jij 
toen net aan was begonnen. Van het vertalen van “dinges, dingen, dingetje, ding, 
je-weet-wel.. dinges” tot databases bouwen. Altijd gezellig met een kopje thee. 
Blijf vooral zoals je bent, veel plezier en succes als stafarts!
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Voor al het statistisch werk kon ik altijd terecht bij “ons Hans”, drs. Groenewoud. 
Wat een monnikengeduld heb jij. Helaas werd een van je collega’s gedurende 
het onderzoek ook echt monnik en kwamen daardoor sommige projecten in wat 
zwaarder weer, waardoor jij veel extra werk op je hebt genomen. Dank voor al je 
geduldige uitleg en statistisch werk. 
Prof. dr. Van der Wilt, beste Gert Jan, dank voor de samenwerking. Tevens gaf 
jouw kritische blik op het kwaliteit van leven artikel net dat extra zetje dat het 
nodig had. 
Dr. Verhaak, beste Chris, psychologie en oogheelkunde…… het is een gebied waar 
nog veel in te winnen valt. Dank voor je geduld en samenwerking. 
Prof. dr. Den Dunnen, Beste Johan, dank voor je laagdrempelig overleg met 
betrekking tot de LOVD database. 
Ellen en Jelina, “De Stargardt- meisjes”: dank voor het mede opzetten van het 
Stargardt onderzoek. Ondertussen zijn jullie nu al werkzaam als oogarts (gelukkig 
in de regio). Het wordt snel weer tijd voor een etentje. 
Stéphanie: ik ben blij dat je uit de sollicitatie naar voren rolde als degene die we 
zochten voor het genetisch database project. Wat een werk heb jij in korte tijd 
verzet! Er is een mooi artikel uitgekomen en dankzij je inzet werk je nu ook bij de 
genetica! Veel succes in je verdere carrière. 
De collegae van de afdeling genetica: Susanne, Lonneke D, Lonneke HW, Saskia, 
Alex, Galuh, Mahesh, Imran en Shazia, dank voor de fijne samenwerking en extra 
uitleg over GGUGAAAAUGAAACUAUUUGUGCU. 
Marijke: ondertussen ben je van een welverdiend pensioen aan het genieten, 
maar ik mocht nog op de valreep kennis maken met jouw ervaring in het genetisch 
lab. Dank voor je begeleiding. 
Dr. Collin, Beste Rob, ondertussen weet ik dat je niet de secretaresse bent van 
Frans… (hoe lang heb ik dat geloofd??). Je doet fantastisch werk op de afdeling, 
hopelijk komt de AON therapie snel van de grond. Veel succes!
Prof. dr. Den Hollander, Beste Anneke, dank voor je interesse en laagdrempeligheid. 
Ongelofelijk hoe succesvol jij onderzoek doet. Hopelijk komt er snel een antwoord 
op de etiologie van leeftijds- gebonden macula degeneratie. 
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Dr. Albert, Cara Silvia, grazie mille per tutto il lavoro genetico svolto. Ora finalmente 
avró piu’ tempo per migliorare il mio italiano con te. In bocca al lupo con la tua 
futura ricerca.  
Dr. Sangermano, Caro Riccardo, grazie per la tua collaborazione con “ABCA4”. Ti 
auguro tanto piacere e successo nella tua futura carriera. A presto! 
Bert en Bjorn: dank dat ik veelvuldig gebruik kon maken van jullie kamer. En Bert: 
ik kom snel langs bij de atletiekvereniging om weer aan mijn hardloop skills te 
werken (op de Pegasus!). 
De samenwerking met de afdeling radiologie: dankjewel Mark en Freerk; naast 
het werk natuurlijk ook voor alle gezelligheid! Dr. Sánchez, Dear Clarisa, thank you 
for your collaboration. Finally, we can go to Madrid!! Vamos!
De afronding van mijn proefschrift heb ik gedaan tijdens mijn opleiding tot oogarts 
en daarom ook dank naar mijn opleider: prof. dr. Keunen, beste Jan, dank voor je 
steun en begrip. Tevens kan jij als de beste iemand een hart onder de riem steken 
en afsluiten met een high-five. Eind dit jaar ga je met welverdiend pensioen, 
geniet er van! Of ga je toch kiezen voor een politieke carrière? 
Dr. Keijser, Beste Sander, als nieuwbakken opleider maak je zo nog het einde van 
mijn proefschrift mee. Dank voor je interesse en luisterend oor. Veel succes en 
plezier met het opleider-schap.
Dr. Tilanus, Caro Mauk, grazie per essere stato il mio mentor. Sono contenta di 
aver sempre potuto contare su di te e sui tuoi consigli. Ora finalmente avró il 
tempo di rispolverare il mio italiano con te. 
Dr. Theelen, Beste Thomas, dank voor je laagdrempelig overleg over imaging 
en wat daar nu precies op te zien is. Helaas hebben we met de “bearfoot” niet 
gewonnen, misschien weer tijd voor een nieuwe wedstrijd? 
Uiteraard ook alle andere stafleden van de afdeling Oogheelkunde in het 
Radboudumc die ik hierboven niet specifiek heb genoemd: dank voor jullie wijze 
lessen in het dagelijkse oogheelkunde-leven. 
Het ondersteunend personeel, jullie zijn wel de Atlas van de afdeling:
Lief stafsecretariaat; Berna, Francis en Bart in het bijzonder. Jullie zijn echt 
onmisbaar voor alle planningen, technische zaken, het organiseren van alles, als 
luisterend oor etc. etc. etc. Ik ben blij dat ik de nieuwe opzet van het secretariaat 
niet heb meegemaakt, want er valt nu minder te kletsen haha. 
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Lieve optometristen, Jack en Liesbeth in het bijzonder, dank voor het ondersteunen 
op de patiënten dagen en dat ik van jullie het oogheelkundig onderzoek van ERG 
tot fundus foto’s maken heb geleerd. 
Dames en heren van de administratie: dank voor het altijd weer opspeuren van 
dossiers en andere ondersteunende taken. 
Lieve dames van “de VP”: tijdens mijn onderzoek hebben wij niet heel veel met 
elkaar te maken gehad, maar tijdens mij opleiding des te meer. Dank voor het 
luisterend oor en alle dropjes waardoor ik weer even door kon. 
Tijdens mijn onderzoek hebben ook verschillende studenten geholpen. Dankjewel 
Cécile, veel succes bij je opleiding tot SEH-arts! Lieve Mara, regelen stelt voor jou 
niks voor. Wat je ook gaat doen, met jou komt het wel goed! En Dyon: blijkbaar 
heb ik je niet afgeschrikt, maar je zelfs enthousiast genoeg kunnen krijgen om ook 
een PhD traject te volgen waarin je veel van het Stargardt werk over hebt kunnen 
nemen. Ik wens je veel succes bij het afronden van je eigen proefschrift en bij je 
opleiding tot oogarts. 
Ook de PhD’s die later zijn gestart: Sanne, Vivian, Tom en Anita, bedankt voor de 
gezelligheid. Esmée en Patty: dank voor het overnemen van het “Stargardt werk”. 
Het is bij jullie in goede handen en fijn te weten dat al het werk door kan gaan en 
niet verloren gaat. Zet ‘m op en veel succes!
PhD’s van andere Nederlandse centra: dank voor jullie gezelligheid op cursussen 
en congressen!
De AIOS oogheelkunde: Carla, John, Dzenita, Anita, Stefan, Jelina, Ellen, Ramon, 
Artin, Nicole, Yara, Myrte, Mustapha, Martijn, Stanley, Elise, Eveline, Linde, Robert, 
Freekje, Vivian en Sanne; dank voor jullie gezelligheid en fijne samenwerking. 
Vooral “team Sesame”. Fijn dat wij tegelijk zijn gestart en alles kunnen delen! 
Mijn mede PhD’s: dank voor het welkom voelen in Nijmegen! Het was een warm 
bad waarin ik terecht kwam. Wij zijn allemaal erg verschillend, maar desondanks 
konden wij het allemaal goed met elkaar vinden en hebben wij met elkaar een 
mooie tijd gehad. Dear “Connie”, thank you for your discussions on almost 
everything. You have a very creative mind, so your career as photographer will 
be fine! I wish you a lot of success in your new career. Michel, je deed me vaak 
denken aan de zin “het is een bijzonder kind, en dat is-ie!” Dank voor je soms totaal 
andere kijk op dingen, maar dat geeft andere mensen dan weer stof tot nadenken. 
Ik denk dat je in Heidelberg op een mooie plek zit en wens je daar veel succes. 
Dear Laura, Guapa, thank you for your nice talks, you are a very kind person. I am 
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happy that you are continuing your work as post-doc in Nijmegen. Lieve Myrte, 
je bent ontzettend collegiaal en kan jezelf soms totaal wegcijferen voor ‘het grote 
goed’. Dank voor je scherpzinnigheid en gezelligheid zowel binnen als buiten het 
werk. Ik denk dat de nieuwe bewoners nog steeds confetti tegenkomen (ik vond 
het een goed idee, haha). Lieve Yara, je bent een fijne collega, ook buiten het werk 
kunnen we het goed met elkaar vinden en dat waardeer ik. Ik wens je veel succes 
in je verdere (academische) carrière! Lieve Nicole, ik bewonder je doelgerichtheid 
en effectiviteit. Ik denk dat weinig mensen weten dat achter jou “als machine”, 
juist een hele lieve persoonlijkheid schuilt. Dankjewel voor je fijne samenwerking. 
Lieve Roos, dank voor wie je bent. Ik heb denk ik nooit zo met iemand gelachen 
tijdens het winkelen als met jou in de Victoria’s Secret en dankzij jou heb ik 
Mickey Mouse sneakers in mijn kast. Blijf wie je bent en veel succes in je verdere 
loopbaan! En dan “mijn” Zwelgjes: dankjulliewel voor jullie vriendschap. Als mijn 
PhD klaar is (als laatste van het stel), dan is er weer tijd voor veel leuke dingen: 
escape room, eten, drinken, feestjes, eten, drinken, winkelen, eten, drinken. Lieve 
Maartje, dank voor je fijne aanwezigheid en dat ik bij je terecht kan. Lieve Freekje, 
gelukkig hebben wij dezelfde humor, dan vindt iemand het ten minste nog leuk. 
Ik ben blij dat je weer terug bent uit Amerika en nu ook bent begonnen aan de 
opleiding tot oogarts. Lieve Eveline, “dat-dacht-ik-ook!”, wat fijn dat we samen 
hetzelfde traject doorlopen. Dank voor je steun en gezelligheid. 
“Oogappeltjes”: fijn om het met elkaar buiten het werk, alsnog over oogheelkunde 
te hebben, haha. 
Linda en Ann Laure: dank voor jullie gezelligheid, jullie steun toen het even niet 
lekker liep en de introductie in HET hockeyteam.  
Het hockeyteam was (en is) in Nijmegen toch mijn grote afleiding buiten het 
ziekenhuis. Bedankt meidties (+ “Tabata” Joost) van het allerleukste hockeyteam: 
Union Dames “11”.  Ik ben ontzettend blij dat ik in dit team terecht ben gekomen. 
We zijn een echt vriendinnen-team, we hebben veel samen gelachen en gehuild 
(maar gelukkig vooral het eerste, dat laatste doen nu de vele baby’s). Komend 
seizoen zal ik weer een stuk fitter aanwezig zijn en mij vaker op feestjes kunnen 
melden! Ik hoop dat we nog lang naar festivals gaan, eten, feesten, vakanties 
samen vieren, nog meer lekker eten etc. etc. 
Mijn vrienden uit “de goeie ouwe tijd”. Lieve Charlotte, Erik, Anne Fleur, Joost, 
Renske, Gijs, Pauline, Annelieke, Heleen, Freija, Esther, Jan Maarten, Jacqueline, 
Aimée en Karmijn: dank voor jullie vriendschap. Altijd fijn dat in de periode van 
mijn sociale afwezigheid, jullie er toch gewoon zijn en blijven. Er moet weer wat 
quality time worden ingehaald! 
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Ik ben blij dat op deze dag 2 lieve vriendinnen die ik al zo lang ken mij bij staan. 
Jullie kennen mij door-en-door, heb ik aan een blik of half woord genoeg, kan ik 
mijzelf zijn en we hebben elkaar altijd gesteund en gesupporterd. 
Lieve Charlotte:  als klinisch geneticus begrijp jij hoofdstuk 3 als de beste, haha. 
Ondanks ons drukke leven hebben wij gelukkig nog oog en tijd voor elkaar. Hoe 
jij de balans houdt van jouw werk en privéleven is erg knap. Je bent een topper!
Lieve Anne Fleur: “niet lullen, maar poetsen” is je op het lijf geschreven. Daarnaast 
sta je altijd voor ieder klaar die je lief is (en ook niet lief), en heb je ook in moeilijke 
tijden je altijd staande gehouden. Je ouders zullen, net als ik, trots op je zijn!
Mijn familie: dank voor jullie aanhoudende belangstelling en support. Ik heb heel 
wat visites en feestjes de laatste tijd moeten laten schieten, maar vanaf nu kan ik 
er weer gezellig bij zijn!
Lieve pap en mam, ik had niet verwacht dat ik jullie zo zou missen. Ik beschouwde 
mijzelf wel als een globetrotter, maar werken en wonen aan de andere kant van 
het land en niet zomaar even langs kunnen gaan, viel toch wat zwaarder dan ik 
van tevoren in had geschat. Gelukkig zijn jullie beiden met pensioen en toen jullie 
merkten dat ik het toch wel erg fijn vond om jullie vaker te zien, zijn jullie vaak 
deze kant op gekomen. Bedankt voor jullie onvoorwaardelijke steun en hulp. Jullie 
hebben mij nooit gepusht of gestuurd, maar altijd vertrouwen in mij gehad in wat 
ik wilde doen. Ik ben blij dat ik jullie nog “heb” en hoop dat jullie er nog heel lang 
zijn in goede gezondheid.   
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